

別添 1

厚生労働科学研究費補助金  
難治性疾患等政策研究事業  
( 難治性疾患政策研究事業 )

指定難病を目指した 2 型コラーゲン  
異常症の疾患概念と診断基準の確立

平成 2 8 年度 総括研究報告書

研究代表者 澤井 英明

平成 2 9 ( 2 0 1 7 ) 年 3 月

別添 2

I . 総括研究報告

指定難病を目指した 2 型コラーゲン異常症の疾患概念と診断基準の確立

----- 4

澤井英明

(資料) 指定難病の検討資料

II . 研究成果の刊行に関する一覧表

----- 17

III . 研究成果の刊行物

----- 20

研究者名簿

氏名	所属	職名
澤井 英明	兵庫医科大学、医学部、産科婦人科	教授
芳賀 信彦	東京大学医学部附属病院、リハビリテーション科	教授
大藪 恵一	大阪大学大学院医学系研究科、小児科・骨代謝学（医学系研究科小児科学）	教授
宮崎 治	国立成育医療研究センター、放射線科	医長
室月 淳	東北大学大学院、胎児医学分野、産科	客員教授
山田 崇弘	北海道大学大学院医学研究科、総合女性医療システム学講座、産科	特任准教授
高橋 雄一郎	長良医療センター、産科	産科医長
鬼頭 浩史	名古屋大学、整形外科	准教授
大森 崇	神戸大学、医療統計学	特命教授

厚生労働科学研究費補助金

難治性疾患等政策（難治性疾患政策研究事業） 総括研究報告書

指定難病を目指した2型コラーゲン異常症の疾患概念と

診断基準の確立

研究代表者 澤井英明

研究要旨

2型コラーゲン異常症は、同遺伝子の変異で発症するX線所見が類似した複数の疾患をまとめた疾患概念である。これまでは細分化された各疾患単位で取り扱われ、各疾患頻度は極端に少ないため、研究・診療が進まず、指定難病にも認定されておらず、客観的な指標に基づく疾患概念が確立していない。本症は原因遺伝子こそ共通であるが、疾患ごとに症状は多彩である。周産期致死の最重症型からそれより軽症のものもあるが、椎体や長管骨の変形から日常的な生活や歩行に大きな障害がある。遺伝子検査で診断可能であるが、現実にはあまり実施されていない。そこで本研究では、いまだに多くの患者が適切な診断と治療を受けていない、本症の疾患概念と診断基準を確立し、指定難病の認定を目指すことである。

2型コラーゲン異常症の関連する診療科領域の専門家で、診断基準を検討して、作成した。細分化されているすべての2型コラーゲン異常症を個別に診断することは極めて困難であることから、すべての2型コラーゲン異常症について、細分化された診断は行わず、一括して診断する方向でとりまとめた。

また指定難病に申請する上で重要な疾患頻度の調査については、これまでに胎児骨系統疾患フォーラムに寄せられた症例を分析して、他の骨系統疾患と比較して、疾患頻度の概数を求めることとした。その結果としては、2型コラーゲン異常症の疾患頻度は個別の疾患を合計すると2万人に一人程度となった。ただしコホート研究では1名であった。

研究分担者

芳賀 信彦・東京大学・教授

大藪 恵一・大阪大学・教授

宮崎 治・国立成育医療研究センター・  
医長

室月 淳・東北大学・客員教授

山田 崇弘・北海道大学・特任准教授

高橋 雄一郎・長良医療センター・産科

医長

鬼頭 浩史・名古屋大学・准教授

大森 崇 神戸大学・特命教授

A. 研究目的

本研究の目的は、いまだに診断基準が明確でないため、多くの患者が適切な診断と治療を受けることができていない、2型コラーゲン異常症の疾患概念と診断基準を確立し、指定難病の認定を目指すことである。

2型コラーゲン異常症は、同遺伝子の変異で発症するX線所見が類似した複数の疾患をまとめた疾患概念である。従来のX線所見による疾患分類は新たな遺伝子変異

による疾患分類と必ずしも一致しないうえ、臨床症状とX線所見からの適切な診断基準がなく、この疾患を疑うことすら困難で遺伝子検査に至らないことも多い。そこで臨床的に本症を疑い、確定診断に至るプロセスの確立を目指す。

## B. 研究方法

### 【診断基準の作成】

2型コラーゲン異常症という名称は本邦ではひとつの疾患名ではなく、2型コラーゲン遺伝子の異常により発症する複数の疾患を一括して表す疾患概念(疾患グループ)として使用されている。最新の2010年に改定された骨系統疾患国際分類(Nosology and Classification of Genetic Skeletal Disorders: 2010 Revision, Am J Med Genet A, 2011)では2型コラーゲン異常症として以下の10疾患が提示されている。

2010年国際分類改訂で示された2型コラーゲン異常症は以下の通りである。

原著に示された英語の名称と日本整形外科学会(小児整形外科委員会)による和文名称(研究分担者:芳賀信彦ら2013)

Achondrogenesis type 2 (ACG2; Langer-Saldino):軟骨無発生症2型(Langer-Saldino型)

Platyspondylic dysplasia, Torrance type:扁平椎異形成症,Torrance型

Hypochondrogenesis:軟骨低発生症  
Spondyloepiphyseal dysplasia congenita (SEDC):先天性脊椎骨端異形成症(SEDC)

Spondyloepimetaphyseal dysplasia (SEMD) Strudwick type:脊椎骨端骨幹端異形成症(SEMD)Strudwick型

Kniest dysplasia:Kniest骨異形成症

Spondyloperipheral dysplasia:脊椎末梢異形成症

Mild SED with premature onsetarthritis:早発性関節症を伴う軽症脊椎骨端異形成症

SED with metatarsal shortening (formerly Czech dysplasia):中足骨短縮を伴う脊椎骨端異形成症(以前のCzech異形成症)

Stickler syndrome type 1:Stickler症候群1型、

Stickler-like syndrome(s):  
Stickler様症候群

これらの疾患を2型コラーゲン異常症という疾患概念でとらえて、一括して診断できる診断基準の作成を目指す。

### 【症例数の分析】

特定地域を対象とした骨系統疾患の出生コホート調査を実施する。具体的には北海道、宮城県、山形県、岐阜県、兵庫県、山口県での骨系統疾患出生コホート調査から、2型コラーゲン異常症の児の出生と死産を把握し、全国患者数を推定する研究を実施中である。またこれまでに胎児骨系統疾患フォーラムで診断の依頼を受けた症例について分析して、疾患頻度を推定した。

## C. 研究結果

### 【診断基準の作成】

次ページ以降に研究班で作成した診断基準案を示す。本案については、日本整形外科学会と日本小児科学会に審議を依頼した。

### 【症例数の分析】

現在症例を収集中であり、平成27年度は本研究採択開始後の研究期間が2ヶ月ほどしかないため、研究結果を記載するに至っていない。

## D. 考察

診断基準は2型コラーゲン異常症として一括した診断群が提示できるように作成した。今後の予定として日本整形外科学会と日本小児科学会にて審議され承認を受ける必要がある。その上で正式な診断基準として厚生労働省に提案することとなる。

なお、これらの検討の過程で2型コラーゲン異常症としての一括ではなく、個々の疾患についての診断基準を求められるようであれば、現在日本整形外科学会において改訂作業中の国際分類の和文翻訳作業とも関連するので、もしそのような指摘が今後なされるようであれば、個々の疾患について再検討の必要がある。

F . 健康危険情報  
なし

G . 研究発表

1. 論文発表

研究成果の刊行に関する一覧表：刊行書籍  
又は雑誌名（雑誌の時は、雑誌名、巻数、  
論文名）、刊行年月日、刊行書店名、執筆者  
氏名

Takahashi Y, Sawai H, Murotsuki J, Satoh S, Yamada T, Hayakawa H, Kouduma Y, Sase M, Watanabe A, Miyazaki O, Nishimura G. Parental serum alkaline phosphatase activity as an auxiliary tool for prenatal diagnosis of hypophosphatasia. *Prenat Diagn.* 2017 May;37(5):491-496.

Miyazaki O, Sawai H, Yamada T, Murotsuki J, Nishimura G. Follow-Up Study on Fetal CT Radiation Dose in Japan: Validating the Decrease in Radiation Dose. *AJR Am J Roentgenol.* 2017 Apr;208(4):862-867.

Saito T, Nagasaki K, Nishimura G, Wada M, Nyuzuki H, Takagi M, Hasegawa T, Amano N, Murotsuki J, Sawai H, Yamada T, Sato S, Saitoh A. Criteria for radiologic diagnosis of hypochondroplasia in neonates. *Pediatr Radiol.* 2016 Apr;46(4):513-8.

Calongos G, Hori M, Ogino M, Sawai H. A Case of Thanatophoric Dysplasia Type I with Fetal Hydrops in the First Trimester. *Case Rep Obstet Gynecol.* 2016;2016:1821230.

大園恵一, 大理石骨病, 今日の整形外科治療指針, 2016, P251.

Ohata Y, Ozono K, Michigami T. Current concepts in perinatal mineral metabolism. *Clin Pediatr Endocrinol* 2016, 25(1):9-17.

大園恵一, 低ホスファターゼ症, 小児科, 2016, 57(3):225-261.

大園恵一, 低ホスファターゼ症の治療薬開発, 内分泌・糖尿病・代謝内科, 2016, 42(3):203-207.

Bishop N, Munns CF, Ozono K. Transformative therapy in hypophosphatasia. *Arch Dis Child* ,2016, 101(6):514-5.

大園恵一, 低ホスファターゼ症, 最新医学,

2016, 71(10):57-62.

大園恵一, 骨発育, 小児疾患診療のための病態生理, 2016, 48(601):584-588.

河野智敬, 鈴木秀一, 小澤綾子, 会津克哉, 道上敏美, 大園恵一, 望月弘, 経過良好な低ホスファターゼ症の臨床像と遺伝学的診断, 日本小児科学会雑誌 2016, 120(7):1066-1071.

Okazaki Y, Kitajima H, Mochizuki N, Kitaoka T, Michigami T, Ozono K. Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth. *Eur J Pediatr* , 2016, 175:433-437.

Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, Thompson DD, Bishop N, Hofmann C. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. *J Clin Endocrinol Metab*, 2016

Kimura T, Yamashita A, Ozono K, Tsumaki N. Limited immunogenicity of human induced pluripotent stem cell-derived cartilages. *Tissue Eng Part A*. 2016 Oct 31.

芳賀信彦: 骨系統疾患のリハビリテーション(特集: 小児リハビリテーション - その歴史と各疾患への対応, 未来への展望について - ). *Jpn J Rehabil Med* 53(5):374-378, 2016

Nishimura G, Nakajima M, Takikawa K, Haga N, Ikegawa S. Distinctive skeletal phenotype in high bone mass osteogenesis imperfecta due to a COL1A2 cleavage site mutation. *Am J Med Genet A* 170(8):2212-2214, 2016

Hasegawa S, Nishimura G, Victoria T, Zackai E, Kayserili H, Haga N, Nakashima Y, Miyazaki O, Kitoh H. Characteristic calcaneal ossification: an additional early radiographic finding in infants with fibrodysplasia ossificans progressiva. *Pediatric Radiology* 46(11):1568-1572, 2016

芳賀信彦: 骨系統疾患の臨床診断、骨系統疾患国際命名・分類 2010、Pyle 病。今日の整形外科治療指針、第7版(土屋弘行、紺野慎一、田中康仁、田中栄、松田秀一、編集) 医学書院、東京、220-222、222-225、

255-256、2016

- 芳賀信彦:FGFR3 異常症(軟骨無形成症、軟骨低形成症、タナトフォリック骨異形成症), II 型コラーゲン異常症(先天性脊椎骨端異形成症、Kniest 骨異形成症、Stickler 症候群 1 型). 小児整形外科テキスト、第 2 版(日本小児整形外科学会、監修)メジカルビュー社、東京、246-251、262-265、2016
- 芳賀信彦:先天性骨系統疾患、先天異常症候群. 標準整形外科学、第 13 版(中村利孝、松野丈夫、総編集)医学書院、東京、291-306、307-316、2017
- 芳賀信彦:骨系統疾患. 整形外科学テキスト、改訂第 4 版(高橋邦泰、芳賀信彦、編集)南江堂、東京、341-345、2017
- 鬼頭浩史 FGFR3 グループ概説 今日の整形外科治療指針 7 版(医学書院)第 7 版 231-232、2016
- 鬼頭浩史 軟骨無形成症 今日の整形外科治療指針 7 版(医学書院)第 7 版 232-233、2016
- 鬼頭浩史 軟骨低形成症 今日の整形外科治療指針 7 版(医学書院)第 7 版 233-234、2016
- 鬼頭浩史 濃化異骨症 今日の整形外科治療指針 7 版(医学書院)第 7 版 252-253、2016
- 鬼頭浩史 彎曲骨異形成症概説 今日の整形外科治療指針 7 版(医学書院)第 7 版 249-250、2016
- 鬼頭浩史 培養骨髄細胞移植による骨延長術 骨系統疾患 今日の整形外科治療指針 7 版(医学書院) 242、2016
- 鬼頭浩史 画像診断のピットフォール小児整形外科テキスト改訂第 2 版(メジカルビュー社) 58-63、2016
- Osamu Miyazaki, Hideaki Sawai, Takahiro Yamada, Jun Murotsuki, Gen Nishimura. Follow-Up Study on Fetal CT Radiation Dose in Japan: Validating the Decrease in Radiation Dose. American Journal of Roentgenology AJR 208:862-867; 2017
- Yamada T\*, Obata-Yasuoka M, Hamada H, Baba Y, Ohkuchi A, Yasuda S, Kawabata K, Minakawa S, Hirai C, Kusaka H, Murabayashi N, Inde Y, Nagura M, Umazume T, Itakura A, Maeda M, Sagawa N, Ohno Y, Kataoka S,

Fujimori K, Kudo Y, Ikeda T, Nakai A, Minakami H. Isolated gestational proteinuria preceding the diagnosis of preeclampsia - an observational study. Acta Obstet Gynecol Scand. 95:1048-54,2016

Yamada T\*, Kawakami S, Yoshida Y, Kawamura H, Ohta S, Abe K, Hamada H, Dohi S, Ichizuka K, Takita H, Baba Y, Matsubara S, Mochizuki J, Unno N, Maegawa Y, Maeda M, Inubashiri E, Akutagawa N, Kubo T, Shirota T, Oda Y, Yamada T, Yamagishi E, Nakai A, Fuchi N, Masuzaki H, Urabe S, Kudo Y, Nomizo M, Sagawa N, Maeda T, Kamitomo M, Kawabata K, Kataoka S, Shiozaki A, Saito S, Sekizawa A, Minakami H. Influenza 2014-2015 among pregnant Japanese women: primiparous vs multiparous women. Eur J Clin Microbiol Infect Dis. 35:665-71,2016

Umazume T, Yamada T\*, Morikawa M, Ishikawa S, Furuta I, Koyama T, Maysuno K, Minakami H. Platelet reactivity in twin pregnancies. Thromb Res 138:43-8,2016

Umazume T, Yamada T\*, Morikawa M, Ishikawa S, Kojima T, Cho K, Masauzi N, Minakami H. Occult fetomaternal hemorrhage in women with pathological placenta with respect to permeability. J Obstet Gynecol Res. 42:632-9,2016

Saito T, Nagasaki K, Nyuzaki H, Wada M, Takagi M, Hasegawa T, Amano N, Murotsuki J, Sawai H, Yamada T, Sato S, Saitoh A, Nishimura G. Criteria for Radiological Diagnosis of Hypochondroplasia in Neonates. Pediatr Radiol. 46:513-8,2016

Nobuzane T, Yamada T, Miura K, Sawai H, Masuzaki H, Kudo Y. Survey of prenatal testing for genetic disorders in Japan: Recent report. J Obstet Gynaecol Res. 2016 Feb 18.

Zhai T, Furuta I, Akaishi R, Ishikawa S, Morikawa M, Yamada T, Koyama T, Minakami H. Alteration of podocyte phenotype in the urine of women with preeclampsia. Sci Rep. 6:24258,2016

Suzumori N, Ebara T, Yamada T, Samura O, Yotsumoto J, Nishiyama M,

Miura K, Sawai H, Murotsuki J, Kitagawa M, Kamei Y, Masuzaki H, Hirahara F, Saldivar JS, Dharajiya N, Sago H, Sekizawa A; Japan NIPT Consortium. Fetal cell-free DNA fraction in maternal plasma is affected by fetal trisomy. *J Hum Genet.* 2016 Mar 17.

Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J, Sakuragi N. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. *J Exp Clin Cancer Res.* 35:132,2016

Dong P, Ihira K, Xiong Y, Watari H, Hanley SJ, Yamada T, Hosaka M, Kudo M, Yue J, Sakuragi N. Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. *Oncotarget.* 7:20260-70,2016

Zhai T, Furuta I, Akaishi R, Kawabata K, Chiba K, Umazume T, Ishikawa S, Yamada T, Morikawa M, Minakami H. Feasibility of nephrinuria as a screening tool for the risk of pre-eclampsia: prospective observational study. *BMJ Open.* 6:e011229,2016

Nishiyama M, Sekizawa A, Ogawa K, Sawai H, Nakamura H, Samura O, Suzumori N, Nakayama S, Yamada T, Ogawa M, Katagiri Y, Murotsuki J, Okamoto Y, Namba A, Hamanoue H, Ogawa M, Miura K, Izumi S, Kamei Y, Sago H. Factors affecting parental decisions to terminate pregnancy in the presence of chromosome abnormalities: A Japanese multicenter study. *Prenat Diagn.* 2016 Oct 19. doi: 10.1002/pd.4947.

Hayasaka I, Cho K, Uzuki Y, Morioka K, Akimoto T, Ishikawa S, Takei K, Yamada T, Morikawa M, Yamada T, Ariga T, Minakami H. Frequency of malformed infants in a tertiary center in Hokkaido, Japan over a period of 10 years. *J Obstet Gynaecol Res.* 2016 Dec 17. doi: 10.1111/jog.13229. [Epub ahead of print]

Miyazaki O, Sawai H, Yamada T, Murotsuki J, Nishimura G. Follow-Up Study on Fetal CT Radiation Dose in

Japan: Validating the Decrease in Radiation Dose. *AJR Am J Roentgenol.* 2017 Apr;208(4):862-867. doi: 10.2214/AJR.16.17316.

Takahashi Y, Sawai H, Murotsuki J, Satoh S, Yamada T, Hayakawa H, Kouduma Y, Sase M, Watanabe A, Miyazaki O, Nishimura G. Parental serum alkaline phosphatase activity as an auxiliary tool for prenatal diagnosis of hypophosphatasia. *Prenat Diagn.* 2017 Mar 22. doi: 10.1002/pd.5040.

## 2. 学会発表

Sawai H et., al. Survey of long survival cases of thanatophoric dysplasias.(General Lecture) 20th International Conference on Prenatal Diagnosis and Therapy 2016.7 Berlin  
Hiroshi Kitoh, Kenichi Mishima, Masaki Matsushita. Treatment strategies for short stature in achondroplasia. 13th International Congress of Human Genetics 2016.4.3-7 (Kyoto)

Hiroshi Kitoh, Kenichi Mishima, Masaki Matsushita. Hiroshi Sugiura, Sachi Hasegawa, Naoki Ishiguro. Genu varum in achondroplasia and hypochondroplasia Annual meeting of Pediatric Orthopedic Society of North America 2016.4.27-30 (Indianapolis)

Matsushita M, Kitoh H, Mishima K, Nishida Y, Ishiguro N, Ohno K. Clinically attainable concentration of meclozine promotes bone growth in transgenic mice with achondroplasia. Gordon Research Conference 2016.6.5-10 (Hong Kong)

Masaki Matsushita, Hiroshi Kitoh, Kenichi Mishima, Naoki Ishiguro, Kinji Ohno. Clinically attainable concentration of meclozine has a potent effect on promoting bone growth in achondroplasia. The annual scientific meeting of the endocrine society of Australia, the Society for Reproductive Biology and the Australia and New Zealand Bone and Mineral Society. 2016.8.21-24 (Gold Coast)



Kenichi Mishima, Hiroshi Kitoh, Masaki Matsushita, Hiroshi Sugiura, Sachi Hasegawa, Yoshihiro Nishida, Naoki Ishiguro. Early radiographic parameters predictive of surgery-required relapse in idiopathic clubfoot treated using the Ponseti method. 37th SICOT Orthopaedic World Congress. 2016.9.8-10 (Rome)

なし  
2. 実用新案登録  
なし  
3. その他  
なし

Masaki Matsushita, Hiroshi Kitoh, Kenichi Mishima, Naoki Ishiguro, Kinji Ohno. Clinical feasibility of oral administration of meclozine for the treatment of short stature in achondroplasia. Annual meeting of the American Society for Bone and Mineral Research. 2016.9.16-19 (Atlanta)

Hiroshi Kitoh, Masaki Matsushita, Kenichi Mishima, Naoki Ishiguro. FGFR3-targetted therapy for short stature in achondroplasia. 60th Korean Orthopaedic Association 2016.10.19-22 (Incheon)

Hiroshi Kitoh, Kenichi Mishima, Masaki Matsushita, Naoki Ishiguro. Transplantation of culture-expanded bone marrow cells and platelet rich plasma in limb lengthening –Clinical trial and further improvement. 60th Korean Orthopaedic Association 2016.10.19-22 (Incheon)

Hiroshi Kitoh. Treatment strategies for short stature in achondroplasia. 第50回日本小児内分泌学会・第9回アジア太平洋小児内分泌学会 2016.11.16-20 (東京)

Matsushita M, Kitoh H, Mishima K, Sugiura H, Hasegawa S, Kitamura A, Ishiguro N, Ohno K. Clinically feasible dose of meclozine promotes bone growth in mouse model with achondroplasia. Annual meeting of Orthopaedic Research Society 2017.3.19-22 (San Diego)

H. 知的財産権の出願・登録状況  
(予定を含む。)

1. 特許取得

指定難病の検討資料

(病名) 2型コラーゲン異常症関連疾患

一、指定された疾病の病名等に関する資料

当該疾病は行政的に1つの疾病として取り扱うことが適当である(注1)

はい

別名がある場合は全て記載して下さい

軟骨無発生症2型(Langer-Saldino型)、扁平椎異形成症、Torrance型、

軟骨低発生症、先天性脊椎骨端異形成症(SEDC)

脊椎骨端骨幹端異形成症(SEMD) Strudwick型、Kniest骨異形成症、

脊椎末梢異形成症、早発性関節症を伴う軽症脊椎骨端異形成症、

中足骨短縮を伴う脊椎骨端異形成症(以前のCzech異形成症)

Stickler症候群1型、Stickler様症候群、Stickler骨異形成症

表記の病名も含めて医学的に最も適切な病名を記載して下さい(注2)

2型コラーゲン異常症関連疾患

主として関係する学会(注3)

日本整形外科学会、日本小児科学会、日本人類遺伝学会、日本先天異常学会

その他関係する学会(注4)

日本小児遺伝学会

(注1)一定の客観的指標を伴う診断基準を満たす患者の集合を一つの疾病単位として、多くの傷病が入りうる病態を指し示すものは適切とは言えない(例:気道狭窄など)。また、重症例や難治例のみの一つの疾病の一部を切り出した病名は適切とは言えない(例:重症膵炎 膵炎とすべき)。

(注2)科学的根拠に基づき最も適切な病名をできる限り日本語提示して下さい。必要に応じて根拠となる日本語の文献を求めます。

(注3)学会として意見を聞く場合に最も適切と考えられる日本医学会の分科会である学会名(主に成人を対象とした学会)を記入して下さい。

(注4)その他関係する学会名を記載して下さい。

二、指定された疾病について、指定難病の要件に関する資料

悪性腫瘍と関係性について以下のいずれに該当しますか 答( b )

a.悪性腫瘍である b.全く関係ない c.その他 d.定まった見解がない

c.を選択した場合は、以下に具体的に記載して下さい(例:前癌病変、悪性腫瘍を含む概念、割の患者が合併する、悪性腫瘍の側面がある、悪性腫瘍のリスクが高くなるなど)

答 ( )

精神疾患と関係性について以下のいずれに該当しますか 答( b )

a.精神疾患である b.精神疾患ではない c.その他 d.検討中、定まった見解がない

c.を選択した場合は、以下に具体的に記載して下さい(例:精神疾患という整理がされることもある、一部に精神疾患を伴うなど)

答 ( )

「発病の機構が明らかでない」ことについて以下のいずれに該当するか 答( e )

- a.外傷や薬剤の作用など、特定の外的要因によって発症する
- b.ウイルス等の感染が原因(一般的に知られた感染症状と異なる場合はチェック)
- c.何らかの疾病(原疾患)によって引き起こされることが明らかな二次性の疾病
- d.生活習慣が原因とされている
- e.原因不明または病態が未解明
- f.検討中、定まった見解がない

(混在している場合は重複回答可)

関連因子の有無について以下のいずれに該当するか 答( a )

(関連因子は、原因とは断定されないものの疫学的に有意な相関関係があるもの)

- a. 遺伝子異常 b. 薬剤 c. 生活習慣 d. その他 e. 特になし

それぞれの内容を具体的に記載して下さい(例: アルコール摂取によりオッズ比が 倍になる、遺伝的要因を示唆するデータもあるなど)

答 ( 多くは2型コラーゲン遺伝子変異が認められ、9型・11型コラーゲン遺伝子変異も報告されている )

「治療方法が確立していない」ことについて以下のいずれに該当するか 答 ( b )  
(混在している場合は複数回答可)

- a. 治療方法が全くない。  
b. 対症療法や症状の進行を遅らせる治療方法はあるが、根治のための治療方法はない。  
c. 一部の患者で寛解状態を得られることはあるが、継続的な治療が必要。  
d. 治療を終了することが可能となる標準的な治療方法が存在する  
e 定まった見解がない

注) 移植医療については、機会が限定的であることから現時点では完治することが可能な治療方法には含まないこととする。

「長期の療養を必要とする」ことについて以下のいずれに該当するか 答 ( d )  
(通常の治療を行った場合に多くの症例がたどる転帰をお答え下さい)

- a. 急性疾患  
b. 妊娠時など限られた期間のみ罹患  
c. 治療等により治癒する  
d. 発症後生涯継続または潜在する  
e. 症状が総じて療養を必要としない程度にとどまり、生活面への支障が生じない  
f. 定まった見解がない

「患者数が本邦において一定の人数に達しないこと」について以下のいずれに該当するか 答 ( a )

- a. 疫学調査等により患者数が推計できる

本邦における患者数の推計: 1,500人 このうち成人の患者数の推計: 1,000人  
根拠となった調査: 日本整形学会骨系統疾患全国登録と発生頻度から推計

- b. 本邦での確定診断例は極めて少なく、本邦での症例報告の累計からも、患者数は100人未満と予想される。また、成人の患者が確認できている。

根拠となった検索:(医中誌などで) 年~ 年の検索で合計 例の報告

成人の患者数の推計: \_\_\_\_\_ 人

- c. 本邦での確定診断例は極めて少なく、本邦での症例報告の累計からも、患者数は100人未満と予想される。成人の患者については確認できていない。

- d. 疫学調査を行っておらず患者数が推計できない

- e. 複数の疫学調査があり、ばらつきが多く推計が困難

なお、この患者数について、難治性などの接頭語を用いて疾患概念の一部を切り分けて患者数を割り出すことは適切ではない。

三、指定された疾病の診断基準、重症度分類等についての資料

診断基準について以下のいずれに該当するか 答 ( a, b, c )

- a. 学会で承認された診断基準あり (学会名: 日本整形外科学会、日本小児科学会)

- b. 研究班で作成した診断基準あり

研究班名:

- 1) 厚生労働科学研究費補助金 難治性疾患等政策研究事業(難治性疾患政策研究事業)

「国際標準に立脚した奇形症候群領域の診療指針に関する学際的・網羅的検討」班

- 2) 同 「指定難病を目指した2型コラーゲン異常症の疾患概念と診断基準の確立」班

- c. 広く一般的に用いられている診断基準あり (出典及び活用事例: 新先天奇形症候群アトラス、骨系統疾患マニュアル)

- d. 診断基準未確立または自覚症状を中心とした診断基準しかない

あるとされる場合はいずれも客観的な指標を伴い文献的根拠のある日本語の診断基準とする。原著が英語論文である場合にはその訳も含めて、日本において広く受け入れられていることを示す必要があります（学会の専門医試験で活用されていたり、ガイドラインに掲載されるなど）。

重症度分類等について以下のいずれに該当するか 答（ d ）

- a. 学会で承認された重症度分類あり
- b. 研究班で作成した重症度分類あり
- c. 広く一般的に用いられている重症度分類あり
- d. 重症度分類がない

d. を選択した場合、利用できる可能性のある指標がありましたらお示し下さい。

答（ modified Rankin Scale (mRS) の評価スケール ）

四、指定された疾病について、概要などのとりまとめられた資料別紙様式に従って記入をお願いいたします。

## 2型コラーゲン異常症関連疾患

## 概要

## 1. 概要

多くは2型コラーゲン遺伝子変異が認められ、X線的に共通した所見がある多彩な臨床表現型を示す一連の疾患群である。胎児期や出生直後に周産期死亡を起こす重症例から小児期以降に診断される比較的軽症例まで幅広い症状を呈する。常染色体優性遺伝または突然変異で発症する。椎体や長管骨の異常や顔面正中部の低形成（平坦な顔貌）、小顎症を特徴とする骨系統疾患である。全身骨X線上、脊椎・骨端異形成を特徴とし、合併症としてしばしば進行性近視・難聴・U字型の口蓋裂を伴う。

## 2. 原因

多くの患者は2型コラーゲン遺伝子 type 2 collagen 1 (COL2A1)の変異が原因である。類似した臨床表現型を示す COL11A1 変異や COL9A1、COL9A2 変異が原因も場合もある。発症機序は不明である。

## 3. 症状

胎児期や出生直後に周産期死亡を起こす重症例では、X線上長管骨の短縮と骨幹端の拡大を示し、脊椎では椎体全体または頸椎、骨盤では恥骨の非骨化、胸郭低形成が特徴である。

出生時に診断されているが周産期死亡にまでは至らない典型例や小児期以降に診断される比較的軽症例では、上記の症状は比較的軽度が見られないこともあり、X線上脊椎・骨端異形成を呈し、年齢に依存して早発性の変形性関節症合併する。顔面正中部の低形成（平坦な顔貌）と小顎症を特徴とする。感音難聴または伝音難聴が見られる事もある。硝子体・網脈絡膜変性から網膜剥離を来す場合がある。四肢体幹ともに短縮し、低身長となる。

## 4. 治療法

疾患特異的な治療法は確立されていない。重症例では呼吸管理のみの対症療法のみである。軽症例では対症療法に加えて、網膜剥離の治療が必要となる事が多い。難聴に対する早期対応も求められる。小顎症による歯列不正に対して、矯正治療を要する（健康保険の適応）。関節変形や早発性の変形性関節症に対して、整形外科的手術（骨切り術や人工関節置換術等）が行われる。

## 5. 予後

重症型では出生後早期に死亡することが多い。典型例や軽症例では低身長や脊柱側弯、早発性変形性関節症を示し歩行障害があり、日常生活が障害される。失明や難聴のリスクが高い。

## 要件の判定に必要な事項

## 1. 患者数

約1,500人

## 2. 発病の機構

不明（多くは2型コラーゲン遺伝子変異との関連が報告されている）

## 3. 効果的な治療方法

未確立（対症療法のみである）

## 4. 長期の療養

必要（発症後生涯継続し、進行性である）

## 5. 診断基準

あり（研究班作成の診断基準あり）

## 6. 重症度分類

日本小児遺伝学会・日本小児科学会の重症度分類を用いて、いずれかに相当する場合を対象とする。

## 情報提供元

・平成27年度厚生労働科学研究費補助金「指定難病を目指した2型コラーゲン異常症の疾患概念と診断基準の確立」研究班 研究代表者 兵庫医科大学産科婦人科教授 澤井英明

・日本整形外科学会 当該疾病担当者 東京大学リハビリテーション科教授 芳賀信彦

## 付属資料

### < 診断基準 >

#### 2型コラーゲン異常症関連疾患の診断基準

Definite および Probable を 2 型コラーゲン異常症関連疾患と診断する。

#### 1 主症状

- 1) 低身長
- 2) 関節変形または拘縮

#### 副症状

- 1) 小顎症または顔面中部低形成
- 2) U字型口蓋裂
- 3) 進行性近視 または網膜硝子変性
- 4) 難聴

#### 単純 X 線検査

- 1) 脊椎・骨端・骨幹端の全てまたはいずれかの異形成
- 2) 椎体または恥骨の骨化遅延

#### 遺伝学的検査

- 1) 2型コラーゲン遺伝子変異
- 2) 9型または11型コラーゲン遺伝子変異

### < 診断のカテゴリー >

Definite: 1の主症状のうち1項目以上を認め、かつ 単純 X 線検査のうち1項目以上を認め、かつ 遺伝学的検査のうちいずれか1項目を満たす場合。

Probable: 1の主症状の項目すべてを認め、かつ 副症状のうち1項目以上を認め、かつ 単純 X 線検査のうち1項目以上を満たす場合。

### < 重症度分類 >

以下の1)～4)のいずれかを満たす場合を重症とし、対象とする。

#### 1) 評価スケール

modified Rankin Scale (mRS) 日本脳卒中学会の 食事・栄養、呼吸のそれぞれの評価スケールを用いて、いずれかが3以上を対象とする。

日本版 modified Rankin Scale (mRS)

日本版 modified Rankin Scale (mRS) 判定基準書

modified Rankin Scale

参考にすべき点

- |   |   |   |
|---|---|---|
| 0 | まったく症候がない   | 自覚症状および他覚徴候がともにない状態である  |
| 1 | 症候はあっても明らかな障害はない：<br>日常の勤めや活動は行える                   | 自覚症状および他覚徴候はあるが、発症以前から行っていた仕事や活動に制限はない状態である                           |
| 2 | 軽度の障害：<br>発症以前の活動がすべて行えるわけではないが、自分の身の回りのことは介助なしに行える | 発症以前から行っていた仕事や活動に制限はあるが、日常生活は自立している状態である                              |
| 3 | 中等度の障害：<br>何らかの介助を必要とするが、歩行は介助なしに行える                | 買い物や公共交通機関を利用した外出などには介助を必要とするが、通常歩行、食事、身だしなみの維持、トイレなどには介助を必要としない状態である |
| 4 | 中等度から重度の障害：<br>歩行や身体的要求には介助が必要である                   | 通常歩行、食事、身だしなみの維持、トイレなどには介助を必要とするが、持続的な介護は必要としない                       |

い状態である

- 5 重度の障害：  
- 寝たきり、失禁状態、常に介護と見守りを必要とする
- 6 死亡  
-

常に誰かの介助を必要とする状態である。

#### 日本脳卒中学会版 食事・栄養の評価スケール

##### 食事・栄養 (N)

- 0. 症候なし。
- 1. 時にむせる、食事動作がぎこちないなどの症候があるが、社会生活・日常生活に支障ない。
- 2. 食物形態の工夫や、食事時の道具の工夫を必要とする。
- 3. 食事・栄養摂取に何らかの介助を要する。
- 4. 補助的な非経口的栄養摂取（経管栄養、中心静脈栄養など）を必要とする。
- 5. 全面的に非経口的栄養摂取に依存している。

#### 日本脳卒中学会版 呼吸の評価スケール

##### 呼吸 (R)

- 0. 症候なし。
- 1. 肺活量の低下などの所見はあるが、社会生活・日常生活に支障ない。
- 2. 呼吸障害のために軽度の息切れなどの症状がある。
- 3. 呼吸症状が睡眠の妨げになる、あるいは着替えなどの日常生活動作で息切れが生じる。
- 4. 喀痰の吸引あるいは間欠的な換気補助装置使用が必要。
- 5. 気管切開あるいは継続的な換気補助装置使用が必要。

2) 気管切開、非経口的栄養摂取（経管栄養、中心静脈栄養など）、人工呼吸器使用の場合

3) 聴覚で高度難聴以上（3以上）の場合

- 0. 25dbHL 未満（正常）
  - 1. 25dbHL 以上 40dbHL 未満（軽度難聴）
  - 2. 40dbHL 以上 70dbHL 未満（中等度難聴）
  - 3. 70dbHL 以上 90dbHL 未満（高度難聴）
  - 4. 90dbHL 以上（重度難聴）
- 500、1000、2000Hz の平均値で、聞こえが良い耳（良聴耳）の値で判断

4) 良好な方の目の矯正視力が 0.3 未満の場合

なお、症状の程度が上記の重症度分類等で一定以上に該当しない者であるが、高額な医療を継続することが必要な者については、医療費助成の対象とする。

・研究成果の刊行に関する一覧表

書籍

大園恵一, 大理石骨病, 今日の整形外科治療指針, 2016, P251.

芳賀信彦: FGFR3異常症(軟骨無形成症、軟骨低形成症、タナトフォリック骨異形成症), II型コラーゲン異常症(先天性脊椎骨端異形成症、Kniest骨異形成症、Stickler症候群1型). 小児整形外科テキスト、第2版(日本小児整形外科学会、監修)、メジカルビュー社、東京、246-251, 262-265、2016

芳賀信彦: 骨系統疾患の臨床診断、骨系統疾患国際命名・分類2010、Pyle病. 今日の整形外科治療指針、第7版(土屋弘行、紺野慎一、田中康仁、田中栄、松田秀一、編集)、医学書院、東京、220-222、222-225、255-256、2016

芳賀信彦: 先天性骨系統疾患、先天異常症候群. 標準整形外科学、第13版(中村利孝、松野丈夫、総編集)、医学書院、東京、291-306、307-316、2017

芳賀信彦: 骨系統疾患. 整形外科学テキスト、改訂第4版(高橋邦泰、芳賀信彦、編集)、南江堂、東京、341-345、2017

鬼頭浩史 FGFR3グループ概説 今日の整形外科治療指針 7版(医学書院)第7版 231-232, 2016

鬼頭浩史 軟骨無形成症 今日の整形外科治療指針 7版(医学書院)第7版 232-233, 2016

鬼頭浩史 軟骨低形成症 今日の整形外科治療指針 7版(医学書院)第7版 233-234, 2016

鬼頭浩史 濃化異骨症 今日の整形外科治療指針 7版(医学書院)第7版 252-253, 2016

鬼頭浩史 彎曲骨異形成症概説 今日の整形外科治療指針 7版(医学書院)第7版 249-250, 2016

鬼頭浩史 培養骨髄細胞移植による骨延長術 骨系統疾患 今日の整形外科治療指針 7版(医学書院) 242, 2016

鬼頭浩史 画像診断のピットフォール 小児整形外科テキスト改訂第2版(メジカルビュー社) 58-63, 2016

雑誌

Takahashi Y, Sawai H, Murotsuki J, Satoh S, Yamada T, Hayakawa H, Kouduma Y, Sase M, Watanabe A, Miyazaki O, Nishimura G. Parental serum alkaline phosphatase activity as an auxiliary tool for prenatal diagnosis of hypophosphatasia. Prenat Diagn. 2017 May;37(5):491-496.

Miyazaki O, Sawai H, Yamada T, Murotsuki J, Nishimura G. Follow-Up Study on Fetal CT Radiation Dose in Japan: Validating the Decrease in Radiation Dose. AJR Am J Roentgenol. 2017 Apr;208(4):862-867.

Saito T, Nagasaki K, Nishimura G, Wada M, Nyuzuki H, Takagi M, Hasegawa T, Amano N, Murotsuki J, Sawai H, Yamada T, Sato S, Saitoh A. Criteria for radiologic diagnosis of hypochondroplasia in neonates. Pediatr Radiol. 2016 Apr;46(4):513-8.

Calongos G, Hori M, Ogino M, Sawai H. A Case of Thanatophoric Dysplasia Type I with Fetal Hydrops in the First Trimester. Case Rep Obstet Gynecol. 2016;2016:1821230.

Ohata Y, Ozono K, Michigami T. Current concepts in perinatal mineral metabolism, Clin Pediatr Endocrinol 2016, 25(1): 9-17.

大園恵一, 低ホスファターゼ症, 小児科, 2016, 57(3): 225-261.



大園恵一, 低ホスファターゼ症の治療薬開発, 内分泌・糖尿病・代謝内科, 2016, 42(3):203-207.

Bishop N, Munns CF, Ozono K, Transformative therapy in hypophosphatasia, Arch Dis Child, 2016, 101(6):514-5.

大園恵一, 低ホスファターゼ症, 最新医学, 2016, 71(10):57-62.

大園恵一, 骨発育, 小児疾患診療のための病態生理, 2016, 48(601):584-588.

河野智敬, 鈴木秀一, 小澤綾子, 会津克哉, 道上敏美, 大園恵一, 望月弘, 経過良好な低ホスファターゼ症の臨床像と遺伝学的診断, 日本小児科学会雑誌 2016, 120(7):1066-1071.

Okazaki Y, Kitajima H, Mochizuki N, Kitaoka T, Michigami T, Ozono K, Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth, Eur J Pediatr, 2016, 175:433-437.

Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, Thompson DD, Bishop N, Hofmann C, Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia, J Clin Endocrinol Metab, 2016

Kimura T, Yamashita A, Ozono K, Tsumaki N, Limited immunogenicity of human induced pluripotent stem cell-derived cartilages, Tissue Eng Part A. 2016 Oct 31.

芳賀信彦: 骨系統疾患のリハビリテーション(特集:小児リハビリテーション - その歴史と各疾患への対応, 未来への展望について - ). Jpn J Rehabil Med 53(5):374-378, 2016

Nishimura G, Nakajima M, Takikawa K, Haga N, Ikegawa S: Distinctive skeletal phenotype in high bone mass osteogenesis imperfecta due to a COL1A2 cleavage site mutation. Am J Med Genet A 170(8):2212-2214, 2016

Hasegawa S, Nishimura G, Victoria T, Zackai E, Kayserili H, Haga N, Nakashima Y, Miyazaki O, Kitoh H: Characteristic calcaneal ossification: an additional early radiographic finding in infants with fibrodysplasia ossificans progressiva. Pediatric Radiology 46(11):1568-1572, 2016

Osamu Miyazaki, Hideaki Sawai, Takahiro Yamada, Jun Murotsuki, Gen Nishimura. Follow-Up Study on Fetal CT Radiation Dose in Japan: Validating the Decrease in Radiation Dose. American Journal of Roentgenology AJR 208:862-867; 2017

Yamada T\*, Obata-Yasuoka M, Hamada H, Baba Y, Ohkuchi A, Yasuda S, Kawabata K, Minakawa S, Hirai C, Kusaka H, Murabayashi N, Inde Y, Nagura M, Umazume T, Itakura A, Maeda M, Sagawa N, Ohno Y, Kataoka S, Fujimori K, Kudo Y, Ikeda T, Nakai A, Minakami H. Isolated gestational proteinuria preceding the diagnosis of preeclampsia - an observational study. Acta Obstet Gynecol Scand. 95:1048-54, 2016

Yamada T\*, Kawakami S, Yoshida Y, Kawamura H, Ohta S, Abe K, Hamada H, Dohi S, Ichizuka K, Takita H, Baba Y, Matsubara S, Mochizuki J, Unno N, Maegawa Y, Maeda M, Inubashiri E, Akutagawa N, Kubo T, Shiota T, Oda Y, Yamada T, Yamagishi E, Nakai A, Fuchi N, Masuzaki H, Urabe S, Kudo Y, Nomizo M, Sagawa N, Maeda T, Kamitomo M, Kawabata K, Kataoka S, Shiozaki A, Saito S, Sekizawa A, Minakami H. Influenza 2014-2015 among pregnant Japanese women: primiparous vs multiparous women. Eur J Clin Microbiol Infect Dis. 35:665-71, 2016

Umazume T, Yamada T\*, Morikawa M, Ishikawa S, Furuta I, Koyama T, Maysuno K, Minakami H. Platelet reactivity in twin pregnancies. Thromb Res 138:43-8, 2016

Umazume T, Yamada T\*, Morikawa M, Ishikawa S, Kojima T, Cho K, Masuzaki N, Minakami H. Occult fetal/maternal hemorrhage in women with pathological placenta with respect to permeability. J Obstet Gynecol Res. 42:632-9, 2016

Saito T, Nagasaki K, Nyuzaki H, Wada M, Takagi M, Hasegawa T, Amano N, Murotsuki J, Sawai H, Yamada T, Sato S, Saitoh A, Nishimura G. Criteria for Radiological Diagnosis of Hypochondroplasia in Neonates. Pediatr Radiol. 46:513-8, 2016

Nobuzane T, Yamada T, Miura K, Sawai H, Masuzaki H, Kudo Y. Survey of prenatal testing for genet

ic disorders in Japan: Recent report. *J Obstet Gynaecol Res.* 2016 Feb 18. doi: 10.1111/jog.12948. [Epub ahead of print]

Zhai T, Furuta I, Akaishi R, Ishikawa S, Morikawa M, Yamada T, Koyama T, Minakami H. Alteration of podocyte phenotype in the urine of women with preeclampsia. *Sci Rep.* 6:24258,2016

Suzumori N, Ebara T, Yamada T, Samura O, Yotsumoto J, Nishiyama M, Miura K, Sawai H, Murotsuki J, Kitagawa M, Kamei Y, Masuzaki H, Hirahara F, Saldivar JS, Dharajiya N, Sago H, Sekizawa A; Japan NIPT Consortium. Fetal cell-free DNA fraction in maternal plasma is affected by fetal trisomy. *J Hum Genet.* 2016 Mar 17. doi: 10.1038/jhg.2016.25. [Epub ahead of print] PMID: 26984559

Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J, Sakuragi N. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. *J Exp Clin Cancer Res.* 35:132,2016

Dong P, Ihira K, Xiong Y, Watari H, Hanley SJ, Yamada T, Hosaka M, Kudo M, Yue J, Sakuragi N. Re-activation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. *Oncotarget.* 7:20260-70,2016

Zhai T, Furuta I, Akaishi R, Kawabata K, Chiba K, Umazume T, Ishikawa S, Yamada T, Morikawa M, Minakami H. Feasibility of nephrinuria as a screening tool for the risk of pre-eclampsia: prospective observational study. *BMJ Open.* 6:e011229,2016

Nishiyama M, Sekizawa A, Ogawa K, Sawai H, Nakamura H, Samura O, Suzumori N, Nakayama S, Yamada T, Ogawa M, Katagiri Y, Murotsuki J, Okamoto Y, Namba A, Hamanoue H, Ogawa M, Miura K, Izumi S, Kamei Y, Sago H. Factors affecting parental decisions to terminate pregnancy in the presence of chromosome abnormalities: A Japanese multicenter study. *Prenat Diagn.* 2016 Oct 19. doi: 10.1002/pd.4947.

Hayasaka I, Cho K, Uzuki Y, Morioka K, Akimoto T, Ishikawa S, Takei K, Yamada T, Morikawa M, Yamada T, Ariga T, Minakami H. Frequency of malformed infants in a tertiary center in Hokkaido, Japan over a period of 10 years. *J Obstet Gynaecol Res.* 2016 Dec 17. doi: 10.1111/jog.13229. [Epub ahead of print]

Miyazaki O, Sawai H, Yamada T, Murotsuki J, Nishimura G. Follow-Up Study on Fetal CT Radiation Dose in Japan: Validating the Decrease in Radiation Dose. *AJR Am J Roentgenol.* 2017 Apr;208(4):862-867. doi: 10.2214/AJR.16.17316.

Takahashi Y, Sawai H, Murotsuki J, Satoh S, Yamada T, Hayakawa H, Kouduma Y, Sase M, Watanabe A, Miyazaki O, Nishimura G. Parental serum alkaline phosphatase activity as an auxiliary tool for prenatal diagnosis of hypophosphatasia. *Prenat Diagn.* 2017 Mar 22. doi: 10.1002/pd.5040.

# Distinctive Skeletal Phenotype in High Bone Mass Osteogenesis Imperfecta Due to a *COL1A2* Cleavage Site Mutation

Gen Nishimura,<sup>1\*</sup> Masahiro Nakajima,<sup>2</sup> Kazuharu Takikawa,<sup>3</sup> Nobuhiko Haga,<sup>4</sup> and Shiro Ikegawa<sup>2</sup>

<sup>1</sup>Department of Pediatric Imaging, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan

<sup>2</sup>Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan

<sup>3</sup>Department of Orthopedics, Shizuoka Children's Hospital, Shizuoka, Japan

<sup>4</sup>Department of Rehabilitation Medicine, University of Tokyo, Tokyo, Japan

Manuscript Received: 12 January 2016; Manuscript Accepted: 2 May 2016

## TO THE EDITOR:


Over 15 years ago, we encountered a family (six affected individuals) with a fragile bone disease inherited as an autosomal dominant trait. We reported the family as having a “new brittle bone disorder” in AJMG [Nishimura et al., 1999]. At that time, we presumed that the disorder differed from osteogenesis imperfecta (OI), because the clinical hallmark was bent bones rather than fractures.

We recently performed molecular analyses for the family (the proband, affected mother, and healthy father). After informed

### How to Cite this Article:

Nishimura G, Nakajima M, Takikawa K, Haga N, Ikegawa S. 2016. Distinctive skeletal phenotype in high bone mass osteogenesis imperfecta due to a *COL1A2* cleavage site mutation.

Am J Med Genet Part A 170A:2212–2214.



**FIG. 1.** Sanger sequencing for the novel C-propeptide cleavage site mutation of *COL1A2* (c.3358G>A) in the family. [Color figure can be seen in the online version of this article, available at <http://wileyonlinelibrary.com/journal/ajmga>].

consent, the DNAs of the family members were obtained. Whole exome sequencing revealed a novel C-propeptide cleavage site mutation in *COL1A2* (c.3358G>A, p.Asp1120Asn) in the proband and affected mother, which was confirmed by subsequent Sanger sequencing (Fig. 1). We report here on the recent skeletal phenotype of the proband, and also discuss the radiological characteristics of patients with mutations that impair C-propeptide cleavage of type 1 procollagen.

As we previously reported, the phenotypic variations in this family were remarkable. Affected family members had varying degrees of bone fragility and abnormal bone mineralization. The proband was a boy who was most severely affected in this family. He presented with progressive symmetric bowing of the forearms and legs despite only a few episodes of fractures. The distal femora and distal ulnae showed sharp angular deformities associated

Conflicts of interest: none.

Grant sponsor: Japan Agency for Medical Research and Development (AMED); Grant number: 14525125.

\*Correspondence to:

Gen Nishimura, M.D., Department of Pediatric Imaging, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-8561, Japan.

E-mail: gen-n@pc4.so-net.ne.jp

Article first published online in Wiley Online Library (wileyonlinelibrary.com): 5 June 2016


DOI 10.1002/ajmg.a.37744

with pseudo-fractures, the proximal fibulae were attenuated, and the right fibula showed a pseudo-fracture (Fig. 1A and B). The distal ulnae showed progressive shortening and constriction with increasing age. The bone trabecular pattern appeared coarse. He underwent corrective surgery for his leg and forearm deformities on a few occasions. His male cousin also had symmetric bowing of the forearms. Other affected individuals had very few or no fractures; yet, they all showed a coarse bone trabecular pattern.

At the last visit, the proband was 28 years old. No fracture occurred after adolescence. He never received bisphosphonate therapy. Height was 149.3 cm ( $-3.7$  SD) and weight 57.9 kg ( $-0.5$  SD). He presented with genu valgus deformities with patellar dislocation. The knee joints were sometimes painful, and knee flexion was mildly restricted. Forearm movement was mildly restricted as well. Radiological examination at age 19 years and 27 years displayed severe valgus deformities of the knee and irregular contours of the femora, tibiae and fibulae. The radii and ulnae were bowed, the proximal radii were dislocated, the distal ulnae were attenuated, and the proximal ulnae were mildly thickened. The radioulnar interosseous membranes exhibited mild ossification (Fig. 2). Radio-

graphically the bone appeared dense, but unfortunately skeletal densitometry was not performed.

Recent investigations on OI have demonstrated that mono-allelic C-propeptide cleavage site mutations in *COL1A1* and *COL1A2* and bi-allelic mutations in *BMP1* (the gene encoding a C-propeptide cleavage enzyme) constitute a distinctive subgroup of OI. These mutations interfere with the removal of the global C-terminal propeptide from the type 1 pro-collagen chain in the endoplasmic reticulum, and cause incorporation of uncleaved C-propeptides into the extracellular matrices. The morphological consequences include increased osteoid and high bone mineral density; thus the phenotype is termed “high bone mass OI” [Lindahl et al., 2011; Asharani et al., 2012; Hoyer-Kuhn et al., 2013]. The pathogenesis of the increased osteoid and increased mineralization remains elusive; however, it is assumed that the former is attributed to delayed maturation of osteoid, while the latter is due to abundant mineralization in mature osteoid [Hoyer-Kuhn et al., 2013]. Osteoclastic activities are increased as well [Hoyer-Kuhn et al., 2013; Asharani et al., 2012]. Similarly, double knock-out mice of *Bmp1* and *Tll1* (another propeptide cleaving enzyme) show not only bone fragility but also histological evidence increased osteoid seams [Muir et al., 2014].



**FIG. 2.** A: Radiographs of the knees at age 22 months: the distal femora show sharp posterior angulation. The proximal fibulae are constricted. A pseudo-fracture is noted in the right proximal fibula. B: Radiographs of the forearms at age 3 3/12 years: The radii and ulnae are mildly bowed. The distal ulnae are constricted along with pseudo-fractures. C: Radiographs of the knees at age 19 years: Valgus deformity is remarkable. Irregular contours are seen in the left femur and right tibia. D: Radiographs of the forearms at age 27 years: The radii and ulnae are bowed, and the proximal radii are dislocated. The distal ulnae are narrow, while the proximal ulnae appear mildly thick. Mild ossification is seen in the radioulnar interosseous membranes. A and B are reproduced from AJMG 84:320–329 [1999] by permission of the publisher.

In the high bone mass OI, osteosclerosis is progressive with age, and may not be easily identifiable in younger patients. In the present patient, osteosclerosis did not initially come to our attention. In retrospect, however, sclerotic changes were discernible in the long bones, particularly the femora, radii and ulnae. His recent radiographs demonstrated more clearly the presence of osteosclerosis in the long bones (Fig. 2). His other skeletal hallmarks, including coarse trabeculae, pseudo-fractures, and metaphyseal constriction are quite similar to those of patients with *BMP1* mutations [Asharani et al., 2012; Cho et al., 2015]. Thus, these skeletal changes are likely to be an essential component in the high bone mass OI, which are probably related to hyperosteoidosis (increased osteoid) and/or increased osteoclastic activity.

From the clinical viewpoint, the high bone mass OI belongs to a benign form of OI spectrum [Lindahl et al., 2011; Asharani et al., 2012; Hoyer-Kuhn et al., 2013]. Fractures are not so frequent, deformities are not severely progressive, blue sclera and dentinogenesis imperfecta are absent, and short stature absent or mild, as was seen in the present patient. The benign clinical course is quite different from severe or lethal outcome in the other subset of dense bone OI due to C-propeptide mutations at the non-cleavage site [Pace et al., 2002; Takagi et al., 2011].

In conclusion, a phenotypically distinctive group of OI is caused by a mono-allelic *COL1* C-propeptide cleavage site mutations and biallelic *BMP1* mutations. The subgroup is characterized by high bone mass and other unique skeletal changes, such as coarse trabeculae, pseudo-fractures, and metaphyseal constriction.

## ACKNOWLEDGMENT

This study is supported by research grants from Japan Agency For Medical Research and Development (AMED) (contract No. 14525125).

## REFERENCES

- Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, Yigit G, Pohl E, Becker J, Frommolt P, Sonntag C, Altmüller J, Zimmermann K, Greenspan DS, Akarsu NA, Netzer C, Schönau E, Wirth R, Hammerschmidt M, Nürnberg P, Wollnik B, Carney TJ. 2012. Attenuated *BMP1* function compromises osteogenesis, leading to bone fragility in humans and zebrafish. *Am J Hum Genet* 90:661–674.
- Cho SY, Asharani PV, Kim OH, Iida A, Miyake N, Matsumoto N, Nishimura G, Ki CS, Hong G, Kim SJ, Sohn YB, Park SW, Lee J, Kwun Y, Carney TJ, Huh R, Ikegawa S, Jin DK. 2015. Identification and in vivo functional characterization of novel compound heterozygous *BMP1* variants in osteogenesis imperfecta. *Hum Mutat* 36:191–195.
- Hoyer-Kuhn H, Semler O, Schoenau E, Roschger P, Klaushofer K, Rauch F. 2013. Hyperosteoidosis and hypermineralization in the same bone: Bone tissue analyses in a boy with a homozygous *BMP1* mutation. *Calcif Tissue Int* 93:565–570.
- Lindahl K, Barnes AM, Fratzl-Zelman N, Whyte MP, Hefferan TE, Makareeva E, Brusel M, Yaszemski MJ, Rubin CJ, Kindmark A, Roschger P, Klaushofer K, McAlister WH, Mumm S, Leikin S, Kessler E, Boskey AL, Ljunggren O, Marini JC. 2011. *COL1* C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. *Hum Mutat* 32:598–609.
- Muir AM, Ren Y, Butz DH, Davis NA, Blank RD, Birk DE, Lee SJ, Rowe D, Feng JQ, Greenspan DS. 2014. Induced ablation of *Bmp1* and *Tll1* produces osteogenesis imperfecta in mice. *Hum Mol Genet* 23:3085–3101.
- Nishimura G, Haga N, Aoki K, Hamazaki M, Taniguchi K, Iwaya T. 1999. New brittle bone disorder: Report of a family with six affected individuals. *Am J Med Genet* 84:320–329.
- Pace JM, Chitayat D, Atkinson M, Wilcox WR, Schwarze U, Byers PH. 2002. A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the pro $\alpha$ 1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases. *J Med Genet* 39:23–29.
- Takagi M, Hori N, Chinen Y, Kurosawa K, Tanaka Y, Oku K, Sakata H, Fukuzawa R, Nishimura G, Spranger J, Hasegawa T. 2011. Heterozygous C-propeptide mutations in *COL1A1*: Osteogenesis imperfecta type IIC and dense bone variant. *Am J Med Genet Part A* 155A:2269–2273.

## Case Report

# A Case of Thanatophoric Dysplasia Type I with Fetal Hydrops in the First Trimester

Giannina Calongos,<sup>1</sup> Masateru Hori,<sup>1</sup> Mai Ogino,<sup>1</sup> and Hideaki Sawai<sup>2</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Meiwa General Hospital, Nishinomiya 663-8186, Japan

<sup>2</sup>Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan

Correspondence should be addressed to Giannina Calongos; [calongos.g@meiwa-hospital.com](mailto:calongos.g@meiwa-hospital.com)

Received 6 January 2016; Revised 26 January 2016; Accepted 26 January 2016

Academic Editor: Giovanni Monni

Copyright © 2016 Giannina Calongos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

During a routine prenatal exam, a 36-year-old female in her third pregnancy was diagnosed with fetal hydrops at 11 weeks of gestation. The pregnancy was monitored with periodic ultrasounds; however, spontaneous resolution was not observed. Amniotic fluid examination at 16 weeks of gestation showed a normal karyotype; however, macrocephaly, a narrow thorax, and shortening of the long bones were observed on ultrasonography. With the strong suspicion of a fetal skeletal disease, specifically thanatophoric dysplasia (TD), and after extensive genetic counseling, termination of the pregnancy was performed per the parents' wishes with mechanical cervical dilation and gemeprost (PGE1) administration. Following delivery, the fetus was found to have macrocephaly, a narrow bell-shaped thorax, and a protuberant abdomen, as well as curved long bones, H-shaped platyspondyly, and curved clavicles on skeletal radiography. As a result, the fetus was diagnosed with TD type I. This case illustrates that although TD is a rare disease, an accurate prenatal diagnosis can be made with the use of ultrasonography.

## 1. Introduction

Thanatophoric dysplasia (TD) is a rare and lethal skeletal dysplasia with an estimated incidence of 1 in 20000 to 40000 births [1] and was first described by Maroteaux et al. in 1967 [2]. TD can be classified into two types: type I is characterized by micromelia with bowed femurs and, uncommonly, the presence of cloverleaf skull deformity; type II is characterized by micromelia with straight femurs and moderate to severe cloverleaf skull deformity [3]. A common feature to both types is the presence of a narrow thorax which causes respiratory failure shortly after birth [4, 5].

Fetal hydrops is defined as an abnormal fluid collection in two or more areas of the fetal body. It can be further classified as immune or nonimmune. Immune fetal hydrops develops due to fetal hemolysis secondary to incompatibility of maternal and fetal blood type. Nonimmune hydrops, on the other hand, can result from a large number of causes [6, 7]. However, 20–30% of hydrops is of unknown etiology.

Here, we report a case of TD type I with fetal hydrops diagnosed in the first trimester and thereafter shortening

of the long bones and macrocephaly. Confirmation of the diagnosis was made by clinical examination and radiologic studies after delivery.

## 2. Case Presentation

A 36-year-old female in her third pregnancy came to our hospital at 8 weeks of gestation for a routine prenatal check. The couple and their previous children's past and family histories were unremarkable. Ultrasonographic examination at 8 weeks of gestation was unremarkable, with a crown-rump length (CRL) of 15.9 mm. At 11 weeks of gestation, although the CRL was 49.6 mm corresponding to gestational age, fetal hydrops was evident on ultrasonography (Figure 1(a)). Since screening for immune hydrops and congenital infections were negative, a transvaginal ultrasound was performed the following week for further evaluation. At 12 weeks of gestation, appropriate fetal growth was observed with a CRL of 60 mm; however, fetal hydrops was still present. The couple was counseled on the different etiologies of fetal hydrops; however, at this point the cause was not clear.






FIGURE 1: Fetal ultrasound with skin edema in the posterior part of the head and vertebral column (→) (a). A longitudinal view of the head and the thorax demonstrating skin edema in the posterior part of the neck (→), macrocephaly, and narrow thorax (b). Fetal ultrasound showing short curved femur (→) (c). A three-dimensional image with a view of the upper limbs showing bowed humerus (→) (d).

At 13 weeks of gestation the biparietal diameter (BPD) was measured to be 27.4 mm, corresponding to the 95th percentile. From this week on macrocephaly was observed and a narrow thorax was suspected on subsequent ultrasonographies (Figure 1(b)). At 16 weeks of gestation, amniotic fluid examination showed a normal karyotype (46XX); however, a routine and a four-dimensional ultrasound revealed shortening and bowing of the long bones (femur length (FL) 11.6 mm) (Figures 1(c) and 1(d)) with no subsequent improvement. As a result, a fetal skeletal disease, specifically TD, was strongly suspected. At 20 weeks of gestation, the FL was 1.18 cm, compatible with less than the 5th percentile. Also, the BPD was 5.3 cm, corresponding to more than the 95th percentile. During genetic counseling, a molecular analysis was suggested to the parents in order to make an accurate prenatal diagnosis of TD; however, they opted not to pursue this exam and decided on termination of the pregnancy, instead. The patient was then hospitalized and underwent mechanical cervical dilation. The following day gemeprost (PGE1) was administered intravaginally every three hours. A 400 g female fetus was delivered dead at 20 weeks and 2 days of gestation (Figure 2). All limbs were noted to be extremely short with redundant skin folds. Macrocephaly was evident. A narrow bell-shaped thorax with short ribs

and a protuberant abdomen were noticed; however, the skull and facial characteristics were within normal limits. Skeletal radiography showed telephone receiver-like curved femurs and humeri accompanied by irregular metaphyses, an H-shaped platyspondyly, and curved clavicles (Figure 3). No cloverleaf skull deformity was observed. These characteristics confirmed the diagnosis of TD type I.

### 3. Discussion

The incidence of immune hydrops has decreased due to routine screening and prophylaxis; however, the mortality rate of nonimmune hydrops, during either the fetal or the neonatal period, is up to 75.5% [8]. Although fetal hydrops is considered to be a nonspecific finding on obstetric ultrasounds, previous reports showed that an increased nuchal translucency (NT) and hydrops are common features of serious skeletal dysplasia [9]. Moreover, previous cases of TD reported a NT of 3.4–6.5 mm by 14 weeks of gestation which correlates with the 5.7 mm observed in this case [9].

As previous studies reported, 40–80% of TD cases can be correctly diagnosed by ultrasonography in the prenatal period [10]. Limb shortening in TD is also sonographically apparent from as early as 13 weeks of gestation. Similarly,



FIGURE 2: Female fetus of 20 weeks of pregnancy with short limbs and redundant skin folds. Also, macrocephaly, narrow bell-shaped thorax, and protuberant abdomen were noticed. Skull and facial characteristics were normal.




FIGURE 3: Anteroposterior and lateral radiographs of the fetus showing telephone receiver-like curved femurs and humeri with irregular metaphyses, H-shaped platyspondyly, and curved clavicles. No cloverleaf skull deformity was observed.

head circumference (HC) is increased throughout gestation, a feature that is present as early as the first trimester [10]. With the evidence of short limbs, a hypoplastic thorax, and macrocephaly, we strongly suspected a skeletal disease as TD.

Published reports have used a femur length/abdominal circumference (FL/AC) ratio  $<0.16$  as a predictor for lethal skeletal dysplasia [11]. Also, a hypoplastic thorax is suspected with a thoracic circumference of less than 5% at the level of the four-chamber view of the heart or a thoracic-AC ratio of less than 0.79 [12]. In this case the FL/AC ratio was 0.103 (0.82 cm/7.9 cm) and 0.0769 (1.18 cm/15.34 cm) at 13 and 20 weeks of pregnancy, respectively. A narrow bell-shaped thorax was suspected as early as 13 weeks of pregnancy.

TD is the most frequent lethal skeletal dysplasia caused by mutation of the fibroblast growth factor 3 (FGFR3) gene [13, 14]. Although molecular analysis of fetal cells to detect Arg248Cys, Tyr373Cys, Lys650Glu, and other specific mutations enables an accurate prenatal diagnosis of TD [1], it was not performed in this case per the couple's wishes. However, since limb shortening is associated with a 2.7 relative risk for trisomy 21 [4] and a case of TD type I presented with trisomy 21 was reported previously [15], we considered an amniocentesis at 16 weeks of gestation important to perform. TD is an autosomal dominant genetic disease; however, it is almost always caused by a de novo mutation in FGFR3 [3]. As a result, a general empiric recurrence risk is estimated in only 2% [16]. This fact is important to consider in order to relieve parental anxiety over future pregnancies. After counseling, the patient had a fourth pregnancy without complications and delivered a normal female baby at term.

In summary, even though TD is a rare condition, ultrasonography can be used to obtain an accurate prenatal diagnosis and facilitate early parental counseling.

### Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

### References

- [1] H. Sawai, S. Komori, A. Ida, T. Henmi, T. Bessho, and K. Koyama, "Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results," *Prenatal Diagnosis*, vol. 19, no. 1, pp. 21–24, 1999.
- [2] P. Maroteaux, M. Lamy, and J. M. Robbert, "Le nanisme thanatophore," *La Presse Médicale*, vol. 49, pp. 2519–2524, 1967.
- [3] B. Karczeski and G. R. Cutting, "Thanatophoric dysplasia," in *GeneReviews*, NCBI Bookshelf, 2013.
- [4] G. Nishimura, J. Murotsuki, and H. Sawai, "Fetal diagnosis and perinatal management of skeletal dysplasias. Medical View," *Sawai H. Fetal diagnosis and perinatal management of skeletal dysplasias. Medical View*, p. 122, 2011.
- [5] S. M. Nikkel, N. Major, and W. J. King, "Growth and development in thanatophoric dysplasia—an update 25 years later," *Clinical Case Reports*, vol. 1, no. 2, pp. 75–78, 2013.
- [6] K. Amano and Y. Ushibashi, *Compact Atlas of Obstetrics and Gynecology Ultrasound*, Vector Core, 2012.
- [7] W. Yeom, E. S. Paik, J.-J. An et al., "Clinical characteristics and perinatal outcome of fetal hydrops," *Obstetrics & Gynecology Science*, vol. 58, no. 2, pp. 90–97, 2015.
- [8] M. E. Abrams, K. S. Meredith, P. Kinnard, and R. H. Clark, "Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death," *Pediatrics*, vol. 120, no. 1, pp. 84–89, 2007.
- [9] A. Khalil, E. Pajkrt, and L. S. Chitty, "Early prenatal diagnosis of skeletal anomalies," *Prenatal Diagnosis*, vol. 31, no. 1, pp. 115–124, 2011.
- [10] L. S. Chitty, A. Khalil, A. N. Barrett, E. Pajkrt, D. R. Griffin, and T. J. Cole, "Safe, accurate, prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA," *Prenatal Diagnosis*, vol. 33, no. 5, pp. 416–423, 2013.



- [11] A. Rahemtullah, B. McGillivray, and R. D. Wilson, "Suspected skeletal dysplasias: femur length to abdominal circumference ratio can be used in ultrasonographic prediction of fetal outcome," *American Journal of Obstetrics and Gynecology*, vol. 177, no. 4, pp. 864–869, 1997.
- [12] A. Johnson, N. A. Callan, and V. K. Bhutani, "Ultrasonic ratio of fetal thoracic to abdominal circumference: an association with fetal pulmonary hypoplasia," *American Journal of Obstetrics & Gynecology*, vol. 157, no. 3, pp. 764–769, 1987.
- [13] P. L. Tavormina, R. Shiang, L. M. Thompson et al., "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3," *Nature Genetics*, vol. 9, no. 3, pp. 321–328, 1995.
- [14] L. Legeai-Mallet, C. Benoist-Lasselien, A.-L. Delezoide, A. Munnich, and J. Bonaventure, "Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia," *The Journal of Biological Chemistry*, vol. 273, no. 21, pp. 13007–13014, 1998.
- [15] T. Yamada, H. Sawai, G. Nishimura, H. Numabe, K. Cho, and H. Minakami, "Platyspondylic lethal skeletal dysplasia San Diego type (thanatophoric dysplasia type 1) associated with trisomy 21 presenting with nuchal translucency: a case report," *Prenatal Diagnosis*, vol. 29, no. 7, pp. 715–717, 2009.
- [16] N. S. Naveen, B. V. Murlimanju, V. Kumar, T. Pulakunta, and H. Jeeyar, "Thanatophoric dysplasia: a rare entity," *Oman Medical Journal*, vol. 26, no. 3, pp. 196–197, 2011.



**Hindawi**  
Submit your manuscripts at  
<http://www.hindawi.com>



## ORIGINAL ARTICLE

# Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia

Takuo Kubota, Wei Wang, Kohji Miura, Hirofumi Nakayama, Keiko Yamamoto, Makoto Fujiwara, Yasuhisa Ohata, Makiko Tachibana, Taichi Kitaoka, Satoshi Takakuwa, Yoko Miyoshi, Noriyuki Namba and Keiichi Ozono

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan

## Summary

**Objective** Serum amino-terminal propeptide of C-type natriuretic peptide (NT-proCNP) levels have been proposed as a biomarker of linear growth in healthy children. The usefulness of NT-proCNP in patients with achondroplasia (ACH)/hypochondroplasia (HCH) remains to be elucidated. The objective was to study whether serum NT-proCNP level is a good biomarker for growth in ACH/HCH and other patients of short stature.

**Design** This was a longitudinal cohort study.

**Patients** Sixteen children with ACH (aged 0.4–4.3 years), six children with HCH (2.7–6.3 years), 23 children with idiopathic short stature (ISS) (2.2–9.0 years), eight short children with GH deficiency (GHD) (2.9–6.8 years) and five short children born small for gestational age (SGA) (2.0–6.6 years). Patients with ACH/HCH received GH treatment for 1 year.

**Measurements** Serum NT-proCNP levels and height were measured.

**Results** NT-proCNP levels positively correlated with height velocity in these short children ( $P < 0.05$ ,  $r = 0.27$ ). NT-proCNP levels inversely correlated with age in children with ISS alone ( $P < 0.01$ ,  $r = -0.55$ ). Serum NT-proCNP levels in patients with ACH/HCH were increased 3 months following the initiation of GH treatment ( $P < 0.05$ ). Height SDS gain during GH treatment for 1 year was positively correlated with the changes in NT-proCNP levels after the initiation of GH ( $P < 0.01$ ,  $r = 0.72$ ).

**Conclusion** Serum NT-proCNP levels may be a good biomarker to indicate the effect of GH treatment on growth in patients with ACH/HCH at least in the first year and height velocity in short stature patients.

(Received 11 August 2015; returned for revision 7 December 2015; finally revised 22 December 2015; accepted 19 January 2016)

## Introduction

C-type natriuretic peptide (CNP) has been shown to be a critical determinant of body height and length.<sup>1,2</sup> Studies in genetically modified mice have revealed that defects of the genes coding for CNP and natriuretic peptide receptor 2 (Npr2), the cognate receptor for CNP, result in dwarfism<sup>3,4</sup>; both the ligand and its receptor are expressed in the growth plate as well as in other tissues.<sup>5</sup> In humans, loss-of-function mutations in the *NPR2* gene cause an autosomal recessive skeletal dysplasia known as acromesomelic dysplasia, Maroteaux type (AMDM) (OMIM #602875), characterized by severe short stature with disproportionate shortened limbs. Heterozygous loss-of-function mutations in the gene have been recently identified in patients with idiopathic short stature (ISS).<sup>6,7</sup>

In contrast, overproduction of CNP in transgenic mice gives rise to excessive growth<sup>8</sup> and a similar phenotype is observed in patients with the overexpression of CNP due to chromosomal translocations.<sup>9,10</sup> We have established the disease entity of a heterozygous gain-of-function mutation in the *NPR2* gene in a family with tall stature (OMIM #615923), which was replicated in mice with overexpression of the activating mutation in cartilage.<sup>11</sup> Functional analyses demonstrated that the gain-of-function mutation increases maximal enzymatic velocity and blocks desensitization of NPR2.<sup>12</sup> Two additional families with tall stature have been described that harbour gain-of-function mutations in the *NPR2* gene.<sup>13,14</sup> These human and mouse genetic studies have shed light on the role of the CNP and NPR2 signalling pathway in determining growth and height.

Achondroplasia (ACH) (OMIM #100800) is the most common form of short-limb dwarfism in humans, affecting more than 250 000 individuals worldwide.<sup>15</sup> ACH and the milder form, hypochondroplasia (HCH) (OMIM #146000), occur because of constitutively active mutations in the fibroblast growth factor receptor 3 (*FGFR3*) gene, which influence the proliferation and differentiation of chondrocytes in growth plates. GH treatment improves height velocity at least during the first year and is approved in Japan for ACH and HCH patients with height standard deviation scores (SDS) below  $-3.0$  SD.<sup>16–20</sup> However, a biomarker to predict growth stimulated by GH treatment remains to be established.

Correspondence: Takuo Kubota, Department of Pediatrics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel.: +81 6 6879 3932; Fax: +81 6 6879 3939; E-mail: tkubota@ped.med.osaka-u.ac.jp

The amino-terminal propeptide of CNP (NT-proCNP) is an equimolar product of CNP biosynthesis<sup>21</sup> and is more easily measured in serum because of its longer half-life compared to CNP.<sup>22,23</sup> Serum NT-proCNP levels have been recently reported to correlate with height velocity and change with age in healthy children.<sup>23,24</sup> In addition, serum NT-proCNP levels have been proposed as a novel biomarker of growth during GH treatment in patients with ISS and GH deficiency (GHD),<sup>25,26</sup> although age-associated changes in these levels have not been proven in ISS patients. In the current study, we determined the association of serum NT-proCNP levels with age in ISS patients and the relationship between response to GH treatment and height gain in patients with ACH/HCH.

## Subjects and methods

### Subjects

This study included 58 prepubertal patients who attended Osaka University Hospital, Osaka, Japan, from January 2009 through December 2013 and who were diagnosed with ACH, HCH, ISS, GH-deficient short stature and short stature born small for gestational age (SGA). Patients treated with GH and other drugs related to growth before and at the first visit were excluded. The diagnostic criteria for ACH included short stature, shortened limbs, abnormal facial features (prominent forehead, nasal root depression, mid-face hypoplasia and mandibular protrusion), an enlarged head size, and trident hands as clinical signs, and thick and short long bones, metaphyseal cupping, bullet-shaped vertebra, fibula that are longer than the tibia, decreased distance of lumbar spine pedicles, a large cranial base yet with small facial bones, a small ischial notch and a small cavity of the lesser pelvis as radiographic signs.<sup>27</sup> An ACH patient with a traumatic acute epidural haematoma was excluded. Patients with HCH were diagnosed based on clinical and radiographic findings similar to but milder than those with ACH and the p.N540K mutation in the *FGFR3* gene on genetic analysis. The diagnostic criteria for GH-deficient short stature were the following: proportional short children with height SDS below  $-2.0$ , GH peak values less than  $4.29 \mu\text{g/l}$  in two different provocation tests measured using a chemiluminescent enzyme immunoassay (Beckman Coulter) and no clinical and biochemical evidence of other disorders. The diagnostic criteria for short stature born SGA were the following: both birth length and weight for gestational age less than the 10th percentile, either birth length or weight SDS for gestational age less than  $-2.0$ , height SDS less than  $-2.0$  at the age of 2 years and no clinical or biochemical findings of other disorders including GHD. Patients with ISS exhibited a proportional short stature with height SDS below  $-2.0$  and lacked any features and findings of disorders with short stature, including GHD, other endocrine disorders, short stature born SGA, skeletal dysplasias, malformation syndromes and malnutrition.

Sixteen patients with ACH (8 boys, 8 girls) were included in the current study. Gene analysis in 13 of these patients revealed that all had p.G380R mutation in *FGFR3*. Median age and

height SDS in patients with ACH was 3.1 years (minimum 0.4, 25th percentile 2.9, 75th percentile 3.4, maximum 4.3) and  $-5.2$  (interquartile range:  $-5.7$  to  $-4.2$ ), respectively. Six patients with HCH (3 boys, 3 girls) were included: median age 3.2 years (2.7, 2.9, 4.1, 6.3) and height SDS  $-3.3$  ( $-4.3$  to  $-2.3$ ). GH treatment is approved in Japan for both patients with ACH and HCH over the age of 3 with height SDS below  $-3.0$ , at a dose of  $0.35 \text{ mg/kg/week}$  ( $50 \mu\text{g/kg/day}$ ). Fifteen of the ACH/HCH patients (11 ACH; 4 HCH) with GH treatment and 1-year follow-up were included where serum NT-proCNP levels were examined after the initiation of GH treatment. Mean height SDS increased significantly from  $-4.8$  (1.0) [mean (SD)] to  $-4.3$  (1.2) after GH treatment for 1 year. The remaining seven patients with ACH/HCH were not included for studies after the initiation of GH treatment due to the following reasons: two patients with ACH and two patients with HCH did not meet the criteria for GH treatment; two patients with ACH moved to a new location and were not followed up; one patient with ACH had GH treatment for a very short time. Twenty-three patients with ISS (14 boys, 9 girls) were included in this study: median age 5.4 years (2.2, 3.7, 6.7, 9.0) and height SDS  $-2.5$  ( $-2.6$  to  $-2.2$ ). The study also included eight GH-deficient short patients (all boys) [median age 4.5 years (2.9, 4.0, 5.4, 6.8) and height SDS  $-2.9$  ( $-3.1$  to  $-2.5$ )] and five short stature born SGA patients (2 boys, 3 girls) [median age 3.0 years (2.0, 2.3, 5.8, 6.6) and height SDS  $-2.4$  ( $-3.1$  to  $-2.2$ )].

### Measurements

Laboratory measurements included serum levels of alkaline phosphatase (AP) (reference range:  $134\text{--}359 \text{ U/l}$  for adults) and IGF-1 [for reference range see<sup>28</sup>]. Serum NT-proCNP levels were measured using an ELISA method (Biomedica, Austria). Measurement of serum NT-proCNP levels was approved by the Institutional Review Board at Osaka University Hospital, and written informed consent was obtained from parents or guardians of the patients.

### Statistical analysis


Data were analysed by Wilcoxon rank-sum test, regression analysis, paired *t*-test or Smirnov-Grubbs' test using JMP (SAS Institute, Cary, NC, USA) and R (GNU General Public License, Free Software Foundation, Inc., Boston, MA, USA) statistical software.

## Results

### Serum NT-proCNP levels in patients with ACH/HCH, ISS, GHD and short stature born SGA

Serum NT-proCNP levels were positively correlated with height velocity in prepubertal patients with short stature (Fig. 1a), implying that the serum NT-proCNP level can be a biomarker of growth in short children independently of their pathogenesis. As the numbers of patients with GHD and short stature born SGA were small, we subsequently focused on patients with





**Fig. 1** Serum NT-proCNP levels in patients with short stature. (a) Height velocity positively correlates with serum NT-proCNP levels in prepubertal short children with ACH, HCH, ISS, GHD and SGA ( $P < 0.05$ ,  $r = 0.27$ ,  $n = 58$ ). (b) Serum NT-proCNP levels were negatively correlated with age in ISS children ( $P < 0.01$ ,  $r = -0.55$ ,  $n = 23$ ).

ACH/HCH and ISS. On division of ISS patients into two subgroups by the median age of the group, serum NT-proCNP levels were higher in those  $<5.4$  years of age (median [interquartile range]: 12.0 [10.8–16.6]) compared to those  $>5.4$  years of age (10.0 [5.2–10.5]). Consistently, serum NT-proCNP levels were negatively correlated with age in ISS children (Fig. 1b). Unlike in ISS patients, there was no obvious correlation between serum NT-proCNP levels and age in patients with ACH/HCH, probably due to small distribution of age (data not shown). In addition, serum NT-proCNP levels in patients with ACH/HCH ( $n = 15$ ; median [interquartile range], 12.8 [9.2–16.3]) and ACH alone (11; 12.8 [9.2–16.3]) were similar to those in patients with ISS (5; 12.2 [11.1–17.0]) at 3 years of age, implying that CNP production is comparable between patients with ACH/HCH and ISS, at least at that age, even though there was a difference in height SDS between ACH/HCH or ACH alone and ISS.


#### Association of serum NT-proCNP levels with growth during GH treatment in patients with ACH/HCH

Serum NT-proCNP levels were assessed in patients with ACH/HCH before and after the initiation of GH treatment to determine the effect of GH on serum NT-proCNP levels. Serum NT-proCNP levels were increased in patients with ACH/HCH 3 months following the initiation of GH, which is consistent with increments in serum IGF-1 SDS and AP levels induced by GH (Fig. 2a–c). To test whether serum NT-proCNP levels can be a good biomarker of the effect of GH treatment on growth in


patients with ACH/HCH, we examined the association of an increase in serum NT-proCNP levels following the initiation of GH treatment with height gain after 1 year of treatment. When patients with ACH/HCH were divided into subgroups with respect to their increase in serum NT-proCNP levels 3 months after the initiation of GH (lower and upper subgroups), the increase in height SDS was larger after 12 months' treatment in the subgroup with the higher increase in serum NT-proCNP levels (Figure 3a). In addition, the change in height SDS 1 year after GH treatment was positively correlated with fold change in NT-proCNP 3 months after the treatment (Fig. 3b). The association of NT-proCNP levels with height gain may differ between patients with ACH and HCH, as growth response to GH treatment in patients with HCH has been reported to be larger than that in patients with ACH.<sup>29</sup> We therefore examined this association in patients with ACH alone. The results in these patients were similar to those in patients with ACH/HCH; that is, the increase in serum NT-proCNP levels was positively correlated with height gain following the initiation of GH treatment (Fig. 4a, b). On the other hand, the association of height gain with an increment in serum IGF-1 SDS or AP levels following the initiation of GH treatment was not observed in patients with ACH/HCH (Figure 3c–f) or ACH alone (Fig. 4c–f), although these markers increased after GH treatment.

#### Discussion


Our study confirms that serum NT-proCNP levels are positively correlated with height velocity in children with short stature. In



**Fig. 2** Increase in serum NT-proCNP levels, IGF-1 SDS and AP levels of patients with ACH/HCH following the initiation of GH treatment. (a) NT-proCNP ( $P < 0.05$ ), (b) IGF-1 SDS ( $P < 0.01$ ), (c) and AP ( $P < 0.05$ ) levels were increased in patients with ACH ( $n = 11$ )/HCH ( $n = 4$ ) 3 months after the initiation of GH treatment compared to prior to treatment. Bold lines show mean  $\pm$  SD. ACH, achondroplasia; AP, alkaline phosphatase; HCH, hypochondroplasia; mo, month; NT-proCNP, amino-terminal propeptide of C-type natriuretic peptide; SDS, standard deviation score.



**Fig. 3** Association of  $\Delta$  Ht SDS with serum NT-proCNP level, IGF-1 SDS and AP level following the initiation of GH treatment in patients with ACH ( $n = 10$ )/HCH ( $n = 4$ ). Upper panels show box plots and lower panels correlation. (a) When patients were divided into subgroups [lower ( $n = 7$ ) and upper ( $n = 7$ )] according to a 35% cut-off increase in NT-proCNP level 3 months after starting GH treatment,  $\Delta$  Ht SDS was significantly ( $P < 0.05$ ) higher 1 year after GH treatment in the upper compared to the lower subgroup. (b)  $\Delta$  Ht SDS 1 year after GH treatment was positively correlated with fold change of serum NT-proCNP 3 months after GH treatment ( $P < 0.01$ ,  $r = 0.72$ ,  $n = 13$ ). (c) When patients were divided into subgroups [lower ( $n = 7$ ) and upper ( $n = 7$ )] according to a 1.7 cut-off increase in IGF-1 SDS 3 months after starting GH treatment,  $\Delta$  Ht SDS was comparable in the subgroups. (d)  $\Delta$  Ht SDS 1 year after GH treatment was not correlated with  $\Delta$  serum IGF-1 SDS 3 months after GH treatment. (e) When patients were divided into subgroups [lower ( $n = 7$ ) and upper ( $n = 7$ )] according to a 10% cut-off increase in serum AP 3 months after starting GH treatment,  $\Delta$  Ht SDS was comparable in the subgroups. (f)  $\Delta$  Ht SDS 1 year after GH treatment was not significantly correlated with fold change of serum AP 3 months after GH treatment. ACH, achondroplasia; AP, alkaline phosphatase; HCH, hypochondroplasia; NT-proCNP, amino-terminal propeptide of C-type natriuretic peptide; SDS, standard deviation score.



**Fig. 4** Association of  $\Delta$  Ht SDS with serum NT-proCNP level, IGF-1 SDS and AP level following the initiation of GH treatment in patients with ACH ( $n = 10$ ). Upper panels show box plots and lower panels correlation. (a) When patients were divided into subgroups [lower ( $n = 5$ ) and upper ( $n = 5$ )] according to a 20% cut-off increase in NT-proCNP level 3 months after starting GH treatment,  $\Delta$  Ht SDS was significantly ( $P < 0.05$ ) higher 1 year after GH treatment in the upper compared to the lower subgroup. (b)  $\Delta$  Ht SDS 1 year after GH treatment was positively correlated with fold change of serum NT-proCNP 3 months after GH treatment ( $P < 0.05$ ,  $r = 0.67$ ,  $n = 10$ ). (c) When patients were divided into subgroups [lower ( $n = 5$ ) and upper ( $n = 5$ )] according to a 2.2 cut-off increase in IGF-1 SDS 3 months after starting GH treatment,  $\Delta$  Ht SDS was comparable in the subgroups. (d)  $\Delta$  Ht SDS 1 year after GH treatment was not correlated with  $\Delta$  serum IGF-1 SDS 3 months after GH treatment. (e) When patients were divided into subgroups [lower ( $n = 5$ ) and upper ( $n = 5$ )] according to a 7% cut-off increase in serum AP 3 months after starting GH treatment,  $\Delta$  Ht SDS was comparable in the subgroups. (f)  $\Delta$  Ht SDS 1 year after GH treatment was not significantly correlated with fold change of serum AP 3 months after GH treatment. ACH, achondroplasia; AP, alkaline phosphatase; HCH, hypochondroplasia; NT-proCNP, amino-terminal propeptide of C-type natriuretic peptide; SDS, standard deviation score.

addition, we showed the increase in NT-proCNP following the initiation of GH treatment in patients with ACH/HCH was significantly correlated with the gain in height velocity. A similar study has reported that changes in NT-proCNP levels are positively correlated with growth velocity in the first year of GH treatment in ISS patients.<sup>25</sup> Therefore, CNP production in response to GH treatment may be maintained even in chondrocytes carrying the *FGFR3* mutation.

Serum NT-proCNP levels were increased 3 months following the initiation of GH treatment in patients with ACH/HCH, as well as serum IGF-1 SDS and AP levels, indicating that CNP is produced in response to GH and/or IGF-1 stimulation in these patients. This is in agreement with previous reports on the effect of GH treatment in ISS and GHD patients.<sup>25,26</sup> However, the mechanisms by which GH and/or IGF-1 stimulate CNP expression are unclear. Although CNP expression *in vitro* is regulated by TGF- $\beta$  and receptor tyrosine kinase growth factors in a cell/tissue-specific and sometimes species-specific manner, crucial details of the regulatory pathways that lead to suppression or induction of CNP transcription remain unknown.<sup>30</sup> Our *in vivo* data suggest that CNP production may be upregulated, at least in part, by the endocrine GH and IGF-1 system.

We also found that an increase in serum NT-proCNP levels by GH treatment is positively correlated with the increase in height velocity during treatment in patients with ACH/HCH. Serum IGF-1 SDS and AP levels were also increased but they were not correlated, which is consistent with the results of ISS patients in previous studies in terms of serum IGF-1 levels.<sup>25,31</sup> A previous report did not show a correlation in patients with ACH.<sup>17</sup> With respect to serum levels of AP, a marker of bone formation, a study of patients with HCH treated with GH found no correlation between height gain and increase in osteocalcin, another bone formation marker,<sup>19</sup> which is consistent with the AP data in the current study. These results indicate that serum NT-proCNP levels may be a useful marker to indicate the effect of GH treatment on growth in patients with ACH/HCH. Moreover, the positive correlation between height velocity and NT-proCNP after GH treatment may indicate that CNP production promotes height gain in patients with ACH/HCH, which has been reported in a mouse ACH model.<sup>32</sup>

Serum NT-proCNP levels were negatively correlated with age in prepubertal children with ISS and positively correlated with height velocity in short children with ACH/HCH, ISS, GHD and short stature born SGA. The correlation of NT-proCNP levels with height velocity in each of the conditions was not proven, probably due to the small numbers in each group (data not shown). Regarding ISS patients, serum NT-proCNP levels are likely to be positively correlated with height velocity due to the decline of height velocity with age in prepubertal children. These results are consistent with those in healthy children and patients with ACH.<sup>24,33</sup> This indicates that serum NT-proCNP levels may be a biomarker of growth velocity in patients with ISS, and presumably other short children with ACH, HCH, GHD and short stature born SGA.

Serum NT-proCNP levels were comparable in ISS patients to those in patients with ACH/HCH and ACH alone at 3 of years age despite a difference in height SDS. This was not studied at other ages because GH treatment is generally initiated in most patients with ACH/HCH at 3 years of age. Furthermore, comparable NT-proCNP SDS has been described for patients with ACH and HCH despite a difference in height SDS.<sup>33</sup> These results indicate that NT-proCNP levels might not reflect height SDS at the time of measurement. On the other hand, NT-proCNP SDS has been reported to be elevated in patients with ACH and HCH compared to the reference population.<sup>33</sup> The difference in NT-proCNP levels in ACH may be due to a difference in NT-proCNP assay and/or a difference in the age of patients with ACH. Whatever, it is noteworthy that CNP production is not reduced in patients with ACH even though chondrocytes carry the *FGFR3* mutation and develop in an abnormal pattern.

Our study has some limitations. First, the sample size is small. However, our results indicate that serum NT-proCNP levels are a biomarker of growth velocity in patients with ACH/HCH following the initiation of GH treatment. Secondly, we did not have a control group composed of healthy infants, as sampling from healthy children was not permitted from an ethical point of view.

In summary, our study revealed that serum NT-proCNP level is a biomarker of growth velocity in patients with ACH/HCH following the initiation of GH treatment. It is also suggested that serum NT-proCNP levels might be a biomarker of growth in ISS patients.

## Acknowledgements

This work was supported in part by Grants-in-Aid for the Ministry of Health, Labour and Welfare of Japan (to KO).

## Grants

This study was supported in part by Grants-in-Aid for the Ministry of Health, Labour and Welfare of Japan.

## Disclosure summary

The authors have no conflicts to disclose.

## References

- 1 Vasques, G.A., Arnhold, I.J.P. & Jorge, A.A.L. (2014) Role of the natriuretic peptide system in normal growth and growth disorders. *Hormone Research in Paediatrics*, **82**, 222–229.
- 2 Yasoda, A. & Nakao, K. (2010) Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. *Endocrine Journal*, **57**, 659–666.
- 3 Chusho, H., Tamura, N., Ogawa, Y. *et al.* (2001) Dwarfism and early death in mice lacking C-type natriuretic peptide. *Proceedings of the National Academy of Sciences of the United States of America*, **98**, 4016–4021.
- 4 Tamura, N., Doolittle, L.K., Hammer, R.E. *et al.* (2004) Critical roles of the guanylyl cyclase B receptor in endochondral

- ossification and development of female reproductive organs. *Proceedings of the National Academy of Sciences of the United States of America*, **101**, 17300–17305.
- 5 Potter, L.R., Abbey-Hosch, S. & Dickey, D.M. (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. *Endocrine Reviews*, **27**, 47–72.
  - 6 Vasques, G.A., Amano, N., Docko, A.J. *et al.* (2013) Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. *Journal of Clinical Endocrinology and Metabolism*, **98**, E1636–E1644.
  - 7 Amano, N., Mukai, T., Ito, Y. *et al.* (2014) Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature. *Journal of Clinical Endocrinology and Metabolism*, **99**, E713–E718.
  - 8 Yasoda, A., Komatsu, Y., Chusho, H. *et al.* (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. *Nature Medicine*, **10**, 80–86.
  - 9 Moncla, A., Missirian, C., Cacciagli, P. *et al.* (2007) A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype. *Human Mutation*, **28**, 1183–1188.
  - 10 Bocciardi, R., Giorda, R., Buttgerit, J. *et al.* (2007) Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. *Human Mutation*, **28**, 724–731.
  - 11 Miura, K., Namba, N., Fujiwara, M. *et al.* (2012) An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene. *PLoS ONE*, **7**, e42180.
  - 12 Robinson, J.W., Dickey, D.M., Miura, K. *et al.* (2013) A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B. *Bone*, **56**, 375–382.
  - 13 Miura, K., Kim, O.-H., Lee, H.R. *et al.* (2014) Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene. *American Journal of Medical Genetics Part A*, **164A**, 156–163.
  - 14 Hannema, S.E., van Duyvenvoorde, H.A., Premisler, T. *et al.* (2013) An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. *Journal of Clinical Endocrinology and Metabolism*, **98**, E1988–E1998.
  - 15 Horton, W.A., Hall, J.G. & Hecht, J.T. (2007) Achondroplasia. *Lancet*, **370**, 162–172.
  - 16 Tanaka, H., Kubo, T., Yamate, T. *et al.* (1998) Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. *European Journal of Endocrinology*, **138**, 275–280.
  - 17 Hertel, N.T., Eklöf, O., Ivarsson, S. *et al.* (2005) Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. *Acta Paediatrica*, **94**, 1402–1410.
  - 18 Horton, W.A., Hecht, J.T., Hood, O.J. *et al.* (1992) Growth hormone therapy in achondroplasia. *American Journal of Medical Genetics*, **42**, 667–670.
  - 19 Pinto, G., Cormier-Daire, V., Le Merrer, M. *et al.* (2014) Efficacy and safety of growth hormone treatment in children with hypochondroplasia: Comparison with an historical cohort. *Hormone Research in Paediatrics*, **86**, 355–363.
  - 20 Rothenbuhler, A., Linglart, A., Piquard, C. *et al.* (2012) A pilot study of discontinuous, insulin-like growth factor 1-dosing growth hormone treatment in young children with FGFR3 N540K-mutated hypochondroplasia. *Journal of Pediatrics*, **160**, 849–853.
  - 21 Wu, C., Wu, F., Pan, J. *et al.* (2003) Furin-mediated processing of pro-C-type natriuretic peptide. *Journal of Biological Chemistry*, **278**, 25847–25852.
  - 22 Prickett, T.C., Yandle, T.G., Nicholls, M.G. *et al.* (2001) Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. *Biochemical and Biophysical Research Communications*, **286**, 513–517.
  - 23 Prickett, T.C., Lynn, A.M., Barrell, G.K. *et al.* (2005) Amino-terminal proCNP: a putative marker of cartilage activity in post-natal growth. *Pediatric Research*, **58**, 334–340.
  - 24 Olney, R.C., Permuy, J.W., Prickett, T.C.R. *et al.* (2012) Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) predicts height velocity in healthy children. *Clinical Endocrinology (Oxford)*, **77**, 416–422.
  - 25 Xiao, Y., Dong, Z., Lu, W. *et al.* (2011) Measurement of amino-terminal propeptide of C-type natriuretic peptide in patients with idiopathic short stature or isolated growth hormone deficiency. *Journal of Pediatric Endocrinology and Metabolism*, **24**, 989–994.
  - 26 Olney, R.C., Prickett, T.C.R., Yandle, T.G. *et al.* (2007) Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children: effects of puberty, testosterone, and growth hormone. *Journal of Clinical Endocrinology and Metabolism*, **92**, 4294–4298.
  - 27 Ozono, K., Namba, N., Kubota, T. *et al.* (2012) Pediatric aspects of skeletal dysplasia. *Pediatric Endocrinology Reviews*, **10**(Suppl 1), 35–43.
  - 28 Isojima, T., Shimatsu, A., Yokoya, S. *et al.* (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. *Endocrine Journal*, **59**, 771–780.
  - 29 Tanaka, N., Katsumata, N., Horikawa, R. *et al.* (2003) The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. *Endocrine Journal*, **50**, 69–75.
  - 30 Sellitti, D.F., Koles, N. & Mendonça, M.C. (2011) Regulation of C-type natriuretic peptide expression. *Peptides*, **32**, 1964–1971.
  - 31 Mortensen, H.B., Main, K., Michaelsen, K.F. *et al.* (1991) Predicting and monitoring of growth in children with short stature during the first year of growth hormone treatment. *Acta Paediatrica Scandinavica*, **80**, 1150–1157.
  - 32 Lorget, F., Kaci, N., Peng, J. *et al.* (2012) Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. *American Journal of Human Genetics*, **91**, 1108–1114.
  - 33 Olney, R.C., Prickett, T.C.R., Espiner, E.A. *et al.* (2014) C-type natriuretic peptide (CNP) plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia. *Journal of Clinical Endocrinology and Metabolism*, **100**, E355–E359.



DR TAICHI KITAOKA (Orcid ID : 0000-0002-3531-884X)

Article type : 3 Original Article - Australia, Japan, SE Asia

## **Safety and Efficacy of Treatment with Asfotase Alfa in Patients with Hypophosphatasia: Results from a Japanese Clinical Trial**

**Short title:** Clinical Trial of Asfotase Alfa

**Authors:** Taichi Kitaoka<sup>1</sup>, Toshihiro Tajima<sup>2</sup>, Keisuke Nagasaki<sup>3</sup>, Toru Kikuchi<sup>3</sup>, Katsusuke Yamamoto<sup>4</sup>, Toshimi Michigami<sup>5</sup>, Satoshi Okada<sup>6</sup>, Ikuma Fujiwara<sup>7</sup>, Masayuki Kokaji<sup>8</sup>, Hiroshi Mochizuki<sup>9</sup>, Tsutomu Ogata<sup>10</sup>, Koji Tatebayashi<sup>11</sup>, Atsushi Watanabe<sup>12</sup>, Shuichi Yatsuga<sup>13</sup>, Takuo Kubota<sup>1</sup>, Keiichi Ozono<sup>1</sup>

**Affiliations:** <sup>1</sup>Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan <sup>2</sup>Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan <sup>3</sup>Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cen.13343

This article is protected by copyright. All rights reserved.

<sup>4</sup>Department of Pediatric Nephrology and Metabolism, Osaka Medical Center and Research

Institute for Maternal and Child Health, Osaka, Japan <sup>5</sup>Department of Bone and Mineral

Research, Osaka Medical Center and Research Institute for Maternal and Child Health,

Osaka, Japan <sup>6</sup>Department of Pediatrics, Hiroshima University Graduate School of

Biomedical & Health Sciences, Hiroshima, Japan <sup>7</sup>Department of Pediatrics, Tohoku

University School of Medicine, Miyagi, Japan, <sup>8</sup>Department of Pediatrics, Showa General

Hospital, Tokyo, Japan <sup>9</sup>Division of Endocrinology and Metabolism, Saitama Children's

Medical Center, Saitama, Japan <sup>10</sup>Department of Pediatrics, Hamamatsu University School of

Medicine, Hamamatsu, Japan <sup>11</sup>Department of Pediatrics, Nagara Medical Center, Gifu,

Japan <sup>12</sup>Division of Clinical Genetics, Nippon Medical School Hospital, Tokyo, Japan

<sup>13</sup>Department of Pediatrics and Child Health, Kurume University School of Medicine,

Fukuoka, Japan

Toshihiro Tajima's present affiliation is Jichi Children's Medical Center Tochigi, Tochigi,

Japan

Toru Kikuchi's present affiliation is Department of Pediatrics, Saitama Medical University,

Saitama, Japan

**Correspondence:** Keiichi Ozono, MD, PhD, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan,

Tel: +81-6-6879-3932, Fax: +81-6-6879-3939, Email: keioz@ped.med.osaka-u.ac.jp

**Key words:** alkaline phosphatase, hypocalcemia, convulsion, enzyme replacement therapy, hypophosphatasia, asfotase alfa

**Acknowledgements:** The authors thank Kanako Tachikawa (Department of Bone and Mineral Research, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan) for gene mutation analysis. We thank all the study participants and staff at our collaborating centers.

**Financial disclosure/conflicts of interest:** AM, TKu, and KO report consulting fees as a consultant to Alexion Pharmaceuticals, Inc., outside the submitted work. TM and TKu report receiving lectures honorarium support from Alexion Pharmaceuticals, Inc., outside the submitted work.

**Funding:** The current study was an investigator-initiated trial, where Alexion Pharma provided financial support and study drugs but had no role in the design or execution of the trial; the interpretation, analysis, or publication of data; or the decision to submit the written

This article is protected by copyright. All rights reserved.

report. The participating institutions are supported by the Japanese Health Authority and the Ministry of Health, Labour and Welfare.

**Authors' roles:** Study design: TK, TKu, and KO. Study conduct: TK, TT, KN, ToK, KY, TM, SO, IF, MK, HM, TO, KT, AW, SY, and KO. Data collection: TT, KN, KY, SO, IF, MK, HM, TO, KT, AW, and SY. Data interpretation: TK and KO. Drafting manuscript: TK, TKu, and KO. Approving final version of manuscript: TK, TT, KN, ToK, KY, TM, SO, IF, MK, HM, TO, KT, AW, SY, and KO. All authors take responsibility for and attest to the integrity of the data.

**Abstract length:** 246 words

**Text length:** 3311 words

**No. of graphics:** 6 (4 tables, 2 figures)

**No. of references:** 24

**Supplementary information:** Provided as separate file

## Summary

**Objective** Hypophosphatasia (HPP) is a rare skeletal disease characterized by hypomineralization and low alkaline phosphatase activity. Asfotase alfa (AA) has been recently developed to treat HPP complications. This study evaluated its safety and efficacy in Japan.

**Design** Open-label, multicenter, prospective trial. Patients were enrolled in 11 hospitals from June 2014 to July 2015.

**Patients** Thirteen patients (9 females, 4 males) ages 0 days to 34 years at baseline were enrolled and treated with AA (2 mg/kg three times weekly subcutaneously in all but one patient). All had *ALPL* gene mutations. HPP forms were perinatal ( $n = 6$ ), infantile ( $n = 5$ ), childhood ( $n = 1$ ), and adult ( $n = 1$ ).

**Measurements** Safety determined from adverse events (AEs) and laboratory data was the primary outcome measure. Efficacy was assessed as a secondary outcome measure from overall survival, respiratory status, rickets severity, and gross motor development.

**Results** Injection site reactions were the most frequent AEs. Serious AEs possibly related to treatment were convulsion and hypocalcemia observed in a patient with the perinatal form. In addition, hypercalcemia and/or hyperphosphatemia was observed in three patients with the infantile form and a low-calcium and/or low-phosphate formula was given to these patients.

With respect to efficacy, all patients survived and the radiographic findings, developmental milestones, and respiratory function improved.

**Conclusion** AA therapy improved skeletal, respiratory, and physical symptoms with a few serious AEs in patients with HPP. Our results add support to the safety and efficacy of AA therapy for HPP patients.

## **Introduction**

Hypophosphatasia (HPP) is a rare skeletal disease caused by defects of the gene *ALPL*, which encodes tissue-non-specific alkaline phosphatase (TNSALP). More than 300 mutations are registered on the website edited by Prof. Monet E ([http://www.sesep.uvsq.fr/03\\_hypo\\_mutations.php](http://www.sesep.uvsq.fr/03_hypo_mutations.php)). Impaired bone mineralization due to low levels of alkaline phosphatase (ALP) activity is characteristic of HPP.<sup>1,2</sup> However, the phenotype of HPP varies and is usually classified into six forms based on age at onset and severity of clinical features: perinatal, benign pre-natal, infantile, childhood, adult, and odonto forms.<sup>1-7</sup> The mutations leading to a complete loss of ALP enzyme activity are generally associated with severe forms. In Japanese patients, c.1559delT is the most frequent mutation and is often associated with severe forms.<sup>8-11</sup>

The prognosis associated with the most severe form of HPP is very poor, because such patients suffer from respiratory failure due to marked hypomineralization of bones. Advances in neonatal intensive care including respiratory and circulatory support have improved prognosis. However, patients with the severe form of HPP require highly effective therapy to survive because its associated survival rate has been reported to be 42% and 27% at the age of 1 and 5 years, respectively.<sup>12</sup> Enzyme replacement therapy using bone-targeting recombinant alkaline phosphatase (asfotase alfa: AA) has been developed and is expected to improve prognosis. A clinical trial of AA has reported it to be safe and effective for 10 patients with perinatal, infantile, and childhood HPP.<sup>13,14</sup> Moreover, a long-term study of AA demonstrated the improvement of mineralization, respiratory function, and survival rate in 37 patients with perinatal and infantile HPP compared to 48 historical controls.<sup>12</sup> However, more experience is needed to better establish its safety and efficacy. We therefore conducted an investigator-initiated clinical trial of AA in Japan to further evaluate its safety and efficacy.

## **Methods**

### ***Study design***

The study design was devised by the authors at Osaka University with the assistance of Dr. Kiyoshi Okada (Medical Center for Translational and Clinical Research, Department of

Medical Innovation, Osaka University Hospital, Osaka, Japan). Dr. Keiichi Ozono acted as the coordinating investigator. Data on the safety and efficacy and the statistical analyses were monitored by Translational Research Informatics Center (Kobe, Japan). The protocol was approved by the local institutional review boards of the participating institutions. The study was conducted following Good Clinical Practice guidelines and adhered to the Declaration of Helsinki. Written informed consent was obtained from the parents of the patients except for an adult patient who gave informed consent himself. The trial was registered (NCT02456038, UMIN000014816, and HPPJEAP-01).

We studied the safety and efficacy of treatment with repeated subcutaneous (SC) injections of AA in patients with HPP in an open-label, single-arm, multicenter, investigator-initiated clinical study. The primary outcome measure was the safety of AA. Secondary outcome measures included overall survival, respiratory status, rickets severity, physical growth, and gross motor development. Patients were enrolled in 11 hospitals from June 2014 to July 2015 when AA received marketing approval in Japan.

Eligible patients included those of any age who had been already diagnosed with HPP, who had been already treated with AA outside of this clinical trial, or who had one or more features of HPP such as serum ALP activity below age-adjusted lower limits of normal, HPP related-findings, or positive genetic testing (*ALPL* mutations). All of the patients enrolled in the study, in fact, had mutations of the *ALPL* gene. Exclusion criteria included treatable forms



of rickets, hypocalcemia, hypophosphatemia, or treatment with bisphosphonates. Detailed inclusion/exclusion criteria are provided as Supplementary Information (Supplementary Methods).

Clinical assessments including physical growth, vital signs, and laboratory data were collected at baseline, every 4 weeks until 24 weeks, and every 12 weeks thereafter. **All laboratory data, including serum levels of ALP, calcium (Ca), and phosphate (P), were measured in the laboratory of each institute. Abnormal levels of ALP, Ca and P were based on the age-matched reference range.** Renal ultrasonographic and ophthalmologic examinations were performed at baseline and every 24 weeks. In patients who had been already treated by AA outside of this clinical trial, data at the initiation of that treatment were defined as baseline.

### ***Treatment***

All of the patients except one received AA by SC injection three times weekly at a dose of 2 mg/kg and the maximum volume of a single injection was 1 mL (40 or 80 mg/ml concentration). Patient 004-001, with the adult form, received AA at a dose of 1.17 mg/kg (1 mL SC at a concentration of 80 mg/ml) because that volume was the maximum permitted for a single injection. The mean  $\pm$  SD duration of the treatment was  $363.6 \pm 275.3$  days (median 251, range 49–868).

## *Safety*

Adverse events (AEs) including injection-associated reactions and injection site reactions (ISRs) were graded by the investigator as mild, moderate, or severe, and whether or not related to treatment. **ISRs are defined as related AEs that are localized to the area surrounding the injection occurring either during or at any time point after administration of the study drug injection.** Safety was also assessed from change of vital signs and laboratory data, renal ultrasonographic findings, ophthalmologic findings, and drugs used concomitantly during the study. Regarding laboratory data, changes from baseline after treatment were calculated at every visit.

## *Efficacy*

Overall survival was defined as the time from birth to death during the study. Ventilator-free survival for patients who were not mechanically ventilated at the time of enrollment was defined as the percentage of patients who were alive and ventilator-free at the end of the study after treatment.

Respiratory function in patients with respiratory support was evaluated by ventilator status, time on respiratory support (including time on ventilator or supplemental oxygen), ventilator rate, oxygen volume, ventilator pressures, and fraction of inspired oxygen.

Radiological findings of the wrists and knees were evaluated according to Thacher and colleagues.<sup>15</sup> This scoring method was developed to assess nutritional rickets. Radiographs were evaluated and scored on the rickets severity scale (RSS) every 12 weeks and changes from baseline were calculated.

The effect of AA treatment on physical growth was measured from height, weight, arm span, head circumference, and chest circumference. Height and weight data were transformed to age- and sex-specific z-scores from the average results for the reference Japanese population.<sup>16</sup> Changes of all measurements from baseline were calculated at every visit.

Assessment of changes in gross motor development was based on developmental milestones using a gross motor milestone checklist for this study (**see Supplementary Methods**). The checklist consisted of four sections assessing each postural position: supine, prone, sitting, and standing. Each section had different numbers of items for gross motor skills: supine ( $n = 9$ ), prone ( $n = 10$ ), sitting ( $n = 6$ ), and standing ( $n = 16$ ). **Examiner checked skills, “yes” or “no” depending on if the patient was able to perform each activity.** The number of skills that had been achieved was scored and totaled.

### *Statistical analysis*

Paired *t*-tests were used to assess changes from baseline in measurements. A *P*-value of  $<0.05$  was considered as significant. Statistical analyses were performed using SAS (version 9.3, SAS Institute Inc., Cary, NC, USA).

## **Results**

### *Patient baseline characteristics*

Baseline patient characteristics are summarized in Table 1. Thirteen patients (9 females and 4 males) were enrolled in this study. Their median age was 91 days (range 0 days to 34 years).

Ethnically, all were Japanese except for two patients (007-001 and 008-001). The father of patient 007-001 was American and his mother was Japanese. Patient 008-001 was Chinese.

Ten hospitals each enrolled single patients and one hospital three patients. HPP form was:

perinatal ( $n = 6$ ), infantile ( $n = 5$ ), childhood ( $n = 1$ ), and adult ( $n = 1$ ). **No patients with**

**benign pre-natal and odonto form were included.** All patients had low levels of serum

ALP at 0–240 IU/l (median 39.0) (see Supplementary Information Table S1 for reference

range). Five of the 13 patients had already been treated with AA prior to this study. Mean

height z-score was  $-2.5 \pm 1.8$  SD and mean weight z-score was  $-1.6 \pm 1.5$  SD.

The medical history of the patients at baseline is summarized in Table 2. In patients with perinatal and infantile forms, the main symptoms at the onset of HPP were poor weight gain (30.7%), dyspnea (30.7%), and hypomineralization of bone (30.7%). Four patients (30.7%) had family members with HPP. While there were no patients with pseudo-fracture, three patients (23.1%) had a history of bone fractures. Four patients (30.7%) had muscle weakness, and two of these (004-001 and 007-001) had difficulty walking and an unusual gait. Furthermore, patient 004-001 had impaired activities of daily living caused by myalgia and arthralgia. The clinical course of two patients had already been reported before treatment with AA (007-001) or on the compassionate use of AA (003-001) before recruitment into the study.<sup>17,18</sup>

Mean serum Ca was  $9.93 \pm 0.59$  mg/dl, serum P  $5.73 \pm 1.32$  mg/dl, and spot urine calcium/creatinine ratio (Ca/Cr)  $0.45 \pm 0.50$  g/gCr (Supplementary Information Fig. S1).

Serum Ca and P levels were within the reference range at baseline (see Supplementary Information Table S2 for reference range). All other laboratory data were normal at baseline.

### **Safety**

A total of 195 AEs was reported: mild 177 (91%), moderate 14 (7%), and severe 4 (2%). Of these, 104 AEs (53%) were assessed by the investigators as related to AA. The most common treatment-related AEs were injection site reactions (total 88 events in 7 patients), which

consisted of mild, localized, and transient erythema that was sometimes associated with induration and pruritus. No generalized injection-associated reactions, including anaphylactic shock or hypotension, were observed in any of the patients (see Supplementary Information Tables S3–S7 for additional AE data).

A total of six serious AEs was reported in two patients (003-001 and 006-001) [Table 3]. Two of these serious AEs (convulsion and hypocalcemia) were possibly related to the treatment in patient 003-001. The convulsion occurred on day 28 and was attributed to hypocalcemia that appeared from day 23. Serum Ca level was improved from 4.7 mg/dl on day 28 to 9.7 mg/dl on day 33 by increasing the dose of Ca administration. No convulsion was observed after the serum Ca level had been stabilized. The other four serious AEs were considered unrelated to treatment. Two of them were associated with infections. **One of 4 serious AEs was mixed deafness in case 003-001.** None of the serious AEs necessitated a change in the doses of the study drug.

Renal ultrasonographic examinations detected nephrocalcinosis (23%) in three patients (001-001, 002-001, and 007-001). These findings were not considered by the investigators as AEs because of the lack of exacerbation during treatment. No patients had ophthalmologic findings, including papilledema and ectopic calcification.

With respect to laboratory data, all measurements except ALP, Ca, and P remained within the normal range (see Supplementary Information Tables S1 and S2 for age-specific reference

Accepted Article

ranges for ALP, Ca, and P). For all patients, mean serum ALP level increased rapidly and markedly from  $79 \pm 86$  IU/l at the baseline to  $24\,407 \pm 12\,701$  IU/l 4 weeks after starting AA treatment. High levels of serum ALP persisted during AA treatment. Serum P levels were transiently or continuously increased above the upper limit of normal (ULN) in 11 patients (84.6%) during treatment. The highest level of serum P (9.7 mg/dl) was observed in patient 003-001 at 4 weeks concomitantly with hypocalcemia (Ca 4.7 mg/dl), as previously described. At a later time point, a high serum P level was also observed in the same patient (8.3 mg/d at 120 weeks). All patients had normal renal function.

In eight patients (61.5%), serum Ca levels were transiently or continuously elevated above the ULN during treatment. The highest serum Ca level during the study was 11.9 mg/dl, observed in patient 009-001 at 16 weeks. In addition, the highest Ca/Cr was observed in patient 001-001 at 8 weeks (3.05 g/gCr), while using a low-calcium formula as additional management for hypercalcemia. Transient or continuous elevations of serum Ca and P levels during AA treatment were observed in three patients (001-001, 005-001, and 008-001). They used low-calcium formula and/or a low-phosphorus formula (see Supplementary Information for details of additional management in these patients).

## *Efficacy*

The survival rate was 100% (95% CI 75.3–100.0) at the end of the study (median 24, range 4–120 weeks).

Five patients (004-001, 005-001, 007-001, 008-001, and 010-001) did not require mechanical respiratory support at baseline nor during the study. Ventilator-free survival among them was 100% at the end of the study (median 24, range 12–60 weeks).

A total of eight patients (61.5%) required some form of respiratory support and three (37.5%) of them were managed with non-invasive respiratory support. Five patients (62.5%) [3 perinatal and 2 infantile form] required invasive mechanical ventilation (IMV) support.

Since three perinatal patients had respiratory failure at birth, mainly due to bronchomalacia and hypomineralized ribs, they received IMV support from day 0 and continued after baseline.

On the other hand, two infantile patients did not show apparent respiratory failure at birth.

However, they had failure to thrive and showed a gradually deteriorating respiratory condition during infancy. At baseline, they had poorly mineralized ribs on radiological findings and received respiratory support (Table 4). Four patients also received tracheostomy to maintain their quality of life during mechanical ventilation support (see Supplementary Information Results for detail).

Respiratory status and mineralization of ribs improved in all patients during AA treatment (see Supplementary Information Results **and Fig. S3** for details). Three patients (37.5%) did



not require respiratory support and two patients were starting to wean off support during the first month of treatment. At the end of the study, one patient was on mechanical ventilation and two received supplementary oxygen, making a total of three patients requiring some form of respiratory support at the end of the study.

Baseline radiographs showed undermineralized metaphyses as hypophosphatasia-associated skeletal lesions in all except two patients with a closed growth plate (004-001 and 007-001). Mineralization gradually improved in all patients. At week 24, these metaphyses were mineralized with distinct provisional zones of calcification, and the metacarpals had wider widths, better-defined cortices, and no lytic areas at their proximal ends. Mean RSS score decreased during treatment and the changes from the baseline to 12 and 24 weeks were  $-3.4 \pm 3.4$  ( $P = 0.016$ ) and  $-5.4 \pm 2.7$  ( $P = 0.002$ ), respectively (Fig. 1).

Weight was assessed in all patients and height were evaluated in 11 patients. Height data at baseline were not obtained for two patients who had already been treated with AA prior to this study. Mean weight z-score did not markedly change from  $-1.6 \pm 1.5$  SD at the baseline to  $-1.6 \pm 1.7$  SD at the end of the study ( $P = 0.881$ ). Mean height z-score, also, did not change significantly from  $-2.5 \pm 1.9$  SD at the baseline to  $-2.0 \pm 1.4$  SD at the end of the study ( $P = 0.139$ ) [Fig. 2]. Additional data on physical growth are provided in Supplementary Information (Results).

Gross motor milestones were evaluated in 10 patients. Five infants were assessed at baseline, of whom four were evaluated at 12 weeks. Mean total score for gross motor milestones was significantly increased at 12 weeks compared to baseline ( $P = 0.003$ ). Although no baseline data were obtained in five patients who had already been treated with AA prior to this study, the total score of four infants gradually increased during treatment (see Supplementary Information Fig. S2).

## Discussion

The safety and efficacy of AA have been reported in patients with HPP in international, multicenter clinical trials, following which SC treatment with AA was approved in several countries including Japan and the USA.<sup>19</sup> Treatment with the recombinant enzyme is generally safe, although some AEs have to be carefully monitored. The most frequent AE is a local reaction to the injection. Hypotensive shock due to anaphylaxis was not observed in our trial. Our clinical study provides evidence supporting the tolerability of AA treatment at the recommended dose.

An important AE is hypocalcemia on AA treatment. The recombinant enzyme stimulates mineralization in bone and this process requires calcium deposition in bone. This may account for hypocalcemia during treatment. Newborns or infants with HPP sometimes show

hypercalcemia and receive low-calcium formula, which may facilitate the development of hypocalcemia during AA treatment. We recommend ordinary milk when starting AA treatment and monitoring serum calcium levels during treatment. Administration of calcium and vitamin D may be necessary to prevent or resolve hypocalcemia.

Hyperphosphatemia can also be an AE. However, serum phosphate levels were not particularly high in our study: often less than 8 mg/dl but sometimes over 8 mg/dl up to 9.7 mg/dl. The elevation of serum phosphate levels may aggravate ectopic calcification. Thus, careful observation is necessary and hyperphosphatemia may require the restriction of phosphorus intake. While ectopic calcification in the kidney and retina was not observed, craniosynostosis **that is one of the complications of HPP** occurred in this clinical trial.

These potential AEs should be carefully monitored during treatment. **Mixed deafness was considered a serious AE in case 003-001 by doctors who treated the patient.**

**Sensorineural hearing loss was indicated by auditory brainstem response test, and conductive deafness was suggested by deformities of the middle ear ossicles detected by computed tomography. They might be due to their hypomineralization in HPP. In addition, deafness is reported to be one of clinical features in HPP.<sup>11</sup> Thus, mixed deafness in this case might be one of the complications in HPP.**

Convulsion was observed after the initiation of treatment in one patient. Indeed, vitamin B6-dependent convulsion is one of the complications of HPP.<sup>1</sup> However, the convulsion in

the patient was due to hypocalcemia. Thus, it is necessary to consider both vitamin B6-dependent and hypocalcemia-induced convulsions during treatment.

AA clearly stimulated bone formation. Patients with severe HPP showed marked hypomineralization in all bones, especially the skull, long bones, and ribs. The long bones and ribs thickened during treatment. The effect was observed at 1 month after starting treatment. Lung function was improved after bone formation became evident. Thus, supportive therapy for the respiratory and circulatory functions is essential even after the initiation of treatment with AA. The survival rate and respiratory function improved in the trial. Six patients suffered from perinatal HPP, of whom five required mechanical ventilation and two underwent tracheostomy. **Although AA improved respiratory status, periods to the end of respiratory support were different among the patients with perinatal HPP (Table 4). Patients with high-frequency oscillatory ventilation or synchronized intermittent mandatory ventilation at baseline required longer respiratory support than those with nasal continuous positive airway pressure or supplemental oxygen, suggesting that respiratory status at baseline predicts periods of respiratory support after the initiation of AA. In agreement with our study, the previous report describes that severe or long-standing pulmonary impairment at baseline might influence the improvement period of respiratory status.**<sup>12</sup> The six patients with perinatal HPP were all

alive at the final visit (median 48, range 4–120 weeks) and four of them were free from respiratory support including oxygen supply.

It is strongly suggested that AA treatment of patients with HPP improves prognosis.<sup>13,14</sup> The treatment has been called transformative.<sup>5</sup> Thus, the early diagnosis of HPP is important in this situation. A treatment algorithm for HPP has been proposed.<sup>20,21</sup> Other therapies including teriparatide, bone marrow transplantation, and gene induction have been reported.<sup>22–24</sup> We hope to develop a guide on how to manage patients with HPP in terms of diagnosis and treatment in the near future. In summary, asfotase alfa was safe and effective for the treatment of 13 patients with HPP including perinatal and childhood forms.

## References

- 1) Whyte, M.P. (2016) Hypophosphatasia: aetiology, nosology, pathogenesis, diagnosis and treatment. *Nature Reviews Endocrinology*, **12**, 233–246.
- 2) Millán, J.L. & Whyte, M.P. (2016) Alkaline phosphatase and hypophosphatasia. *Calcified Tissue International*, **98**, 398–416.
- 3) Ozono, K., Yamagata, M., Michigami, T., *et al.* (1996) Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. *Journal of Clinical Endocrinology and Metabolism*, **81**, 4458–4461.

- Accepted Article
- 4) Wenkert, D., McAlister, W.H., Coburn, S.P., *et al.* (2011) Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). *Journal of Bone and Mineral Research*, **26**, 2389–2398.
  - 5) Bishop, N., Munns, C.F. & Ozono, K. (2016) Transformative therapy in hypophosphatasia. *Archives of Disease in Childhood*, **101**, 514–515.
  - 6) Linglart, A. & Biosse-Duplan, M. (2016) Hypophosphatasia. *Current Osteoporosis Reports*, **14**, 95–105.
  - 7) Whyte, M.P., Zhang, F., Wenkert, D., *et al.* (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. *Bone*, **75**, 229–239.
  - 8) Michigami, T., Uchihashi, T., Suzuki, A., *et al.* (2005) Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. *European Journal of Pediatrics*, **164**, 277–282.
  - 9) Watanabe, A., Karasugi, T., Sawai, H., *et al.* (2011) Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers. *Journal of Human Genetics*, **56**, 166–168.

- Accepted Article
- 10) Ozono, K. & Michigami, T. (2011) Hypophosphatasia now draws more attention of both clinicians and researchers: a commentary on prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasias in Japanese and effects of the mutation on heterozygous carriers. *Journal of Human Genetics*, **56**, 174–176.
  - 11) Taketani, T., Onigata, K., Kobayashi, H., *et al.* (2014) Clinical and genetic aspects of hypophosphatasia in Japanese patients. *Archives of Disease in Childhood*, **99**, 211–215.
  - 12) Whyte, M.P., Rockman-Greenberg, C., Ozono, K., *et al.* (2016) Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. *Journal of Clinical Endocrinology and Metabolism*, **101**, 334–342.
  - 13) Whyte, M.P., Greenberg, C.R., Salman, N.J., *et al.* (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. *New England Journal of Medicine*, **366**, 904–913.
  - 14) Whyte, M.P., Madson, K.L., Phillips, D., *et al.* (2016) Asfotase alfa therapy for children with hypophosphatasia. *JCI Insight*, **1**, e85971.
  - 15) Thacher, T.D., Fischer, P.R., Pettifor, J.M., *et al.* (2000) Radiographic scoring method for the assessment of the severity of nutritional rickets. *Journal of Tropical Pediatrics*, **46**, 132–139.
  - 16) Ito, Y., Kato, N., Tachibana, K., *et al.* (2005) "Standard height" and "standard growth curve" 2000 version conform to the standardized height in Treatment Support Program

for the Chronic Pediatric Diseases of Specified Categories. *The Journal of Pediatric Practice*, **68**, 1343–1351.

- 17) Mochizuki, H., Saito, M., Michigami, T., *et al.* (2000) Severe hypercalcaemia and respiratory insufficiency associated with infantile hypophosphatasia caused by two novel mutations of the tissue-nonspecific alkaline phosphatase gene. *European Journal of Pediatrics*, **159**, 375–379.
- 18) Okazaki, Y., Kitajima, H., Mochizuki, N., *et al.* (2016) Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth. *European Journal of Pediatrics*, **175**, 433–437.
- 19) Scott, L.J. (2016) Asfotase alfa in perinatal/infantile-onset and juvenile-onset hypophosphatasia: a guide to its use in the USA. *BioDrugs*, **30**, 41–48.
- 20) Saraff, V., Narayanan, V.K., Lawson, A.J., *et al.* (2016) A diagnostic algorithm for children with low alkaline phosphatase activities: lessons learned from laboratory screening for hypophosphatasia. *Journal of Pediatrics*, **172**, 181–186.
- 21) Taillandier, A., Domingues, C., De Cazanove, C., *et al.* (2015) Molecular diagnosis of hypophosphatasia and differential diagnosis by targeted next generation sequencing. *Molecular Genetics and Metabolism*, **116**, 215–220.
- 22) Whyte, M.P., Mumm, S. & Deal C. (2007) Adult hypophosphatasia treated with teriparatide. *The Journal of Clinical Endocrinology and Metabolism*, **92**, 1203–1208.



- 23) Iijima, O., Miyake, K., Watanabe, A., *et al.* (2015) Prevention of lethal murine hypophosphatasia by neonatal *ex vivo* gene therapy using lentivirally transduced bone marrow cells. *Human Gene Therapy*, **26**, 801–812.
- 24) Sugano, H., Matsumoto, T., Miyake, K., *et al.* (2012) Successful gene therapy *in utero* for lethal murine hypophosphatasia. *Human Gene Therapy*, **23**, 399–406.

### Figure legends

**Fig. 1 A)** Change of rickets severity scale (RSS) score during treatment. Mean RSS score decreased from  $8.0 \pm 2.9$  at baseline to  $4.9 \pm 3.8$  at 12 weeks ( $n = 10$ ) and  $3.0 \pm 2.8$  at 24 weeks ( $n = 9$ ). **B) Change of the wrist and knee radiographs during treatment. Patient 011-001, with the perinatal form, is shown. Undermineralized methaphyses were improved at week 12. RSS, Rickets Severity Score.**

**Fig. 2** Change in (A) height and (B) weight z-scores during treatment. Mean weight z-score did not markedly changed from  $-1.6 \pm 1.5$  SD at baseline to  $-1.6 \pm 1.7$  SD at the end of the study ( $P = 0.881$ ). Mean height z-score did not change significantly from  $-2.5 \pm 1.9$  SD at baseline to  $-2.0 \pm 1.4$  SD at the end of the study ( $P = 0.139$ ).

**Table 1.** Baseline patient characteristics

Case no.	Sex	Age	HPP form	Mutations of <i>ALPL</i>	ALP (U/l)*	Height z-score (cm)	Weight z-score (kg)	Final visit (week)
001-001	F	113 days	I	p.M295I/c.1559delT	70	51.0 (-4.1)	4.25 (-2.4)	36
002-001	F	230 days	I	p.H336R/c.1559delT	21	61.0 (-2.8)	4.80 (-4.2)	120
002-002	M	16 days	P	c.1559delT/c.1559delT	23	51.0 (1.0)	2.89 (-0.3)	84
002-003	F	0 days	P	c.1559delT/c.1559delT	0	41.0 (-3.6)	2.43 (-1.2)	4
003-001	F	1 day	P	p.G491R/p.G491R	1	42.8 (-2.7)	2.68 (-0.6)	120
004-001	M	34 years	A	c.1559delT heterozygous	51	159.4 (-2.3)	68.6 (-0.0)	24
005-001	F	158 days	I	p.E191G/c.1559delT	144	57.0 (-3.4)	6.06 (-1.1)	24
006-001	F	54 days	P	c.1559delT/c.1559delT	15	46.6 (-2.8)	2.93 (-2.3)	24
007-001	M	17 years	I	p.K224E/p.G426C	195	148.8 (-3.7)	40.0 (-3.9)	24
008-001†	F	36 days	I	p.R136C/p.F327L	240	57.0 (2.1)	4.70 (0.9)	60
009-001	F	0 days	P	p.R450C/c.1559delT	39	41.0 (-3.6)	2.30 (-1.6)	72
010-001	M	10 years	C	p.F327L/p.G339R	209	119.2 (-3.1)	24.4 (-1.7)	12
011-001	F	91 days	P	c.1559delT/c.1559delT	23	52.0 (-3.6)	4.68 (-1.7)	12

A, adult; ALP, alkaline phosphatase; C, childhood; F, female; HPP, hypophosphatemia; I, infantile; M, male; P, perinatal.

\* Reference range at 0–1 months: 530–1620 U/l.

†Height measured at 3 days after the baseline.

**Table 2.** Baseline patient medical history

Case no.	HPP form	Age at onset	Symptoms at HPP onset	Family members with HPP	Fracture history (age detected)	Orthopedic findings	Respiratory status	Serum calcium and phosphate levels, and nephrocalcinosis
001-001	I	2m	Poor weight gain (poor feeding)	Elder brother*	Rib (at infancy)	Chest deformity, cranial deformity	Pneumonia	Nephrocalcinosis, hypercalcemia
002-001	I	1m	Poor weight gain			Chest deformity, cranial deformity, muscle weakness	Dyspnea	Nephrocalcinosis, hypercalcemia
002-002	P	0m	Seizure, dyspnea, hypercalcemia, hyperphosphatemia				Dyspnea	Hypercalcemia, hyperphosphatemia
002-003	P	0m	Chest deformity, dyspnea, short extremities	Elder brother (002-002)			Dyspnea	
003-001	P	0m	Hypomineralization of bone (pre-natal)			Chest deformity	Dyspnea	
004-001†	A	24y	Muscle pain, muscle weakness	Child	Rt. humerus (6y) Lt. clavicle (23y)	Gait disturbance, arthralgia		

005-001	I	0m	Bowed legs		Genu varum, forearm curvature		Hypercalcemia
006-001	P	0m	Short extremities, hypomineralization of bone, chest deformity, dyspnea	Lt. radius (1m) Rt. ulna (1m)	Genu varum, muscle weakness	Dyspnea, pneumonia	
007-001‡	I	2m	Poor weight gain, bad mood		Delayed walking, chest deformity, cranial deformity, bone pain, arthralgia, gait disturbance, muscle weakness	Dyspnea, pneumonia	Nephrocalcinosis, hypercalcemia
008-001	I	0m	Hypomineralization of bones (metaphyseal flaring)				Hyperphosphatemia
009-001	P	0m	Short extremities, hypomineralization of bones		Genu varum		
010-001	C	3y	Premature tooth loss		Gait disturbance, arthralgia		
011-001	P	1m	Dyspnea, poor weight			Dyspnea	Hypercalcemia

gain

---

A, adult; C, childhood; HPP, hypophosphatasia; I, infantile; Lt, left; m, month; P, perinatal; Rt, right; y, year

\*Brother of 001-001, died of respiratory dysfunction from pneumonia at the age of 3 months, diagnosed with HPP by genetic testing.

†Patient 004-001 had internal plate fixation of humerus fracture and muscle biopsy for muscle weakness.

‡Patient 007-001 underwent surgery for craniosynostosis at the age of 1 year.

**Table 3.** Serious adverse events

Case no.	Age at AE onset	Preferred term	Severity	Causality	Outcome	AE duration
003-001	28 days	Convulsion	Severe	Probable	Resolved	16 days
	23 days	Hypocalcemia	Severe	Probable	Resolved	21 days
	7-7 months	Mixed deafness*	Severe	Unrelated	Unresolved	
	1-3 years	Upper respiratory tract infection†	Moderate	Unrelated	Resolved	5 days
006-001	3-4 months	Staphylococcal infection‡	Severe	Unrelated	Resolved	20 days
	5-3 months	Convulsion§	Moderate	Unrelated	Resolved	2 days

AE, adverse event.

\*Mixed deafness was based on auditory brainstem response. Deformities of the middle ear ossicles were detected using computed tomography.

†Upper respiratory tract infection resolved by intravenous fluid therapy for 5 days while hospitalized.

‡Staphylococcal infection caused by catheter infection and cured by antibacterial therapy.

§Convulsion was a withdrawal symptom from benzodiazepine given for sedation during respiratory management.

**Table 4.** Respiratory support


Case no.	HPP form	Respiratory status at the baseline	Period from baseline to weaning off mechanical ventilation	Period from baseline to the end of respiratory support*
001-001	I	SIMV (started at 8 days before baseline)	121 days (tracheostomy at 9 days from baseline: SIMV for 23 days and CPAP for 98 days.)	Ongoing supplemental oxygen at the final visit (36 weeks)
002-001	I	BiPAP (SIMV for 32 days before BiPAP)	205 days	272 days
002-002	P	Nasal CPAP	No mechanical ventilation support	23 days
002-003	P	Nasal CPAP	No mechanical ventilation support	34 days (nasal CPAP for 3 days and nasal high flow for 31 days)
003-001	P	HFO (with inhaled nitric oxide)	225 days (tracheostomy at 78 days from baseline. HFO control for 108 days; SIMV for 7 days and then gradually tapered)	1·8 years
006-001	P	HFO	110 days (tracheostomy at 90 days from baseline. HFO control for 35 days; A/C mode for 51 days and then SIMV control.)	Ongoing supplemental oxygen at the final visit (24 weeks)
009-001	P	Supplemental oxygen	No mechanical ventilation support	3 days
011-001	P	SIMV (tracheostomy at 14 days before baseline)	Ongoing SIMV control	Ongoing SIMV control at the final visit (12 weeks)




A/C, assist control ventilation; BiPAP, biphasic positive airway pressure; CPAP, continuous positive airway pressure; HFO, high-frequency oscillatory ventilation; I, infantile; P, perinatal; SIMV, synchronized intermittent mandatory ventilation.

\*Respiratory support including oxygen supply.


A. Rickets severity scale




B. Representative radiographic change



A. Height SD score



B. Weight SD score



# Characteristic calcaneal ossification: an additional early radiographic finding in infants with fibrodysplasia ossificans progressiva

Sachi Hasegawa<sup>1</sup> · Teresa Victoria<sup>2</sup> · Hülya Kayserili<sup>3</sup> · Elaine Zackai<sup>4</sup> ·  
Gen Nishimura<sup>5</sup> · Nobuhiko Haga<sup>5</sup> · Yasuharu Nakashima<sup>5</sup> · Osamu Miyazaki<sup>5</sup> ·  
Hiroshi Kitoh<sup>1,5</sup> 

Received: 29 March 2016 / Revised: 18 May 2016 / Accepted: 21 June 2016 / Published online: 4 August 2016  
© Springer-Verlag Berlin Heidelberg 2016

## Abstract

**Background** We have clinically encountered children with fibrodysplasia ossificans progressiva who had abnormal calcaneal ossification.

**Objective** To evaluate whether calcaneal ossification variants are significant radiographic findings in children with fibrodysplasia ossificans progressiva.

**Materials and methods** Lateral feet radiographs in nine children who fulfilled the diagnostic criteria of fibrodysplasia ossificans progressiva were reviewed. The studies were obtained during infancy or early childhood.

**Results** Fourteen lateral foot radiographs of fibrodysplasia ossificans progressiva were available for this study (ages at examination: 1–104 months). Four children ages 2 months to 11 months showed double calcaneal ossification centers; 7 children had plantar calcaneal spurs that decreased in size with age. Overall, eight of nine children with fibrodysplasia

ossificans progressiva demonstrated double calcaneal ossifications and/or plantar calcaneal spurs in infancy or childhood. **Conclusion** Double calcaneal ossification centers in early infancy and plantar calcaneal spurs in childhood are frequently seen in children with fibrodysplasia ossificans progressiva and may be a useful radiologic indicator for early diagnosis.

**Keywords** Calcaneal spur · Children · Double calcaneal ossification center · Early diagnosis · Fibrodysplasia ossificans progressiva · Radiography

## Introduction

Fibrodysplasia ossificans progressiva is a genetic disorder of the connective tissues caused by activating mutations in the gene-encoding activin receptor IA/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor [1]. Most affected individuals have a common mutation (c.617G > A, p.R206H). The clinical hallmark of fibrodysplasia ossificans progressiva is progressive heterotopic ossification of soft tissues, such as muscles, ligaments, tendons, fasciae and aponeuroses, which causes significant physical morbidity and may lead to early mortality. Traumatic injury and surgical intervention induce explosive heterotopic ossification in patients with fibrodysplasia ossificans progressiva. Early diagnosis is necessary to prevent additional trauma or iatrogenic harm [2].

Fibrodysplasia ossificans progressiva is associated with a variety of bone malformations as well as variant ossification. Awareness of the bone anomalies may facilitate prompt diagnosis. Malformations of the great toes are well-known and are the most prevalent indicators of this disorder [3]. Other anomalies include shortening of the first metacarpal bones and

✉ Hiroshi Kitoh  
hkitoh@med.nagoya-u.ac.jp

<sup>1</sup> Department of Orthopaedic Surgery,  
Nagoya University Graduate School of Medicine,  
65 Tsurumai, Showa-ku, Nagoya, Aichi 466-8550, Japan

<sup>2</sup> Department of Radiology, Children's Hospital of Philadelphia,  
Philadelphia, PA, USA

<sup>3</sup> Medical Genetics Department,  
Koç University School of Medicine (KUSOM),  
İstanbul, Turkey

<sup>4</sup> Department of Medical Genetics,  
Children's Hospital of Philadelphia,  
Philadelphia, PA, USA

<sup>5</sup> The Research Committee on Fibrodysplasia Ossificans Progressiva,  
Tokyo, Japan

hypertrophy of the posterior element of the cervical spine [4]. Quantitative analyses of bone changes in the hand and cervical spine are also available [5]. Recently, we encountered two children with distinctive double ossification centers and plantar spurs in the calcaneus. Search of the database identified seven additional children with fibrodysplasia ossificans progressiva. We evaluate whether the presence of calcaneal changes may be commonly seen in patients with fibrodysplasia ossificans progressiva.

**Materials and methods**

Two children (cases 2 and 3 in Table 1) were seen clinically and subsequently presented and discussed in web case consultations. The online discussion enabled us to collect clinical data and foot radiographs from members of the Research Committee on Fibrodysplasia Ossificans Progressiva (Japan), who provide pediatric orthopedic services in four hospitals across Japan. Six Japanese children and one Indian child (5 males and 2 females) who underwent lateral feet radiography in infancy or early childhood were thus additionally enrolled. All nine children fulfilled the diagnostic criteria of fibrodysplasia ossificans progressiva, including deformities of the great toes, extraskeletal heterotrophic ossification, joint contractures, fusion of the cervical spine, broad femoral necks and osteochondroma-like lesions. Seven of the nine children underwent molecular testing, showing the common ACVR1/ALK2 mutation within the glycine/serine-rich regulatory (GS) domain (c.617G > A, p.R206H). All radiographs were examined by a single reader (G.N.) with 30 years’ clinical experience in the field of skeletal dysplasias and specifically focused on calcaneal configurations.

**Results**

Fourteen lateral foot radiographs obtained between the ages of 1 month to 104 months were available for this study. Three children (cases 1, 2 and 4) underwent serial radiographic examinations in infancy and early childhood. We found two distinctive findings: 1) double calcaneal ossification centers and 2) plantar calcaneal spurs. These findings were bilateral and symmetrical. The radiologic findings and pertaining clinical information are summarized in Table 1.

**Double calcaneal ossification centers**

Four children (cases 1, 2, 3 and 4) showed double ossification centers in radiographs obtained in infancy (Figs. 1, 2, 3 and 4). Three of them (cases 2, 3 and 4) had a cleft separating the anterior two-thirds from the posterior third in the calcaneus. The posterior ossification centers were small, intermediate and large in size at ages 2, 4 and 10 months, respectively, partially fused with the anterior ossification centers at ages 4 and 10 months, and completely incorporated into the anterior ossifications at ages 12 months and 22 months. The remaining child (case 1) had a cleft separating the anterior third from the posterior two-thirds in the calcaneus. The anterior ossification center manifested as punctate multiple ossifications in early infancy, which evolved into double ossifications at age 11 months and completely coalesced at age 3 years.

**Plantar calcaneal spur**


Seven children showed a small spur from the plantar aspect of the posterior calcaneal body (Figs. 2, 3, 4 and 5). The spurs are pedunculated and projected posteriorly from the posterior

**Table 1** Demographic, clinical, genetic and radiologic summaries of nine children with fibrodysplasia ossificans progressiva


Case number	1		2		3	4		5	6	7	8	9		
Sex	male		male		female	male		male	female	male	male	female		
Current age	4Y8M		6Y		2Y9M	3Y2M		2Y	3Y5M	4Y6M	7Y7M	8Y8M		
Ethnic background	Japanese		Caucasian		Turkish	Japanese		Indian	Japanese	Japanese	Japanese	Japanese		
ACVR1 mutation	R206H		R206H		ND	R206H		R206H	ND	R206H	R206H	R206H		
Great toe abnormalities	+		+		+	+		+	+	+	+	+		
Other radiological findings of FOP	+		NA		NA	+		+	+	+	+	+		
Ectopic ossification	+		-		-	-		-	-	-	+	+		
Age at X-ray (months)	1	3	11	36	2	12	4	10	22	15	18	33	70	104
Double calcaneal ossification centers	punctate	punctate	+	-	+	-	+	+	-	-	-	-	-	-
Plantar calcaneal spur	-	-	-	-	+	+	+	+	+	+	-	+	+	+

NA not available , ND not determined

**Fig. 1** Lateral foot radiographs in a boy with fibrodysplasia ossificans progressiva (case 1 in Table 1). Sequential radiographs at 1 months of age (a), 3 months of age (b), 11 months of age (c), and 3 years of age (d) demonstrate punctate multiple ossifications in early infancy (solid arrows), double ossification centers with a cleft separating the anterior third from the posterior two-thirds of the calcaneus (arrowhead), and normal calcaneal configuration after complete fusion of the ossification centers (open arrow)



**Fig. 2** Lateral foot radiographs in a boy with fibrodysplasia ossificans progressiva (case 2 in Table 1). Sequential radiographs at 2 months of age (a) and 12 months of age (b) show a small posterior ossification (solid arrow) and posteriorly pedunculated calcaneal spur (arrowhead), which became smaller in size with age (open arrow)



aspect of the anterior calcaneal ossification in infancy. They became sessile and projected inferiorly with age. In patient 2, the spur became smaller in size with age.




**Fig. 3** Lateral foot radiograph in a girl with fibrodysplasia ossificans progressiva (case 3 in Table 1) at 4 months of age demonstrates double ossification centers (arrow) and plantar spur (arrowhead) of the calcaneus

## Discussion

Our findings suggest that abnormal/variant calcaneal ossification, double calcaneal ossification and plantar spurs may be of diagnostic significance in patients with fibrodysplasia ossificans progressiva. These are congenital anomalies, which are perceptible in early infancy and can be a clue to the early diagnosis of this disorder, as are malformations of the great toes, shortening of the thumb and hypertrophy of the posterior element of the cervical spine. This finding is not exclusive of fibrodysplasia ossificans progressiva, as double calcaneal ossifications and plantar spurs are also described as rare developmental variations in normal children [6–10].

The normal double calcaneal ossification is sometimes referred to as bifid os calcis [8–10]. This variation has been reported in children with mild foot deformities, such as pes planovalgus, metatarsus varus and mild talipes equinovaglus. Bifid os calcis shows complete coalescence and remodeling of



**Fig. 4** Lateral foot radiographs in a boy with fibrodysplasia ossificans progressiva (case 4 in Table 1). Sequential radiographs at 10 months of age (a) and 22 months of age (b) reveal double ossification centers with a

cleft separating the anterior two-thirds from the posterior third in the calcaneus (arrow) and an inferiorly projected small spur in the plantar calcaneus (arrowhead)

two separate ossifications during early childhood and typically shows a cleft separating the anterior third from the posterior two-thirds of the calcaneus. A patient with bifid os calcis reported by Ogden [9] showed punctate ossification centers in the anterior portion. In three children in our series, double calcaneal ossifications were associated with a cleft separating the anterior two-thirds from the posterior third of the calcaneus. However, the manifestation in the remaining one was similar to that in Ogden’s case.

A duplicate/triplicate calcaneus was observed in specific skeletal dysplasias, including chondrodysplasia punctata, thanatophoric dysplasia and short rib polydactyly syndromes [11]. Double calcaneal ossifications with a cleft separating the anterior two-thirds from the posterior third of the calcaneus resemble those commonly seen in an infant with Larsen syndrome. Larsen syndrome is caused by heterozygous mutations in filamin B gene (*FLNB*). Filamen B is a cytoskeletal protein involved in a multicellular process [12]. Zheng et al. [13] demonstrated that *FLNB* mutant mice display ectopic mineralization in various cartilaginous elements, including carpal and tarsal bones, and this mutant phenotype is rescued by removing *Runx2* through TGFβ-Smad pathway. Overexpression of the R206H mutant *ACVR1*, on the other hand, enhances

Smad1/5 signaling. Molecular interactions between filamin B and Smad signaling in skeletal morphogenesis may lead to similar phenotypes of ossifications in the calcaneal region in Larsen syndrome and fibrodysplasia ossificans progressiva.

The normal plantar calcaneal spur is seen at the posterior two-thirds of the bone, tends to be bilateral and symmetrical, may point anteriorly, posteriorly or inferiorly, and disappears by 1 year of age. The normal calcaneal spur is morphologically indistinguishable from the late manifestation of the calcaneal spur in fibrodysplasia ossificans progressiva. However, the early pedunculated appearance in fibrodysplasia ossificans progressiva is not seen in the normal spur. In addition, the spur in fibrodysplasia ossificans progressiva persists in childhood.

### Conclusion

Double calcaneal ossification centers in early infancy and plantar calcaneal spurs in childhood may be significant radiologic findings useful for early diagnosis of fibrodysplasia ossificans progressiva.


**Acknowledgments** The authors appreciate members of skeldys.org for their enthusiastic web discussion concerning patients 2 and 3. This work was supported in partly by Research Committee on Fibrodysplasia Ossificans Progressiva from the Ministry of Health, Labor and Welfare of Japan.

### Compliance with ethical standards

**Conflicts of interest** None

### References

1. Shore EM, Xu M, Feldman GJ et al (2006) A recurrent mutation in the BMP type I receptor *ACVR1* causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nat Genet* 38:525–527



**Fig. 5** Lateral foot radiograph in a boy with fibrodysplasia ossificans progressiva (case 8 in Table 1) at 5 years, 10 months of age shows a small spur from the plantar aspect of the posterior calcaneal body (arrow)



2. Pignolo RJ, Shore EM, Kaplan FS (2013) Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. *Pediatr Endocrinol Rev* 10:437–448
3. Nakashima Y, Haga N, Kitoh H et al (2010) Deformity of the great toe in fibrodysplasia ossificans progressiva. *J Orthop Sci* 15:804–809
4. Mishima K, Kitoh H, Katagiri T et al (2011) Early clinical and radiographic characteristics in fibrodysplasia ossificans progressiva: a report of two cases. *J Bone Joint Surg Am* 93, e52
5. Mishima K, Kitoh H, Haga N et al (2014) Radiographic characteristics of the hand and cervical spine in fibrodysplasia ossificans progressiva. *Intractable Rare Dis Res* 3:46–51
6. van Wiechen PJ (1987) Reversed calcaneal spurs in children. *Skeletal Radiol* 16:17–18
7. Robinson HM (1976) Symmetrical reversed plantar calcaneal spurs in children. A normal variant? *Radiology* 119:187–188
8. Sever JW (1930) Bifid os calcis. *Surg Gynecol Obstet* 50:1012–1013
9. Ogden JA (1982) Anomalous multifocal ossification of the os calcis. *Clin Orthop Relat Res* 162:112–118
10. Szaboky GT, Anderson JJ, Wiltsie RA (1970) Bifid os calcis. An anomalous ossification of the calcaneus. *Clin Orthop Relat Res* 68:136–137
11. Cormier-Daire V, Savarirayan R, Unger S et al (2001) “Duplicate Calcaneus”: a rare developmental defect observed in several skeletal dysplasias. *Pediatr Radiol* 31:38–42
12. Krakow D, Robertson SP, King LM et al (2004) Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis. *Nat Genet* 36:405–410
13. Zheng L, Baek HJ, Karsenty G et al (2007) Filamin B represses chondrocyte hypertrophy in a Runx2/Smad3-dependent manner. *J Cell Biol* 178:121–128



# Criteria for radiologic diagnosis of hypochondroplasia in neonates

Tomoko Saito<sup>1</sup> · Keisuke Nagasaki<sup>1</sup> · Gen Nishimura<sup>2</sup> · Masaki Wada<sup>1</sup> ·  
Hiromi Nyuzuki<sup>1</sup> · Masaki Takagi<sup>3,4</sup> · Tomonobu Hasegawa<sup>4</sup> · Naoko Amano<sup>4</sup> ·  
Jun Murotsuki<sup>5</sup> · Hideaki Sawai<sup>6</sup> · Takahiro Yamada<sup>7</sup> · Shuhei Sato<sup>8</sup> · Akihiko Saitoh<sup>1</sup>

Received: 26 February 2015 / Revised: 20 October 2015 / Accepted: 19 November 2015 / Published online: 11 February 2016  
© Springer-Verlag Berlin Heidelberg 2016

## Abstract

**Background** A radiologic diagnosis of hypochondroplasia is hampered by the absence of age-dependent radiologic criteria, particularly in the neonatal period.

**Objective** To establish radiologic criteria and scoring system for identifying neonates with fibroblast growth factor receptor 3 (FGFR3)-associated hypochondroplasia.

**Materials and methods** This retrospective study included 7 hypochondroplastic neonates and 30 controls. All subjects underwent radiologic examination within 28 days after birth. We evaluated parameters reflecting the presence of (1) short ilia, (2) squared ilia, (3) short greater sciatic notch, (4) horizontal acetabula, (5) short femora, (6) broad femora, (7) metaphyseal flaring, (8) lumbosacral interpedicular distance narrowing and (9) ovoid radiolucency of the proximal femora.

**Results** Only parameters 1, 3, 4, 5 and 6 were statistically different between the two groups. Parameters 3, 5 and 6 did not overlap between the groups, while parameters 1 and 4 did. Based on these results, we propose a scoring system for hypochondroplasia. Two major criteria (parameters 3 and 6) were assigned scores of 2, whereas 4 minor criteria (parameters 1, 4, 5 and 9) were assigned scores of 1. All neonates with hypochondroplasia in our material scored  $\geq 6$ .

**Conclusion** Our set of diagnostic radiologic criteria might be useful for early identification of hypochondroplastic neonates.

**Keywords** Achondroplasia · FGFR3 · Hypochondroplasia · Neonate · Radiography · Radiologic diagnosis · Scoring system

✉ Keisuke Nagasaki  
nagasaki@med.niigata-u.ac.jp

<sup>1</sup> Division of Pediatrics,  
Department of Homeostatic Regulation and Development,  
Niigata University Graduate School of Medical and Dental Sciences,  
1-757 Asahimachi-Dori, Chu-Ou-Ku,  
Niigata 951-8510, Japan

<sup>2</sup> Department of Radiology,  
Tokyo Metropolitan Children's Medical Center,  
Tokyo, Japan

<sup>3</sup> Department of Endocrinology,  
Tokyo Metropolitan Children's Medical Center,  
Tokyo, Japan

<sup>4</sup> Department of Pediatrics,  
Keio University School of Medicine,  
Tokyo, Japan

<sup>5</sup> Department of Maternal and Fetal Medicine,  
Tohoku University Graduate School of Medicine,  
Miyagi Children's Hospital,  
Sendai, Japan

<sup>6</sup> Departments of Obstetrics and Gynecology,  
Hyogo College of Medicine,  
Hyogo, Japan

<sup>7</sup> Departments of Obstetrics and Gynecology,  
Hokkaido University Hospital,  
Hokkaido, Japan

<sup>8</sup> Department of Obstetrics and Gynecology,  
Aomori Rosai Hospital,  
Aomori, Japan

## Introduction

Hypochondroplasia is the mildest form of fibroblast growth factor receptor 3 (FGFR3)-associated skeletal dysplasia with an incidence of about 1 in 50,000 [1]. Affected individuals usually present after 2 years of age and seek medical help at preschool age because of mild body disproportion and short stature. A diagnosis of hypochondroplasia rests on the presence of several distinctive radiologic findings, such as broad long bones, lumbosacral interpedicular distance narrowing, short femoral necks and elongation of the fibula [2, 3]. However, the diagnosis of hypochondroplasia is hampered by the absence of age-dependent radiologic criteria, particularly in the neonatal period. It has been reported that younger affected children are not definitively diagnosed with hypochondroplasia [4].

We previously reported two cases of hypochondroplasia in children with FGFR3 mutations, focusing on prenatal ultrasonography findings in the third trimester and postnatal radiologic findings [5]. These children had short femora with increased biparietal diameter in utero; however, they were not diagnosed with hypochondroplasia in the neonatal period. The final diagnosis was made at the age of 3 years, when they visited our clinic because of short stature. Upon retrospective radiologic review, we learned that the radiologic findings relevant to hypochondroplasia were apparent in the neonatal period and that radiologic diagnosis may have been even easier in the neonatal period than in early childhood. The manifestations related to the ilia and proximal femora were particularly useful. The identification of short, squared ilia with short greater sciatic notches and horizontal acetabula along with the ovoid radiolucency of the proximal femora mimicking that of achondroplasia warranted the diagnosis.


The present study is dedicated to radiologic features in hypochondroplastic neonates with FGFR3 mutations and quantitative measurements that facilitate definitive diagnosis. We propose radiologic criteria for the identification of hypochondroplasia in the neonatal period.

## Materials and methods

Subjects included seven hypochondroplasia neonates with FGFR3 mutations, three term neonates with nonsyndromic fetal growth restriction, and 30 term control subjects with available results of radiologic examination within 28 days after birth. All hypochondroplasia neonates underwent radiologic examination in the neonatal period, such as partial skeletal survey or chest and abdominal radiographs, because of short femoral length on fetal ultrasonography or clinically suspected disproportionate micromelia. Control subjects and individuals with nonsyndromic growth restriction were hospitalized from

2010 to 2014 and were born after 36 weeks of gestation. They did not have major congenital anomalies, and they underwent radiologic examination with extension position of hip joint and knee joint because of transient tachypnea of the newborn, meconium aspiration syndrome or suspected neonatal infection. We hypothesized that skeletal changes in the pelvic bones, femora and lumbar spine, which were seen in achondroplasia, were most useful for the diagnosis of hypochondroplasia. Accordingly, we calculated eight parameters and monitored one radiologic sign: (1) ratio of maximal transverse diameter of the ilia to its maximal longitudinal diameter (assessment of short ilia), (2) iliac angle (squared ilia), (3) length of the greater sciatic notches (short greater sciatic notch), (4) acetabular angle (horizontal acetabula), (5) ratio of femoral length (FL) to body length (femoral shortening), (6) ratio of diameter of the femoral mid-shaft to femoral length (broad femora), (7) ratio of width of the distal femoral metaphysis to femoral length (metaphyseal flaring), (8) ratio of interpedicular distance of the L1 vertebra to that of L4 (lumbosacral interpedicular distance narrowing) and (9) presence or absence of ovoid radiolucency of the proximal femora. Measurement procedures are illustrated in Fig. 1.

The open-source OsiriX software dedicated to the analysis of Digital Imaging and Communications in Medicine (DICOM) images (<http://homepage.mac.com/rossetantoine/osirix>) was



**Fig. 1** Diagrams illustrate the measurements based on radiologic findings. The dotted line connects the bottom ends of the ilia: **a** maximal transverse iliac diameter, **b** maximal longitudinal iliac diameter, **c** greater sciatic notch, **d** acetabular roof angle, **e** iliac angle (formed by the tangent line of iliac wing with dotted line), **f** femur length, **g** mid-femur width, **h** maximal distal width of the femur

used for performing measurements. Only radiographs taken with the hip and knee joints extended and without significant joint rotation were analyzed.

Statistical significance of differences between control subjects and hypochondroplasia subjects was analyzed with the Mann–Whitney *U* test. A *P*-value<0.01 was considered significant. All analyses were performed with JMP, version 10.0 (SAS Institute Inc., Cary, NC, USA).

This study was approved by the Institutional Review Board Committee at Niigata University School of Medicine, and informed consent was given by the parents or guardians of the patients with hypochondroplasia.

**Results**

Clinical manifestations of hypochondroplasia are summarized in Table 1. All the subjects with hypochondroplasia showed low femoral length and biparietal diameter at or above the higher limit of the normal range on prenatal ultrasonography. The results of the Shapiro-Wilk *W* test showed that all the measurement parameters in the control group followed the Gaussian distribution. The measurement parameters for short ilia, short greater sciatic notch, horizontal acetabula, short femora and broad femora (parameters 1, 3, 4, 5 and 6) were statistically different between the hypochondroplasia and control groups (*P*<0.01), while the remaining parameters were not. Parameters 3, 5 and 6 did not overlap between the 2 groups, while parameters 1 and 4 did (Fig. 2). To distinguish subjects with hypochondroplasia from control subjects, we defined the following cut-off values based on the differences of at least 2 standard deviations from the average values in the control group: >0.80 for parameter 1, <7.5 mm for parameter 3, <22° for parameter 4, <0.14 for parameter 5 and >0.10 for parameter 6. Although assessment of ovoid radiolucency of the proximal femora was somewhat subjective, careful interpretation confirmed its presence in 6 out of 7 children with

hypochondroplasia (Fig. 3). There were no abnormalities in other bones.

Based on these results, we defined a tentative scoring system for the diagnosis of hypochondroplasia (Fig. 4). The 2 major criteria (parameters 3 and 6 – short greater sciatic notch and broad femora) were assigned scores of 2. In addition, 4 minor criteria (parameters 1, 4, 5 and 9) were assigned scores of 1 for the following reasons: (a) femoral shortening (parameter 5) was a nonspecific finding; (b) short ilia and acetabular angle (parameters 1 and 4) showed overlaps between the hypochondroplasia neonates and normal controls and (c) the results of the assessment of ovoid radiolucency (parameter 9) were interpreter-dependent. Because all 7 neonates with hypochondroplasia showed combined scores of 6 points or more (Table 2), we presumed that a total score of 6 points or higher warrants thinking about a diagnosis of FGFR3-associated hypochondroplasia. We applied this scoring system to 30 control subjects and the 3 neonates with nonsyndromic growth restriction. The corresponding total scores were less than two in all these cases.

**Discussion**


It was previously believed that the diagnosis of hypochondroplasia was difficult to establish in infancy. However, recent in utero identification of short femora on prenatal ultrasonography has led to several reports on the early diagnosis of hypochondroplasia [6–10]. It has been found that discrepancy in growth between femoral length and biparietal diameter in the third trimester is highly indicative of this disease [5, 9, 11]. The final diagnosis of hypochondroplasia is established based on the molecular analysis of the FGFR3 gene. This test, however, is relatively expensive and a reliable radiology-based scoring system would be highly beneficial.

**Table 1** Genetic and clinical manifestations in 7 children with hypochondroplasia

Child	1	2	3	4	5	6	7
FGFR3 mutation	L324V	N540K	N540K	N540K	S351C	N540K	N540K
Femur length standard deviation score in last trimester	-2.1	-2	-	-3.3	-3.3	-3.5	-2.7
Biparietal diameter standard deviation score in last trimester	0.3	1.3	-	3.3	0.3	3	1.8
Gestational age (weeks) at birth	38	40	38	38	39	38	39
Birth weight (g)	2,780	3,270	2,603	3,102	3,146	2,936	3,228
Birth length (cm)	45.5	49	44.5	49	47	46	45.5
Sex	M	M	F	F	M	F	M
Age at diagnosis <sup>a</sup>	3y 6 m	3y 6 m	1 m	2y	1y 7 m	1 m	1 m

*M* male, *F* female

<sup>a</sup> The diagnosis was based on the radiologic findings




**Fig. 2** Results of the measurements in 30 controls and in 7 children with hypochondroplasia. The bottoms and tops of the boxes correspond to the first and third quartiles, respectively, and the horizontal lines inside the boxes indicate the median values. Boxes show as follows: (1) Ratio of maximal transverse diameter to maximal longitudinal diameter of the ilia, (2) iliac angle, (3) length of the greater sciatic notches, (4) acetabular

angle, (5) ratio of femoral length to body length, (6) ratio of diameter of the femoral mid-shaft to femoral length, (7) ratio of width of the distal femoral metaphysis to femoral length and (8) ratio of interpediculate distance of L1 to L4. Parameters 1, 3, 4, 5 and 6 were significantly different between the hypochondroplasia and control groups ( $P < 0.01$ ). *HCH* hypochondroplasia, *N* control group

**Fig. 3** Ovoid radiolucency of the femoral neck in anteroposterior radiographs. **a** A child in the control group; **b** Child 5 in the hypochondroplasia group (male neonate); **c** Child 6 in the hypochondroplasia group (female neonate); **d** Child 7 in the hypochondroplasia group (male neonate). An ovoid lucency (arrowheads in **b-d**) is seen in the femoral neck of the children with hypochondroplasia. All the subjects underwent radiologic examination in the neonatal period.





**Fig. 4** Proposed flow chart for diagnosis of hypochondroplasia in the neonatal period

In this study, we used radiologic measurements of the ilia and femora to verify that hypochondroplastic neonates had short ilia with short greater sciatic notches and short, broad long bones. Furthermore, ovoid radiolucency of the proximal femoral metaphysis typical of achondroplasia, was always discernible. Horizontal acetabula were also evident, but their presence was inconsistent among the hypochondroplasia neonates. In contrast, although lumbosacral interpedicular distance narrowing is an important diagnostic sign in childhood, it was not useful in our neonatal patients.

Identification of cases with mildly shortened femoral length has become more common with the widespread utilization of fetal ultrasonography. Such cases indicate the presence of mild bone dysplasia exemplified by hypochondroplasia, chromosome disorders such as trisomy 21, and nonsyndromic or syndromic fetal growth retardation (FGR). Although still tentative, our diagnostic criteria

might be useful for the differentiation between hypochondroplasia and nonsyndromic growth restriction. Moreover, the radiologic changes in neonates with hypochondroplasia are relatively mild, and their identification may be difficult for nonexperts in bone dysplasias. This emphasizes the potential value of the measurement parameters proposed in the present study.

However, our scoring system is based on nonspecific skeletal changes, such as iliac hypoplasia, a scooped-out appearance of the proximal femora and short, broad femora; thus, it does not enable one to distinguish hypochondroplasia from other skeletal dysplasias, including mild achondroplasia [12]. The final radiologic diagnosis should depend on the overall pattern recognition and other distinctive skeletal changes. For example, cartilage hair hypoplasia causes a diagnostic difficulty in the neonatal period, as does hypochondroplasia [13]. However, mild femoral bowing and round distal femoral epiphyseal ossification warrant a diagnosis of cartilage hair hypoplasia. Molecular diagnoses are essential in difficult cases. To be essential, our scoring system would be utilized as screening for mild neonatal skeletal dysplasias.

The relatively small number of subjects is also a limitation of this study. Furthermore, all measurements were obtained in term neonates; it is currently unknown whether these data are applicable to premature neonates. Finally, correct positioning (extended hip and knee joints without joint rotation) is essential for obtaining interpretable measurements. Further studies in a larger population of hypochondroplasia, including premature neonates, are warranted to validate these criteria for the diagnosis of hypochondroplasia.

**Conclusion**

We propose a set of diagnostic radiologic criteria that can be useful for early identification of hypochondroplastic neonates.

**Table 2** Application of the new scoring system to 7 neonates with hypochondroplasia

Parameter	Child	1	2	3	4	5	6	7
3	Short greater sciatic notches	2	2	2	2	2	2	2
6	Broad femora	2	2	2	2	2	2	2
1	Short ilia	1	1	1	1	1	1	0
4	Horizontal acetabula	1	1	0	1	0	1	0
5	Femoral shortening	1	1	1	1	1	1	1
9	Ovoid radiolucency of the femoral neck	1	0	1	1	1	1	1
Total score		8/8	7/8	7/8	8/8	7/8	8/8	6/8

**Acknowledgments** We would like to thank the following associates for their assistance with this study: Norio Shinozuka, MD, Akinori Taguchi, MD, Hidenori Haruna MD, and Kaoru Obinata, MD. This study was supported by the NNPL Growth Hormone Award 2010 and a grant-in-aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan, H26-Nanchitou (Nan)-Ippan-055.

**Compliance with ethical standards**

**Conflict of interest** None



## References

1. Hicks J (2003) Achondroplasia family of skeletal dysplasia. In: The National Organization for Rare Disorders, Inc., editors. *NORD guide to rare disorders*. Lippincott Williams & Wilkins, Philadelphia, p 144
2. Hall BD, Spranger J (1979) Hypochondroplasia: clinical and radiological aspects in 39 cases. *Radiology* 133:95–100
3. Matsui Y, Yasui N, Kimura T et al (1998) Genotype phenotype correlation in achondroplasia and hypochondroplasia. *J Bone Joint Surg (Br)* 80:1052–1056
4. Appan S, Laurent S, Chapman M et al (1990) Growth and growth hormone therapy in hypochondroplasia. *Acta Paediatr Scand* 79: 796–803
5. Saito T, Nagasaki K, Nishimura G et al (2012) Radiological clues to the early diagnosis of hypochondroplasia in the neonatal period: report of two patients. *Am J Med Genet A* 158A:630–634
6. Bonnefoy O, Delbosc JM, Maugey-Laulom B et al (2006) Prenatal diagnosis of hypochondroplasia: three-dimensional multislice computed tomography findings and molecular analysis. *Fetal Diagn Ther* 21:18–217
7. Huggins MJ, Mernagh JR, Steele L et al (1999) Prenatal sonographic diagnosis of hypochondroplasia in a high-risk fetus. *Am J Med Genet* 87:226–229
8. Jones SM, Robinson LK, Sperrazza R (1990) Prenatal diagnosis of skeletal dysplasia identified postnatally as hypochondroplasia. *Am J Med Genet* 36:404–407
9. Karadimas C, Sifakis S, Valsamopoulos P et al (2006) Prenatal diagnosis of hypochondroplasia: report of two cases. *Am J Med Genet A* 140:998–1003
10. Kataoka S, Sawai H, Yamada H et al (2004) Radiographic and genetic diagnosis of sporadic hypochondroplasia early in the neonatal period. *Prenat Diagn* 24:45–49
11. Lemyre E, Azouz EM, Teebi AS et al (1999) Bone dysplasia series. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: review and update. *Can Assoc Radiol J* 50:185–197
12. Xue Y, Sun A, Mekikian PB (2014) FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry. *Mol Genet Genomic Med* 2:497–503
13. Le Merrer M, Maroteaux P (1991) Cartilage hair hypoplasia in infancy: a misleading chondrodysplasia. *Eur J Pediatr* 150: 847–851

# Survey of prenatal testing for genetic disorders in Japan: Recent report

Takahiro Nobuzane<sup>1</sup>, Takahiro Yamada<sup>2</sup>, Kiyonori Miura<sup>3</sup>, Hideaki Sawai<sup>4</sup>,  
Hideaki Masuzaki<sup>3</sup> and Yoshiki Kudo<sup>1</sup>

Departments of Obstetrics and Gynecology, <sup>1</sup>Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima,  
<sup>2</sup>Hokkaido University Graduate School of Medicine, Sapporo, <sup>3</sup>Nagasaki University Graduate School of Biomedical Sciences, Nagasaki,  
and <sup>4</sup>Hyogo College of Medicine, Nishinomiya, Japan

## Abstract

**Aim:** In order to investigate the current status of prenatal testing for genetic disorders, we conducted a multi-center retrospective questionnaire survey.

**Methods:** The questionnaire was sent to 105 facilities with genetic counseling systems. The questionnaire consisted of two parts: (i) the number of prenatal tests conducted for genetic disorders from January 2010 to December 2012, whether the laboratory was combined with the counseling facility or separate, the sampling procedure method, the testing results, and the outcomes of the affected fetus in addition to treatment; and (ii) a survey of personal comments regarding prenatal testing for genetic disorders.

**Results:** We received responses from 69 of the 105 facilities (65.7%), and genetic testing was performed at 26 of these facilities. Nucleic acid sequential testing was performed on 45 disorders and 252 cases during a three-year period. There were 67 cases of affected fetuses. Six cases continued pregnancy and were treated. The comment survey highlighted difficulties in locating a laboratory to assess prenatal samples, as well as inadequate counseling and preparation for genetic disorders.

**Conclusions:** Our study revealed that a number of prenatal testing for genetic disorders are conducted in Japan; however, it is difficult for counselors to locate a laboratory capable of testing for specific genetic disorders. Inadequate counseling and healthcare providers' lack of knowledge is a current problem. A well-established system of prenatal testing for genetic disorders and the further education of general physicians is required.

**Key words:** counseling, genetic disorder, prenatal testing.

## Introduction

The advances in molecular genetics enable us to analyze gene mutations in patients with genetic disorders. Genetic information remains constant over a lifetime; therefore, it requires careful scrutiny via preclinical and prenatal genetic testing. The Japanese Association of Medical Sciences and the Japan Society of Obstetrics and Gynecology (JSOG) developed guidelines and opinions for appropriate genetic counseling prior to prenatal

genetic testing.<sup>2,3</sup> Based on this, pregnant carriers of genetic disorders in the neonatal or childhood periods can obtain adequate genetic counseling before and after prenatal testing for the genetic disorder.

Several methods for the prenatal testing of genetic disorders are available. The majority test for chromosomal abnormalities, such as aneuploidy, by means of a maternal serum blood test, ultrasound examination, and non-invasive prenatal genetic testing.<sup>4</sup> Recent advances in molecular biology have made major contributions to

Received: October 14 2015.

Accepted: December 18 2015.

Correspondence: Dr Takahiro Nobuzane, Chugoku Rosai Hospital, 1-5-1 Hiro-Tagaya, Kure 737-0193, Japan. Email: nobuzane@chugokuh.rofuku.go.jp

This article was previously published in Japanese in *ACTA OBSTETRICA ET GYNAECOLOGICA JAPONICA* 2015; 67: 1551–1554.<sup>1</sup>

prenatal diagnosis. An increasing number of genetic disorders have been identified in the prenatal period using fetal cells derived from invasive testing.<sup>5-9</sup>

In some genetic disorders, such as ornithine transcarbamylase deficiency, prenatal genetic testing is useful for neonatal treatment.<sup>10</sup> However, general obstetricians are not familiar with the requirements for prenatal testing and lack current information regarding genetic testing and neonatal treatment. Additionally, in Japan, private companies that provide DNA testing do not offer the prenatal service, and almost all prenatal molecular testing is performed in non-commercial research laboratories. Therefore, it is difficult to find an appropriate laboratory for the prenatal testing of genetic disorders.

In order to investigate the current status of prenatal testing for genetic disorders, we, as members of the subcommittee in Perinatology Committee of the JSOG, conducted a multicenter retrospective questionnaire survey.

## Methods

The questionnaire was sent to 105 facilities, including Miyagi Children's Hospital and 104 other facilities, which belong to Japan's National Liaison Council for Clinical Sections of Medical Genetics and contain genetic counseling systems.

The questionnaires consisted of two parts: (i) the number of prenatal testing for genetic disorders evaluated from January 2010 to December 2012, whether the laboratory that received the samples contained a counseling facility or the testing was outsourced domestically or abroad, the sampling procedure, the testing results and the outcome of the affected fetus and treatment; and (ii) a survey of personal comments for prenatal genetic testing. We allowed for five options and space for a description.

## Results

We received responses from 69 of the 105 facilities (65.7%). Prenatal testing for genetic disorders was conducted on 46 disorders and 277 cases during a three-year period. Testing was performed at 26 facilities (Table 1). Nucleic acid sequential testing was performed on 45 disorders and 252 cases. Only gender testing was performed on nine disorders and 22 cases, while only enzymatic activity testing was performed on two disorders and two cases. Genetic testing was not performed for a chromosome abnormality in one case.

The number of prenatal tests conducted for each disorder and the testing laboratory is presented in Table 2. The

**Table 1** The number of prenatal tests for genetic disorders conducted at each facility during a three-year period

Number of genetic tests	Number of facilities
1-3	12
4-9	7
More than 9	7

Ninety-four genetic tests were conducted at the National Center for Child Health and Development, 64 at Tokyo Women's Medical University Hospital, 16 at Osaka University Hospital, 12 at Tottori University Hospital, 10 at Hokkaido University Hospital, 10 at Hiroshima University Hospital and 10 at Miyagi Children's Hospital.

testing laboratory and the counseling facilities were the same for 32 disorders and 142 cases (56.3%). The testing was outsourced within Japan for 26 disorders and 107 cases (42.5%). Among them, 13 disorders were tested at another facility that responded to the questionnaire. The remaining disorders were assessed at unknown facilities. Genetic testing was conducted abroad for three disorders and three cases (1.2%); however, all three diseases could have been assessed at one of the domestic facilities that responded to the questionnaire.

In regard to the type of sampling procedure, chorionic villi sampling (CVS) was conducted on 203 cases (73%), amniocentesis on 70 cases (25%), and the other four cases (2%) entailed fetal gender testing via maternal blood examination. There were 67 cases of affected fetuses. Among autosomal dominant disorders, four of 12 cases (33.3%) were affected, while 63 of 240 cases (26.2%) were affected by recessive disorders. Two cases were undefined as a result of contamination.

The outcomes of the affected fetuses are presented in Table 3. In the six cases in which the pregnancy was continued, the disorders were treated. One infant affected with the Wiskott-Aldrich syndrome was treated with an unknown medication after birth. In two cases of a female fetus affected with 21-hydroxylase-deficient congenital adrenal hyperplasia (21-OHD CAH), the mothers continued glucocorticoid intake to prevent neonatal masculinization of genitalia. In a case of a male fetus affected with 21-OHD CAH, the mother discontinued glucocorticoid intake after being apprised of the fetal gender. In another case of a female fetus affected with 21-OHD CAH, the prenatal diagnosis suggested an atypical outcome of 'not affected'. Because of the incorrect prenatal diagnosis, the mother discontinued glucocorticoid intake and the infant exhibited masculinization of genitalia at birth. In a case of myotonic dystrophy, prenatal testing showed that the fetus was not affected; however, the infant was floppy, and was diagnosed with congenital myotonic dystrophy.



**Table 2** The number of genetic disorders identified and destinations of the testing samples

Disease	Number of genetic tests	Number of cases/facilities (Same) <sup>†</sup>	Number of cases/facilities (Domestic) <sup>‡</sup>	Number of cases/facilities (Abroad) <sup>§</sup>
<b>Neuromuscular Diseases</b>				
Fukuyama-type congenital muscular dystrophy	52	24/4	28/7	ND
Spinal muscular atrophy	46	19/1	27/9	ND
Duchenne muscular dystrophy	38	28/6	10/2	1/1
Myotonic dystrophy	9	1/1	8/5	ND
X-linked hydrocephalus	6	2/2	4/4	ND
Myotubular myopathy	5	3/2	2/2	ND
Ryanodine receptor disorders	5	2/2	3/1	ND
Pelizaeus-Merzbacher disease	4	3/1	1/1	ND
Adrenoleukodystrophy	1	ND	1/1	ND
Lissencephaly	1	ND	1/1	ND
Joubert syndrome	1	ND	1/1	ND
<b>Metabolic Diseases</b>				
Ornithine transcarbamylase deficiency	7	6/3	1/1	ND
Hunter syndrome	6	5/1	1/1	ND
Carbamoyl phosphate synthetase deficiency	4	3/2	1/1	ND
Gaucher disease	4	2/1	2/2	ND
Methylmalonic acidemia	3	3/3	ND	ND
Mucopolipidosis II	3	3/2	ND	ND
MCT8 gene disorder	3	ND	3/1	ND
Menkes disease	2	2/1	ND	ND
Krabbe disease	2	2/1	ND	ND
Zellweger syndrome	2	ND	2/2	ND
Pompe disease	1	1/1	ND	ND
Pyruvate dehydrogenase complex deficiency	1	1/1	ND	ND
Glutaric acidemia	1	1/1	ND	ND
Very-long-chain acyl-CoA dehydrogenase deficiency	1	1/1	ND	ND
Trifunctional protein deficiency	1	1/1	ND	ND
Metachromatic leukodystrophy	1	1/1	ND	ND
Tay-Sachs disease	1	1/1	ND	ND
Holocarboxylase synthetase deficiency	1	ND	1/1	ND
Niemann-Pick disease	1	ND	1/1	ND
<b>Endocrine Diseases</b>				
21-Hydroxylase-deficient congenital adrenal hyperplasia	17	13/4	4/3	ND
<b>Skin Diseases</b>				
Xeroderma pigmentosum	3	3/1	ND	ND
Congenital ichthyosis	3	ND	3/3	ND
<b>Bone Diseases</b>				
Hypophosphatasia	3	3/2	ND	ND
Osteogenesis imperfecta II	1	ND	1/1	ND
Achondroplasia	1	1/1	ND	ND
<b>Urinary Tract Disorders</b>				
Lowe syndrome	2	1/1	ND	1/1
Autosomal recessive polycystic kidney	1	1/1	ND	ND
Congenital nephrotic syndrome of the Finnish type	1	ND	1/1	ND
<b>Immunodeficiency Diseases</b>				
X-linked severe combined immunodeficiency	2	2/1	ND	ND
Wiskott-Aldrich syndrome	2	1/1	ND	1/1
Chronic granulomatous disease	1	1/1	ND	ND
<b>Other</b>				
Juvenile polyposis syndrome	1	ND	1/1	ND
Bannayan-Riley-Ruvalcaba syndrome	1	ND	1/1	ND

<sup>†</sup>Same: the laboratory that conducted the genetic testing was the same facility. <sup>‡</sup>Domestic: the laboratory that conducted the genetic testing was another domestic facility (in Japan). <sup>§</sup>Abroad: the laboratory that conducted the genetic testing was abroad (outside Japan). ND, no data.

**Table 3** Outcomes of affected fetuses

Outcome of affected fetuses	Number
Termination of pregnancy	57 (85%)
Continuation of pregnancy	6 (9%)
Unknown	4 (6%)

The percentage of respondents who provided comments is presented in Table 4. Representative descriptions included: 'It is necessary to locate an appropriate laboratory following each instance of genetic counseling, and the requirements for genetic testing differ for each laboratory'; and 'The incomplete system for genetic testing in domestic laboratories forces an increasing number of samples from patients to be sent abroad'.

## Discussion

In this report, we presented the current status of prenatal testing for genetic disorders in Japan. Forty-five disorders and 252 cases of prenatal genetic nuclear acid sequencing testing were conducted during a three-year period. To the best of our knowledge, this is the first nationwide report regarding prenatal testing for genetic disorders in Japan. However, this survey had some limitations.

Any single facility could not conduct all types of genetic testing. The testable genetic disorders differed at each facility. Therefore, it was difficult to ascertain how many samples were submitted to outsourced laboratories. In this survey, 13 genetic disorders could not be assessed at the responding facilities. This indicated that a facility not surveyed or that did not respond to the questionnaire actually conducted a number of prenatal tests for genetic disorders.

**Table 4** Comments for prenatal testing for genetic disorders

Comments	Agreement† (%)
There are no commercial laboratories to treat prenatal genetic samples in Japan.	78.3
Patient consultation was too late for appropriate evaluation (e.g. after pregnancy).	58.0
Case lacks genetic testing of the proband.	52.2
Approval by ethical review board is required in each case.	37.7
Genetic counseling was inadequate.	20.3

†Agreement denotes the percentage of respondents who made the comment.

In the comment survey for prenatal genetic testing, 78% of responding facilities advised that no commercial laboratory was available to assess prenatal genetic samples. This might indicate frustration with suboptimal systems for the prenatal testing of genetic disorders in Japan. Some respondents were unsure of the accuracy of the testing, and misinterpretation could lead to an inappropriate choice. Furthermore, the individuals in charge of the prenatal testing carried a heavy responsibility in terms of the results. It is difficult for counselors to obtain appropriate prenatal testing in Japan. Even if a domestic laboratory could have conducted the prenatal testing for a genetic disorder, the counselors may have thought that it would be easier to send the samples abroad. Testing abroad may often be an expensive and time-consuming process; thus, a well-established system of prenatal genetic testing within Japan is needed.

In the comment survey, 58% of the responding facilities stated that the consultation for prenatal testing was too late for appropriate evaluation (e.g. after establishment of next pregnancy); and 52% of the respondents commented that some cases lacked genetic testing of the proband. Furthermore, some respondents also noted that previous counseling was inadequate, which impacted the counseling quality for subsequent pregnancy. These indicated that general physicians and patients were unfamiliar with the preparation required for appropriate genetic testing in subsequent pregnancy. Therefore, education of general physicians regarding prenatal testing for genetic disorders would be beneficial.

In conclusion, our study revealed that a number of prenatal testing for genetic disorders were conducted in Japan; however, it was difficult for counselors to locate an appropriate laboratory that could test for a specific genetic disorder. Inadequate counseling and testing for genetic disorders is a current problem. Therefore, in Japan, a well-established system of prenatal testing for genetic disorders and further educational programs for general physicians is required.

## Acknowledgments

This work was fully supported by JSOG. We would like to express our sincere gratitude to the 69 facilities for honorably responding to this survey.

## Disclosure

The authors have no conflict of interest to declare.

## References

1. Nobuzane T, Yamada T, Miura K, Sawai H, Kudo Y. Survey of prenatal testing for genetic disorders. *Acta Obstet Gynaecol Jpn* 2015; **67**: 1551–1554 (In Japanese).
2. The Japanese Association of Medical Sciences. Guidelines for Genetic Tests and Diagnoses in Medical Practice. [Cited 18 Feb 2011.] Available from URL: [http://jams.med.or.jp/guideline/genetics-diagnosis\\_e.pdf](http://jams.med.or.jp/guideline/genetics-diagnosis_e.pdf)
3. Japan Society of Obstetrics and Gynecology. [The opinion about prenatal genetic testing and diagnosis.] (in Japanese) [Cited 22 Jun 2013.] Available from URL: [http://www.jsog.or.jp/ethic/H25\\_6\\_shusseimae-idengakutekikensa.html](http://www.jsog.or.jp/ethic/H25_6_shusseimae-idengakutekikensa.html)
4. Sago H, Sekizawa A; Japan NIPT consortium. Nationwide demonstration project of next-generation sequencing of cell-free DNA in maternal plasma in Japan: 1-year experience. *Prenat Diagn* 2015; **35**: 331–336.
5. Suzumori N, Mornet E, Mizutani E, Obayashi S, Ozaki Y, Sugiura-Ogasawara M. Prenatal diagnosis of familial lethal hypophosphatasia using imaging, blood enzyme levels, chorionic villus sampling and archived fetal tissue. *J Obstet Gynaecol Res* 2011; **37**: 1470–1473.
6. Saito K. Prenatal diagnosis of Fukuyama congenital muscular dystrophy. *Prenat Diagn* 2006; **26**: 415–417.
7. Tamasu S, Nishio H, Ayaki H *et al.* Prenatal diagnosis of a Japanese family at risk for Tay-Sachs disease. Application of a fluorescent competitive allele-specific polymerase chain reaction (PCR) method. *Kobe J Med Sci* 1999; **45**: 259–270.
8. Moriwaki S, Yamashita Y, Nakamura S *et al.* Prenatal diagnosis of xeroderma pigmentosum group A in Japan. *J Dermatol* 2012; **39**: 516–519.
9. Yamasaki M, Nonaka M, Suzumori N *et al.* Prenatal molecular diagnosis of a severe type of L1 syndrome (X-linked hydrocephalus). *J Neurosurg Pediatr* 2011; **8**: 411–416.
10. Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. Ornithine Transcarbamylase Deficiency. In: Pagon RA, Adam MP, Ardinger HH *et al.* (eds) *GeneReviews* [Cited 29 Aug 2013.] Available from URL: <http://www.ncbi.nlm.nih.gov/books/NBK154378/>

## ORIGINAL ARTICLE

# Parental serum alkaline phosphatase activity as an auxiliary tool for prenatal diagnosis of hypophosphatasia

Yuichiro Takahashi<sup>1\*</sup> , Hideaki Sawai<sup>2</sup>, Jun Murotsuki<sup>3</sup>, Shuhei Satoh<sup>4</sup>, Takahiro Yamada<sup>5</sup>, Hiromi Hayakawa<sup>6</sup>, Yutaka Kouduma<sup>7</sup>, Masakatsu Sase<sup>8</sup>, Atsushi Watanabe<sup>9</sup>, Osamau Miyazaki<sup>10</sup> and Gen Nishimura<sup>11</sup>

<sup>1</sup>Department of Fetal-Maternal Medicine, Nagara Medical Center, Gifu, Japan

<sup>2</sup>Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan

<sup>3</sup>Department of Obstetrics, Miyagi Children's Hospital, Sendai, Japan

<sup>4</sup>Department of Obstetrics and Gynecology, Elm Josei Clinic, Aomori, Japan

<sup>5</sup>Department of Obstetrics and Gynecology, Hokkaido University, Sapporo, Japan

<sup>6</sup>Department of Obstetrics and Gynecology, Aichi Children's Health and Medical Center, Aichi, Japan

<sup>7</sup>Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan

<sup>8</sup>Department of Obstetrics and Gynecology, Yamaguchi Grand Medical Center, Yamaguchi, Japan

<sup>9</sup>Division of Clinical Genetics, Nippon Medical School Hospital, Tokyo, Japan

<sup>10</sup>Department of Radiology, National Center for Child Health and Development, Tokyo, Japan

<sup>11</sup>Department of Radiology, Tokyo Metropolitan Kiyose Children's Hospital, Tokyo, Japan

\*Correspondence to: Yuichiro Takahashi. E-mail: [yuichiro@nagara-lan.hosp.go.jp](mailto:yuichiro@nagara-lan.hosp.go.jp)

## ABSTRACT

**Objective** The objective of this study is to clarify the usefulness of parental alkaline phosphatase (ALP) for prenatal diagnosis of hypophosphatasia (HPP).

**Methods** Maternal (m) and paternal (p) ALP values were measured in 77 cases from a multicenter cohort (fetal skeletal dysplasia forum in Japan) of cases with short limbs on ultrasonography during pregnancy. After birth, X-rays, cord blood ALP, and gene analysis were evaluated to achieve an exact diagnosis. The screening usefulness of ALP was examined retrospectively.

**Results** Seventeen cases were eventually diagnosed as HPP and 60 as not HPP; the overall mean m-ALP and p-ALP (standard deviation) values were 133.4 (53) versus 197 (69) IU/L and 149.6 (71.8) versus 231 (61.4) IU/L ( $p < 0.001$ ). Receiver operating characteristic curve analysis showed that the optimal m-ALP and p-ALP cutoff values were 123 and 165 IU/L, respectively. Presence of at least one of the m-ALP or p-ALP values abnormally low had a sensitivity, specificity, and positive predictive values of 82% (14/17), 93%, and 78%, respectively, for the diagnosis of HPP.

**Conclusion** Parental ALP measurement might be an auxiliary tool to hone in the prenatal diagnosis of fetal HPP.  
© 2017 John Wiley & Sons, Ltd.

Funding sources: This research is supported by research on rare and intractable diseases, Health and Labour Sciences Research Grants, H28-nanchitou(nan)-ippan-017.

Conflicts of interest: None declared

## INTRODUCTION

Hypophosphatasia (HPP) is a well-known metabolic bone disease caused by a defect involving impaired mineralization with thin limbs and long bone bowing. Short limbs characterize the condition especially in the Japanese population. The perinatal type is defined as a life-threatening fetal disease.<sup>1–3</sup> Recently, new enzyme-replacement therapy after birth has been reported as a possible and promising therapy. Thus, some babies could be saved by this therapy without major sequelae.<sup>4</sup>

After birth, exact diagnosis of HPP can be performed by radiographic examination, enzyme activities, and gene

analysis,<sup>5–7</sup> and, recently in Japan, clinical diagnosis by imaging after birth, gene analysis, and successful enzyme-replacement therapy has been reported.<sup>8</sup> As for the prenatal differential diagnosis of fetal skeletal dysplasia, ultrasonographic imaging is used first as a screening tool.<sup>9,10</sup> However, a definitive imaging diagnosis of HPP has not yet been established. Wenkert *et al.*<sup>11</sup> reported 15 different prenatal diagnoses, including type II osteogenesis imperfecta (OI) and campomelic dysplasia among 17 cases of benign-type HPP confirmed after birth. Given the new medical interventions available after birth, the focus has been on a more precise prenatal diagnosis. A definitive prenatal

diagnosis of HPP can be attained with tools other than imaging, such as parental and fetal gene analysis or measurement of cord blood alkaline phosphatase (ALP) activity. However, both methods are invasive and not cost-effective, given the large number of fetal skeletal dysplasias.

We analyzed the usefulness of parental blood ALP<sup>12,13</sup> as an auxiliary tool for the differential diagnosis of HPP from the many other fetal skeletal dysplasias and causes of short-limb fetuses in order to narrow down the differential diagnosis prior to proceeding to the diagnostic step, such as cord blood analysis of ALP, gene examination, and preparation of neonatal enzyme-replacement therapy. ALP activity increases gradually during pregnancy particularly in the third trimester, because of the contribution of the placental isoenzyme.<sup>13</sup> Thus, we have also assessed the effect of the trimesters of pregnancy on the screening efficacy of ALP measurement.

## MATERIALS AND METHODS

This was a retrospective analysis of all cases submitted to the Fetal Skeletal Dysplasia Forum in Japan from 2007 to 2016. Such forum consists of a panel of voluntary experts in prenatal diagnosis.

Final diagnoses were made by radiographic analysis and gene analysis after birth, when indicated, to attain the final diagnoses of thanatophoric dysplasia (TD), OI, HPP, campomelic dysplasia, spondyloepiphyseal dysplasia congenita, and others. Maternal skeletal diseases with clear phenotype were not included.

In all cases, maternal ALP activity and paternal ALP activity if possible were measured. Maternal ALP activity was measured through the prenatal period just after the initial preliminary diagnosis of fetal bone disease. After final diagnosis, the

parental ALP values and their accuracy for the exact diagnosis of fetal HPP were evaluated. ALP activity assays were performed in a few different ways. The value of the Japanese standard method, such as that of the Japanese Society of Clinical Chemistry,<sup>14</sup> was used, and the adult normal range has been established as 110–350 IU/L in every institute.

In our population, three major skeletal diseases are found more frequently: HPP, TD, and OI. Thus, the possibility of differential diagnosis was evaluated particularly focusing on these three diseases. Furthermore, the impact of gestational age on the accuracy of prenatal diagnosis was analyzed.

Statistical analysis was performed using SPSS version 20 (IBM Inc., Armonk, NY, USA) and PRISM version 5 (MDF Inc., Tokyo, Japan). A *p* value below 0.05 was considered significant. Receiver operating characteristic curve analysis was used to establish optimal screening thresholds of ALP values in maternal and paternal blood samples. All patients who registered with the fetal skeletal dysplasia forum provided written informed consent to participate in this study. The protocol was approved by the Institutional Review Board of Nagara Medical Center with regard to human rights and privacy issues.

## RESULTS

There were 77 cases in the cohort, including 17 of HPP (Table 1), 6 of achondrodysplasia, 18 of TD, 24 of OI, 2 of spondyloepiphyseal dysplasia congenita, 2 of campomelic dysplasia, 3 of fetal growth restriction, and 5 other skeletal dysplasias (Figure 1). The mean  $\pm$  standard deviation gestational age at measurement of maternal ALP was not significantly different between the HPP and non-HPP groups ( $26.7 \pm 5.7$  vs  $25.7 \pm 6.8$  weeks, respectively; *p* > 0.05). Overall,

Table 1 Parental serum ALP value and background of HPP cases

Case	GW measure	Maternal ALP	Paternal ALP	Umbilical ALP	Prognosis	Genetic analysis
1	17	81	54	4	Still birth	
2 <sup>15</sup>	18	160	250	2	Still birth	Paternal 1559delT, UPD
3	19	122	155	8	Still birth	1559delT, parent hetero
4	21	79	127	3	Still birth	
5	21	80	No data	No data	Still birth	
6	24	76	227	6	ND 37 weeks, 2119 g	
7	26	165	No data	No data	Alive, benign type	
8	27	62	No data	No data	Alive	
9	28	117	No data	6	ID 4 months	1559delT
10	29	165	121	7	Still birth 32 weeks, 1794 g	
11 <sup>8</sup>	29	110	No data	0	Alive, ERT	exon 12c 1471G >A
12	31	170	No data	3	ND, 31 weeks, perinatal lethal	1559delT
13	31	121	No data	0	ID 4 months	1559delT, parent hetero
14	32	240	110	82	Alive, ERT	
15	33	183	134	33	Alive, ERT	1559delT
16	33	108	300	205	Alive, benign type	exon 7, hetero
17	35	229	118	9	ND 39 weeks, 2710 g	

ND, neonatal death; ID, infant death; ERT, enzyme-replacement therapy; hetero, heterozygous mutant; ALP, alkaline phosphatase; HPP, hypophosphatasia; GW, gestational weeks; UPD, uniparental disomy.




Figure 1 All maternal alkaline phosphatase (mALP) values for short-limb cases including fetal hypophosphatasia (HPP) and other skeletal disease measured during pregnancy

maternal ALP values were significantly lower in HPP than in non-HPP cases ( $133.4 \pm 53$  vs  $197.4 \pm 69$  IU/L,  $p < 0.001$ ). Significant differences were seen before 28 weeks of gestation ( $103.5 \pm 40$  vs  $172.8 \pm 46.6$  IU/L,  $p < 0.001$ ) and after 28 weeks ( $160.3 \pm 50$  vs  $227.3 \pm 80.5$  IU/L,  $p = 0.0016$ ) (Table 2).

Paternal ALP values were measured in 37 cases, and ALP values were significantly lower in HPP ( $n = 10$ ) than in non-HPP cases ( $149.6 \pm 72$  vs  $231 \pm 61$  IU/L,  $p = 0.0016$ ).

Focusing on the three major skeletal dysplasias (HPP, OI, and TD), maternal ALP values showed significant differences between HPP and OI ( $p < 0.001$ , multiple comparison, post-

hoc Tukey test). Importantly, during the second trimester, significantly different ALP values were noted between both HPP and OI ( $p < 0.001$ ) and HPP and TD ( $p < 0.05$ ). As for paternal ALP values, significant differences were noted between HPP and OI ( $p < 0.05$ ) and between HPP and TD ( $p < 0.001$ ) (Tables 3 and 4).

The optimal maternal ALP cutoff value for diagnosis was established by receiver operating characteristic curve analysis as 123 IU/L (any time during pregnancy), and the optimal paternal ALP value as 165 IU/L (Figure 2). When using 'at least one low value' diagnostic criterion based on these maternal and paternal cutoff values, the sensitivities throughout the entire pregnancy period, before 28 weeks of gestation, and after 28 weeks of gestation until 37 weeks of gestation were 82.4%, 93.3%, and 77.8%. The corresponding specificities were 75%, 93.9%, and 75%, with positive predictive values of 80%, 96.2%, and 88.9%, respectively (Table 5). Although the numbers were small, the paternal low ALP activity had high

Table 2 Parental ALP values for HPP and non-HPP groups

	Maternal ALP HPP all period	Maternal ALP no HPP all period	Statistics
<i>n</i>	17	60	
Mean (SD)	133.4 (53)	197 (69)	0.0008
Range	62–240	91–404	
	Maternal ALP HPP <28 weeks	Maternal ALP no HPP <28 weeks	
<i>n</i>	8	33	
Mean (SD)	103.5 (40.2)	172.8 (46.6)	0.0009
Range	62–165	91–333	
	Maternal ALP HPP 28–37 weeks	Maternal ALP no HPP 28–37 weeks	
<i>n</i>	9	27	
Mean (SD)	160.3 (50.48)	227.3 (80.5)	0.0167
Range	108–240	110–404	
	Paternal ALP HPP	Paternal ALP no HPP	
<i>n</i>	10	27	
Mean (SD)	149.6 (71.8)	231 (61.4)	0.0016
Range	54–300	130–429	

ALP, alkaline phosphatase; HPP, hypophosphatasia; SD, standard deviation.

Table 3 Serum ALP value among three major diseases such as HPP, OI, and TD

	<i>n</i>	Mean	SD	Median	Range
OI all period	24	216	91	192.5	91–404
TD all period	18	174	38.6	178.5	108–263
HPP all period	17	133.6	53	121	62–240
OI <28 weeks	14	179.5	62.8	161	91–333
TD <28 weeks	14	163.7	33.4	173	108–209
HPP <28 weeks	8	103.5	40.1	81	62–165
Paternal ALP OI	14	223.9	79.2	196	178–269
Paternal ALP TD	9	248.7	37.9	232	220–329
Paternal ALP HPP	10	179.6	72	127	54–300

HPP, hypophosphatasia; OI, osteogenesis imperfecta; TD, thanatophoric dysplasia; SD, standard deviation; ALP, alkaline phosphatase.



Table 4 Multiple comparison (post-hoc Tukey test) of serum ALP value among three major diseases such as HPP, OI, and TD

Factors (Tukey)	Mean difference	q	Significance	95% CI of difference
All period HPP vs TD	-40.3	2.46	ns	-96.12 to 15.52
All period HPP vs OI	-83.25	5.422	$p < 0.001$	-135.6 to -30.93
All period TD vs OI	-42.94	2.844	ns	-94.41 to 8.516
HPP <28 weeks vs TD <28 weeks	-60.21	3.975	$p < 0.05$	-112.8 to -7.609
HPP <28 weeks vs OI <28 weeks	-76	5.017	$p < 0.001$	-128.6 to -23.39
TD <28 weeks vs OI <28 weeks	-15.79	1.222	ns	-60.65 to 29.08
Paternal HPP vs paternal TD	-99.07	4.47	$p < 0.001$	-176.3 to -21.81
Paternal HPP vs paternal OI	-74.26	3.718	$p < 0.05$	-143.9 to -4.639
Paternal TD vs paternal OI	24.81	1.204	ns	-47.03 to 96.65

ALP, alkaline phosphatase; HPP, hypophosphatasia; OI, osteogenesis imperfecta; TD, thanatophoric dysplasia; CI, confidence interval; ns, not significant.




Figure 2 Receiver operating characteristic curve of alkaline phosphatase (ALP) for the diagnosis of hypophosphatasia, with an optimal maternal ALP cutoff value of 123 and paternal ALP cutoff value of 165 [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

sensitivity, specificity, and positive predictive values of 80%, 92.6%, and 80%.

## DISCUSSION

Recent medical developments such as enzyme-replacement therapy for HPP have increased survival even without sequelae.<sup>4</sup> It is thus important to reach a precise prenatal diagnosis of HPP. However, because of the many variations and limitations of fetal imaging, exact imaging criteria for the diagnosis for HPP have not yet been established. Although cord blood sampling for fetal ALP and parental gene analysis can allow accurate prenatal diagnosis, both methods are not easy to perform as first routine screening tests in cases of short fetal limbs because of their cost and invasiveness. We have found that parental blood ALP values provide a supportive tool to identify cases which may benefit from further diagnostic examination and preparation for enzyme-replacement therapy soon after delivery.

Because of the natural increase in maternal ALP values in late pregnancy both in normal and fetal HPP cases<sup>13</sup> due to ALP secretion from the placental isoenzyme, many

investigators have abandoned using this method for prenatal diagnosis of the condition. However, the present results show the effectiveness of the 'at least one low' screening criterion (i.e. at least maternal and/or paternal ALP, cutoff below 123 and/or 165 IU/L, respectively). During the period of this study, 17 HPP cases were seen: paternal ALP activity was measured in 10 cases, and the positive rate of 'at least one low' was 82% (14/17 cases). Three cases showed both low maternal and paternal ALP values. Because paternal ALP is not affected by placental secretion of ALP, it can be measured at any time during the pregnancy. Indeed in our series, after 28 weeks, only 3/8 cases would have been detected by low maternal ALP measurement, whereas 4 cases would have been diagnosed using low paternal values. Thus, overall 7/8 cases would have been screened positive using 'at least one low' criterion.

An additional benefit of ALP is that the cost of performing this measurement is low as it is commonly used in daily clinical medicine. Only one case previously reported<sup>15</sup> showed normal ALP activity criteria for both parents. This case was found to have a paternal genomic abnormality of 1559 del and showed uniparental disomy.

Table 5 Diagnosis accuracy of fetal HPP of parental serum ALP activity

	HPP		No HPP		Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	PPA (%) (95% CI)	NPA (%) (95% CI)
	Low	Normal	Low	Normal				
At least 1 low in all period	14	3	4	56	82.4 (59–106)	93.3 (85–101)	77.8 (53–102)	94.9 (88–102)
Maternal low in all period	10	7	3	57	58.8 (29–89)	94.9 (88–102)	76.9 (48–106)	88.9 (79–98)
Paternal low in all period	8	2	2	25	80 (48–112)	92.6 (80–105)	80 (48–112)	92.6 (80–105)
At least 1 low <28 weeks	6	2	2	31	75 (37–113)	93.9 (84–104)	75 (37–113)	93.9 (84–104)
Maternal low <28 weeks	6	2	2	31	75 (37–113)	93.9 (84–104)	75 (37–113)	93.9 (84–104)
Paternal low <28 weeks	4	1	0	19	80 (35–125)	100 (1–1)	100 (1–1)	95 (83–107)
At least 1 low 28–37 weeks	8	2	1	25	80 (48–112)	96.2 (87–106)	88.9 (63–115)	92.6 (80–105)
Maternal low 28–37 weeks	14	3	5	26	82.4 (59–106)	83.9 (67–100)	73.7 (48–99)	89.7 (76–104)
Paternal low 28–37 weeks	8	1	2	25	88.9 (63–115)	92.6 (80–105)	80 (48–112)	96.2 (87–106)

At least 1 low, lower ALP either mother (ALP < 123) or father (ALP < 165) using ROC cutoff, respectively.

PPA, positive predict accuracy; NPA, negative predict accuracy; ROC, receiver operating characteristic; ALP, alkaline phosphatase; HPP, hypophosphatasia; CI, confidence interval.

In considering the genetics of HPP, the mother, the father, or both can be carriers, as the condition follows either an autosomal recessive or – less commonly – an autosomal dominant inheritance. The carrier frequency is estimated to be 1/480 in Japan, based on genetic analyses.<sup>16</sup> Among all of the skeletal diseases, the Japanese population seems to have a higher incidence of fetal HPP. Mulivor *et al.*<sup>1</sup> noted that carriers apparently heterozygous for HPP had enzyme activity levels substantially lower than controls. A heterozygous carrier for HPP might show 50% ALP enzyme activity. So measurement of ALP activities in both parents would be useful for screening the carrier state and the HPP fetus.

Recently, a benign perinatal type of HPP has been diagnosed. Fetal diagnosis by imaging is also difficult for such mild phenotype cases.<sup>12</sup> Thus, ALP as a test is helpful after diagnosis of fetal skeletal dysplasia or bone disease by prenatal screening imaging. We successfully detected a case of benign type by measuring a maternal ALP value of 108 IU/L at 33 weeks of gestation (Table 2, case 16) although the fetus showed only slight bowing of the femur. Our method may contribute to detect benign perinatal types of HPP.

In light of our findings, a practical and cost-effective screening flow chart for HPP would include: (1) short-limb and thin head bone (clear brain imaging) on prenatal imaging and (2) ALP measurements of the parents with a low value of at least one (maternal and/or paternal). Cases fulfilling such criteria would benefit from more invasive or expensive prenatal diagnostic tests.

A limitation of this analysis is that a nomogram of ALP activity during the pregnant period has not been established in all countries outside of Japan. Additional studies are needed to confirm the value of parental ALP in the screening of HPP outside of Japan.

## ACKNOWLEDGEMENTS

The authors would like to express their special gratitude to the other members of the fetal skeletal dysplasia forum in Japan such as consisting of volunteer member of experts for prenatal diagnosis established in 2007.

### WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?

- Prenatal diagnosis of fetal HPP is difficult to achieve.
- An accurate prenatal diagnosis is desirable because enzyme-replacement therapy after birth is beneficial.

### WHAT DOES THIS STUDY ADD?

- In addition to fetal imaging, measuring parental ALP activity is useful to distinguish HPP from osteogenesis imperfecta and other fetal short-limb conditions throughout the whole period of pregnancy.
- Documentation of at least one parent with a low level of ALP seems to be a useful criterion to hone in the diagnosis of fetal HPP.
- ALP assay is not invasive, is inexpensive, and is easy to use.



## REFERENCES

1. Fraser D. Hypophosphatasia. *Am J med* 1957;22:730–46.
2. Mulivor RA, Mennuti M, Zackai EH, *et al.* Prenatal diagnosis of hypophosphatasia; genetic, biochemical, and clinical studies. *Am J hum Genet* 1978;30:271–82.
3. Mornet E. Hypophosphatasia. *Orphanet J Rare Dis* 2007;2:40. Review.
4. Whyte MP, Greenberg CR, Salman NJ, *et al.* Enzyme-replacement therapy in life-threatening hypophosphatasia. *N Engl J med* 2012;366:904–13.
5. Shohat M, Rimoin DL, Gruber HE, *et al.* Perinatal lethal hypophosphatasia; clinical, radiologic and morphologic findings. *Pediatr Radiol* 1991;21:421–7.
6. Ozono K, Yamagata M, Michigami T, *et al.* Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. *J Clin Endocrinol Metab* 1996;81:4458–561.
7. Sawai H, Kanazawa N, Tsukahara Y, *et al.* Severe perinatal hypophosphatasia due to homozygous deletion of T at nucleotide 1559 in the tissue nonspecific alkaline phosphatase gene. *Prenat Diagn* 2003;23:743–6.
8. Okazaki Y, Kitajima H, Mochizuki N, *et al.* Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth. *Eur J Pediatr* 2016;175:433–7.
9. Wladimiroff JW, Niermeijer MF, Van der Harten JJ, *et al.* Early prenatal diagnosis of congenital hypophosphatasia: case report. *Prenat Diagn* 1985;5:47–52.
10. Brock DJ, Barron L. First-trimester prenatal diagnosis of hypophosphatasia: experience with 16 cases. *Prenat Diagn* 1991;11:387–91.
11. Wenkert D, McAlister WH, Coburn SP, *et al.* Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). *J Bone Miner res* 2011;26:2389–98.
12. Aoba H, Hariu Y, Yamaguchi R. Serum heat-stable alkaline phosphatase in normal and abnormal pregnancy. *Tohoku J Exp med* 1967;91:201–7.
13. Whyte MP, Landt M, Ryan LM. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. *J Clin Invest* 1995;95:1440–5.
14. Maekawa M. Standardization of measurement of catalytic activity concentration of enzymes – current situation regarding the external quality assessment program provided by the Japan Medical Association. *Rinsho Byori* 2010;58:58–63 (Japanese).
15. Watanabe A, Satoh S, Fujita A, *et al.* Perinatal hypophosphatasia caused by uniparental isodisomy. *Bone* 2014;60:93–7.
16. Watanabe A, Karasugi T, Sawai H, *et al.* Prevalence of c.1559delT in *ALPL*, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers. *J hum Genet* 2011;56:166–8.

# Follow-Up Study on Fetal CT Radiation Dose in Japan: Validating the Decrease in Radiation Dose

Osamu Miyazaki<sup>1</sup>  
Hideaki Sawai<sup>2</sup>  
Takahiro Yamada<sup>3</sup>  
Jun Murotsuki<sup>4,5</sup>  
Gen Nishimura<sup>6</sup>

**Keywords:** CT, diagnostic reference level, fetus, prenatal diagnosis, skeletal dysplasia

DOI:10.2214/AJR.16.17316

Received September 2, 2016; accepted without revision September 27, 2016.

Based on a presentation at the 2015 annual meeting of the Japan Society of Perinatal and Neonatal Medicine, Hakata, Fukuoka, Japan.

Supported by grant H28-nanchitou(nan)-ippan-017 from Research on Rare and Intractable Diseases, Health and Labour Sciences Research Grants.

<sup>1</sup>Department of Radiology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. Address correspondence to O. Miyazaki (miyazaki-o@ncchd.go.jp).

<sup>2</sup>Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo, Japan.

<sup>3</sup>Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

<sup>4</sup>Department of Maternal and Fetal Medicine, Miyagi Children's Hospital, Miyagi, Japan.

<sup>5</sup>Department of Advanced Fetal and Developmental Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.

<sup>6</sup>Department of Pediatric Imaging, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

AJR 2017; 208:862–867

0361–803X/17/2084–862

© American Roentgen Ray Society

**OBJECTIVE.** In 2011, we collected data on fetal CT radiation dose to determine the diagnostic reference level (DRL); however, continuous evaluation of the DRL is necessary. The hypothesis of this study is that the fetal CT radiation dose has decreased, and we predict a widespread use of iterative reconstruction (IR). We also predict that the national decrease in exposure is because of the DRL reported as a result of the previous national study.

**MATERIALS AND METHODS.** Various testing protocols from each site were summarized as part of the study results. The minimum, one-fourth (25th percentile), median, three-fourths (75th percentile), and maximum values were obtained for volume CT dose index (CTDI<sub>vol</sub>), dose-length product (DLP), and scan length of 120 fetal CT examinations. The trends for IR usage and tube voltage were also investigated.

**RESULTS.** Compared to the results of the 2011 study ( $n = 119$ ), the minimum, 25th percentile, median, and 75th percentile values for CTDI<sub>vol</sub> and DLP have decreased for the tabulated results in 2015 ( $n = 120$ ). The 75th percentile value for CTDI<sub>vol</sub> was 4.9 mGy, which is 43% of the previous value. IR was used in 70% of the sites. The radiation dose was significantly lower among groups that used IR.

**CONCLUSION.** Four years passed between our initial survey on DRL and the present follow-up survey, and it appears that the previous report sufficiently fulfilled its objective and role in contributing to the decrease in DRL observed in this follow-up study.

According to an international classification issued in 2015 [1], there are 436 disease names, classified into 42 disease groups, and 364 responsible genes associated with genetic disease skeletal dysplasia. During the neonatal period, these diseases are found at a rate of two in 10,000 births, and half are lethal [2]. The recent widespread use of fetal ultrasound testing and improvement in diagnostic accuracy has led to the detection of short limbs and more cases of suspected skeletal dysplasia [3]. The advantage of ultrasound is that it can be used for pregnant women without involving x-ray irradiation. However, it is extremely difficult to detect, evaluate, and interpret the abnormal findings of skeletal structures using ultrasound, and a specific diagnosis cannot be made by the ultrasound operator without vast knowledge and experience in making such diagnoses. Unless the region that may contain the abnormalities is searched in detail during the scan, sufficient material for retrospective diagnosis cannot be obtained. This is the dis-

advantage of ultrasound testing that is based on real-time diagnosis.

However, the effectiveness of prenatal 3D CT for detecting fetal skeletal dysplasia has been previously reported, and 93% of pathognomonic abnormal findings confirmed after birth with simple x-ray were diagnosable with fetal skeletal CT. It was reported that the diagnosis determined by ultrasound was revised for about 60% of the cases after fetal CT [4].

Prenatal diagnosis using CT provides visual and clinical information to facilitate planning for a birthing method and selection of treatment by the various people involved, including the parents, family members, obstetrician, and perinatal care staff. It also allows the parents of the fetus to prepare themselves psychologically. Although there are many advantages, the risk of radiation exposure to the fetus and mother cannot be avoided because CT uses x-rays.

In 2011, we surveyed medical institutions in Japan that conduct fetal CT and collected data on CT conditions and radiation exposure; that study was published in 2014 [5].

## Decreasing Fetal CT Radiation Dose in Japan

From the data, we reported the estimated diagnostic reference level (DRL). To our knowledge, that report was the first and only fetal CT DRL study in the world. We decided to investigate DRL again in 2015 because 3 years and 9 months had passed since the initial survey was conducted. Periodic assessment of DRL every few years at each medical institution or at the national level is recommended [6]. Since the first study was conducted, CT equipment has seen further progress in the number of detectors, and high-performance CT equipment with 64 or more detectors are almost in common use. In addition, there are some reports in the pediatric radiology field that show an increase in popularity for using an iterative reconstruction (IR) protocol to reduce the radiation dose [7].

The hypothesis of this study is that the fetal CT radiation dose has decreased throughout the country compared with the nationwide study conducted in Japan in 2011 [5], and we predict the widespread usage of fetal CT with IR. We also predict that the national decrease in exposure is because of the DRL reported as a result of the previous national study.

### Materials and Methods

#### Selection of Target Medical Institutions

This study was approved by the ethics board of the National Center for Child Health and Development and was conducted after approval of the institutional review board.

The 16 sites that were studied in the 2011 survey [5] are major facilities performing fetal CT in Japan and were included in this study. In addition, an Internet forum for fetal skeletal dysplasia based in Japan, the Japan Forum of Fetal Skeletal Dysplasia (with 53 registered users), was used to call for participation by medical institutions that did not participate in the previous study. Medical institutions that consulted the radiologist and obstetrician members of the forum were also selected as candidates. Furthermore, medical institutions that have presented results in past society meetings in Japan and overseas, or submitted journal papers, were sought and considered as candidates. As a result, 25 medical institutions were selected as study sites. These study sites were mailed a CD-ROM with the questionnaire sheet, together with a letter inquiring about their interest regarding participation. The following 22 medical institutions expressed interest: Hokkaido University Hospital; Aomori Prefectural Central Hospital; Miyagi Children's Hospital; Tohoku University Hospital; Yamaga-

ta University Hospital; Chiba Kaihin Municipal Hospital; Juntendo University Urayasu Hospital; National Center for Child Health and Development; Jikei University School of Medicine Hospital; Tokyo Women's Medical University Hospital; Fujita Health University Hospital; Nagara Medical Center; University Hospital, Kyoto Prefectural University of Medicine; Osaka Medical Center and Research Institute for Maternal and Child Health; Hyogo College of Medicine Hospital; Shikoku Medical Center for Children and Adults; Perinatal Medical Center, Ehime Prefectural Central Hospital; Kochi Health Sciences Center; Tokushima University Hospital; Hiroshima University Hospital; Perinatal Medical Center, Yamaguchi Prefectural Grand Medical Center; and Kurume University Hospital.

#### Preparation of the Work Sheet

The first page of the work sheet was to be entered by the obstetrician of the hospital, and the remaining pages were to be entered by the radiologic technologist or radiologist. Eight questions were listed on the first page. First, what is the category of your hospital (choice of three options: university hospital, perinatal medical center, or regional core hospital)? Second, was specific written consent for fetal CT obtained? Third, how many fetal CT examinations have been conducted in the past 3 years and 9 months? Fourth, at what range of fetal stage (weeks) was CT conducted and what was the mean number of weeks? Fifth, on the basis of the 2011 study [5], have there been any changes to the protocol? Sixth, if the protocol has been changed, has the diagnostic ability decreased as a result of lowering the dose? Seventh, is sedation used on the fetus when conducting fetal CT? Finally, do you know the approximate fetal CT radiation dose for your hospital?

The CT survey from the second page onward had entry sheets for four manufacturers: Toshiba, GE Healthcare, Siemens Healthcare, and Philips Healthcare. The sheet for the manufacturer of the equipment used for testing at each site was also filled out. If multiple pieces of CT equipment were used at one site, we requested that each piece was entered into separate work sheets. Because parameters are different depending on the manufacturer, the work sheet entry items tailored for each CT manufacturer were chosen by a subgroup of seven radiologic technologists selected from sites that frequently perform fetal CT. The staff in charge of setting imaging protocols for each manufacturer at each of the four CT manufacturers was requested to check for the appropriateness of the chosen work sheet items, and the revised items were distributed. The content of the work sheet differs for each company, but basic items include tube volt-

age, tube current, scan time, pitch, scan FOV, scan length, volume CT dose index ( $CTDI_{vol}$ ), dose-length product (DLP), whether IR is used for scanning and 3D imaging, and the name and degree of IR protocol used. This questionnaire was prepared using Excel software (version 2013, Microsoft) and was distributed to each site.

The study started when the survey was sent on December 5, 2014, and results were collected by January 31, 2015. The study implementation period was 58 days.

#### Summary of the Collected Data on Fetal CT From the Sites

The frequency of usage for each piece of CT equipment and the protocol was summarized from the survey results. The CT parameters used at the sites were also compared among the results using the same protocol. The trend in results for the protocol that used the lowest dose and the protocol that used the highest dose was studied.

#### CT Exposure Evaluation Method

The minimum, one-fourth (25th percentile), median, three-fourths (75th percentile), and maximum values were obtained for the  $CTDI_{vol}$ , DLP, and scan length from the 139 fetal CT examinations collected in this 2015 study. The results were compared with the previous results in 2011 [5], and the changes over the 4 years were evaluated. In addition, the 75th percentile values of  $CTDI_{vol}$  and DLP in this study were determined as the new DRL. The median value was compared for scan length.

Regarding usage of IR, the frequency of usage was studied and the difference in  $CTDI_{vol}$  value was compared among cases with and without IR use.

Regarding tube voltage, the frequency of usage of 80, 100, and 120 kV was studied. The results were compared with those of the 2011 study [5]. In addition, the  $CTDI_{vol}$  values for the frequently used voltages, 100 and 120 kV, were compared among the different protocols used. For statistical analysis of the data, an unpaired *t* test was used to test for significance (Excel version 2013, Microsoft).

### Results

#### Response to Questions Addressed to the Obstetrician

*Category of your hospital*—The breakdown of the 22 sites was 13 university hospitals (59%), followed by six perinatal centers (27%), and three regional core hospitals (14%). However, there were inconsistencies in CT dose data on two sites. These sites were excluded and a total of 20 sites were used for analysis.

**TABLE 1: Summary of 32 Fetal CT Protocols for Scanners Used at Each Survey Site**

Manufacturer	Brand Name	Tube Voltage (kV)	Rotation Time (s)	Helical Pitch	Volume CT Dose Index (mGy)	Dose-Length Product (mGy·cm)	Iterative Reconstruction
GE Healthcare	Discovery 750HD (n=3)	100 (n=4)	0.4–1	0.5–1.4	0.5–9	18–353	ASiR (n=3)
	LightSpeed 16 (n=1)	120 (n=1)					Veo (n=2)
	LightSpeed VCT (n=1)						
Siemens Healthcare	Sensation (n=2)	120 (n=10)	0.28–0.5	0.6–1.4	1.6–13	52–514	SAFIRE (n=4)
	Definition (n=8)						IRIS (n=1)
Toshiba	Aquilion 16 (n=4)	80 (n=1)	0.3–0.75	0.8–1.5	1.8–27.5	55–943	AIDR3D (n=6)
	Aquilion 64 (n=4)	100 (n=4)					
	Aquilion other (n=4)	120 (n=12)					
	Aquilion ONE (n=3)						QDS (n=1)
Philips Healthcare	iCT Elite (n=1)	80 (n=1)	0.4–0.75	0.6–0.9	1.6–7.9	70–281	IMR SoftTissue (n=1)
	iCT (n=1)	100 (n=1)					iDose 4 (n=1)
Summary of fetal CT protocols	n=32	120 (n=23)	0.28–0.75	0.5–1.5	0.5–27.5	18–943	Hybrid iterative reconstruction (n=17)
		100 (n=9)					Full iterative reconstruction (n=2)

Note—ASiR = adaptive statistical iterative reconstruction, SAFIRE = sinogram-affirmed iterative reconstruction, IRIS = iterative reconstruction in image space, AIDR3D = adaptive iterative dose reduction 3D, QDS = quantum denoising software, IMR = iterative model reconstruction.

*Specific written consent for fetal CT*—Sixteen sites (80%) obtained specific written consent for conducting fetal CT.

*Number of fetal CT examinations conducted in the past 3 years and 9 months*—The number of cases per site during this time period ranged from one to 24 and there were 139 cases in total.

*The range of and mean gestational week when CT was conducted*—The range was 17–36 weeks' gestation, and the mean ( $\pm$  SD) was  $30.1 \pm 3.1$  weeks.

*Knowledge of the previous study report (2011), and whether the protocol has been changed*—Six sites changed their protocol on the basis of the 2011 DRL (30%). Seven sites (35%) each answered that the study results did not affect their protocol or they did not know about the 2011 DRL.

*Whether diagnostic ability decreased because of protocol change*—No sites that changed their protocol answered that diagnostic ability decreased by lowering the dose.

*Use of sedation on fetus during fetal CT*—Two sites (10%) used sedation when conducting fetal CT, but the remaining 18 sites (90%) did not use sedation. One site that used sedation answered “walking, use of Diazepam in some cases,” and the other site did not give a detailed response.

*Knowledge of an approximate fetal CT radiation dose at own site*—Obstetricians at 17 sites (85%) answered that they knew the approximate fetal CT radiation dose at their own site.

#### Summary of Collected Data on Fetal CT From Each Site

Table 1 summarizes the survey results about the 32 CT protocols used by the sites for each scanner manufacturer. The most common scanner manufacturer among the survey sites was Toshiba; however, no obvious difference of parameter setting was identified among CT vendors.

There was a wide range of radiation doses as measured by  $CTDI_{vol}$  and DLP, and the lowest scanning condition was a  $CTDI_{vol}$  of 0.5 mGy with the full IR method (Veo, GE Healthcare), even though full IR was used for only 10% of the protocols. This is somewhat surprising, because the maximum values of  $CTDI_{vol}$  and DLP (27.5 mGy and 943 mGy·cm, respectively) were 50 times as large as the minimum settings (0.5 mGy and 18 mGy·cm, respectively). Approximately

68% of CT protocols were performed using a tube voltage of 120 kV.

#### CT Exposure Evaluation

Among the 139 fetal CT examinations performed at the study sites during the study period, inquiries were made to the staff in charge of setting imaging protocols for each manufacturer regarding incomplete data submitted from the sites to recover and ensure consistency in the data. However, inconsistencies in data on  $CTDI_{vol}$  and DLP for 19 cases could still not be resolved. These data were excluded, and a total of 120 cases were used for analysis.

#### Evaluation and Change of Volume CT Dose Index, Dose-Length Product, and Scan Length

The comparison of values for  $CTDI_{vol}$ , DLP, and scan length in 2011 and 2015 is


**TABLE 2: Comparison of Volume CT Dose Index ( $CTDI_{vol}$ ), Dose-Length Product (DLP), and Scan Length Between 2011 and 2015**

Measurement	$CTDI_{vol}$ (mGy) <sup>a</sup>		DLP (mGy·cm) <sup>a</sup>		Scan Length (mm) <sup>b</sup>	
	2011	2015	2011	2015	2011	2015
Maximum	23.1	27.5	1025.6	943.5	476	520
75th percentile	11.3	4.9	382.6	176.4	356	341
Median	7.7	3.2	276.8	104.3	319	313
25th percentile	3.7	2.4	122.3	84.8	295	287
Minimum	2.1	0.5	69	18.3	190	133


<sup>a</sup> $p < 0.01$ .

<sup>b</sup> $p > 0.05$ .


## Decreasing Fetal CT Radiation Dose in Japan




**Fig. 1**—Boxplot of volume CT dose index ( $CTDI_{vol}$ ) values in 2011 and 2015. Boxes denote ranges, lines in boxes denote medians, and vertical lines and whiskers denote 95% CIs.




**Fig. 2**—Boxplot of dose-length product (DLP) values in 2011 and 2015. Boxes denote ranges, lines in boxes denote medians, and vertical lines and whiskers denote 95% CIs.



**Fig. 3**—Boxplot of scan length values in 2011 and 2015. Boxes denote ranges, lines in boxes denote medians, and vertical lines and whiskers denote 95% CIs.



**Fig. 4**—Comparison of median volume CT dose index ( $CTDI_{vol}$ ) between CT performed with and without iterative reconstruction (IR). If sites surrounded by dashed line are excluded,  $CTDI_{vol}$  values for sites using IR are lower than for those that do not use IR, with statistically significant difference between groups ( $p < 0.01$ ).



**Fig. 5**—Comparison of median volume CT dose index ( $CTDI_{vol}$ ) values at 120 and 100 kV. In contrast to results for iterative reconstruction, results for tube current did not show significant difference in  $CTDI_{vol}$  even when sites surrounded by dashed line were excluded.

shown in Table 2, and boxplots are shown in Figures 1–3. Compared with the study in 2011 ( $n = 119$ ), the minimum, median, 75th percentile, and 25th percentile values of  $CTDI_{vol}$  and DLP for the tabulated results in 2015 ( $n = 120$ ) were lower, although some sites had a higher maximum value than that of the previous study. The 75th percentile value of  $CTDI_{vol}$  that is the DRL for this study was 4.9 mGy, and this was 43% of the previous value of 11.3 mGy. During this period, a 57% reduction in the radiation dose was found (Fig. 1). Similar to  $CTDI_{vol}$ , the 75th percentile value for DLP was 176.4 mGy·cm, and this was 46% (about half) of the previous value of 382.4 mGy·cm. The differences were statistically significant ( $p < 0.01$ ) (Fig. 2). On the other hand, the scan range was almost the same as in the previous study, and although the data included over 100 cases,

the study period but started to incorporate it during the study period. As shown in Figure 4, a comparison of  $CTDI_{vol}$  between CT with IR ( $n = 72$ ) and CT without IR ( $n = 48$ ) shows that it is lower in the group that uses IR than the group that does not use IR, although one site had set a significantly higher radiation dose than the others (section surrounded by the dashed line in Fig. 4). If the site surrounded by the dashed line is excluded, the  $CTDI_{vol}$  for sites using IR compared with those that do not use IR is statistically significantly lower ( $p < 0.01$ ). The group that uses IR had a significantly lower radiation dose setting compared with the group that did not (Table 3).

Tube voltage was 120 kV in 52 cases, 100 kV in 59 cases, and 80 kV in nine cases, with 100 kV the most frequently used voltage. Six sites had the voltage fixed at 120 kV, whereas the other 14 sites used a tube voltage lower than 120 kV.

As with IR, comparison of  $CTDI_{vol}$  values by tube current (120 vs 100 kV) showed that the median  $CTDI_{vol}$  values for 120 and 100 kV were 3.3 and 2.5 mGy, respectively. As shown in Figure 5, the tube voltage was set at a significantly higher radiation dose in one

the median was different by only 6 mm, and the data were considered to be accurate. It was found that the decrease in DLP was not caused by a shortening of the length (Fig. 3).

In this study, 14 of 20 sites (70%) used IR. Among the 14 sites that used IR, six (43%) did not use the method at the beginning of

**TABLE 3: Relationships Between Volume CT Dose Index ( $CTDI_{vol}$ ) and Iterative Reconstruction (IR) and Between  $CTDI_{vol}$  and Tube Voltage**

Measurement	$CTDI_{vol}$ With and Without IR (mGy) <sup>a</sup>		$CTDI_{vol}$ at Different Tube Voltages (mGy) <sup>b</sup>	
	With IR	Without IR	120 kV	100 kV
Maximum	8.8	13.4	8.8	13.4
75th percentile	3.5	5	4.8	4.1
Median	2.5	3.3	3.3	2.5
25th percentile	2	3.2	3.2	2
Minimum	0.5	1.8	1.6	0.5

<sup>a</sup> $p < 0.01$ .

<sup>b</sup> $p > 0.05$ .



site in the group that used IR (section surrounded by a dashed line in Fig. 5). In contrast to the results for IR, the results for tube current did not show a significant difference in  $CTDI_{vol}$  even when the site surrounded with the dashed line was excluded.

## Discussion

From the response to the questions answered by the obstetricians, the following situation was revealed. In Japan, 86% of fetal CT examinations were performed at university hospitals or public perinatal centers that act as the center for medical care in that region. It is assumed that obstetricians and gynecologists at local clinics who detect short limbs by fetal ultrasound send a referral to obstetricians or fetal examination specialists for retesting by ultrasound with higher accuracy, and then the case is indicated for CT if necessary.

In Japan, 80% of the sites obtained specific written consent for fetal CT with informed consent from the parents regarding fetal radiation exposure.

The mean timing for the CT was  $30.1 \pm 3.1$  weeks' gestation. This is thought to be the result of a recommendation by the leading academic research group on fetal CT in Japan, the Japan Forum of Fetal Skeletal Dysplasia, which recommends testing at around 30 weeks. This recommendation is based on several reasons, including the fact that the effect of radiation on the CNS is less of a concern during the third trimester of pregnancy [8] and that depiction of the skeletal structure is clearer compared with the early stages of pregnancy because of fetal growth. The result was almost the same as the previous study [5] (mean,  $30.2 \pm 2.6$  weeks) with essentially no change. It is understandable that the sites that perform CT are actually following the recommendations of the Japan Forum of Fetal Skeletal Dysplasia.

Thirteen sites (65%) were aware of the DRL results from the 2011 study [5], and six sites (30%) had changed their protocol on the basis of the 2011 DRL. On the other hand, seven sites (35%) answered that they were not aware of the study results. DRL was proposed in the 1980s to optimize simple x-ray radiation dose and it was introduced as a method for optimizing CT radiation dose in the 1990s [7, 9]. It is considered that there is high awareness of DRL in the sites performing fetal CT, and DRL is correctly functioning as a regulatory pressure on the entire community as intended. No sites responded that a lower dose resulting from protocol

changes led to decreased diagnostic ability, and this further reinforces that these scanning conditions are appropriate.

It was revealed that 90% of sites did not sedate the fetus for fetal CT. In the previous survey, one site used pancuronium (Mioblock, MSD) to suppress fetal movement, but this response was not found in the current study. It is considered that sedation is not necessary for fetal CT.

Obstetricians at 17 sites (85%) knew the approximate fetal CT radiation dose of their site when they order the scan. According to a literature search, it has been reported in a past survey that only 16% of residents in a radiology department knew the radiation dose for abdominal CT [10]. The obstetricians at sites performing fetal CT may be aware of the dose because they are required to explain the dose to patients. This may be inaccurate because the specific number was not asked, but compared with past reports, obstetricians who are involved in fetal CT are considered to have a fairly high awareness of CT exposure.

This study has revealed that since the 2011 study [5], the DRL for fetal CT in Japan has been reduced by half, a result that was statistically significant. This may be due to three factors. One is the first-ever proposal of fetal CT DRL in Japan from the study results in 2011. The results were widely reported at fetal CT forums and research groups that were active in performing fetal CT. A total of 65% of the sites studied in this analysis answered that they were aware of the results, and, furthermore, 30% of sites responded that they had lowered their dose setting on the basis of the DRL of the previous study. This is the result of DRL fulfilling its correct function, and it could be evaluated as an extremely significant result for managing CT radiation exposure in Japan. It is considered that DRL should be studied every few years and, indeed, this study was conducted at the appropriate time. We should conduct another national survey in 3–4 years and confirm the decrease in DRL as a community.

The next factor is the decrease in dose due to widespread use of IR. In the previous 2011 study [5], only one site of 16 (6%) used IR, but in this study, there was a significant increase with 14 of 20 sites (70%) using IR. This is considered to be due to the recent recognition of IR in all CT scans, including those of children [11] and adults, and the experience of the scanner, who can easily enhance image quality by changing the console setting. Therefore, among the 14 sites that

used IR, the fact that six sites (43%) did not use IR at the beginning of the study but introduced IR later during the study period is considered to be the result of recognizing IR's usefulness in fetal CT.

The site that performs scans with the lowest exposure ( $CTDI_{vol}$ , 0.5 mGy) in this study does not use hybrid type IR but has introduced full IR (Vevo, GE Healthcare) to aim for lower exposure. There are only a few reports on using full IR for fetal CT [12], but a decrease in fetal CT radiation dose would be possible if the full IR method becomes widespread, leading to a further decrease in DRL throughout Japan.

Similarly, this study found that many sites used low tube voltage. No significant difference in  $CTDI_{vol}$  was found between different protocols using 120 or 100 kV, but the use of low tube voltage at these sites may be the result of awareness of lowering exposure and an adjustment to avoid an increase in unnecessary tube current. This is thought to be due to a change in techniques and awareness among the technicians in charge of CT machines in the clinical field.

In this way, radiation exposure of fetal CT has been optimized, but as shown in Figures 4 and 5, there are still sites with conditions leading to high radiation doses, and further education on DRL is required.

On the other hand, a limitation of this and previous studies was that only the radiation dose to set DRL was studied, and we did not collect data on image quality. Focusing on decreasing the dose may lead to a failure to maintain sufficient diagnostic quality for images. Goske et al. [13] have published their thoughts regarding the diagnostic reference range as a method to maintain both an appropriate radiation dose management for CT and diagnostic image quality. They suggest that the upper limit for radiation exposure should be the 75th percentile value and the lower limit should be the 25th percentile value to maintain image quality, and the appropriate scan condition should fall within this range. If this is applied to the results of this study, the appropriate dose for fetal CT would be a  $CTDI_{vol}$  between 2.5 and 5 mGy (median, 3 mGy). In cases without full IR, this range for diagnostic reference range is considered to be appropriate.

A significant reduction in radiation exposure is possible if fetal CT is used only for observation of skeletal structure of the fetus, but it is necessary for each medical institution to consider the characteristics of IR for their fa-

## Decreasing Fetal CT Radiation Dose in Japan

cility's CT equipment and to perform a CT examination with sufficient quality for diagnosis.

In summary, since the previous DRL survey was conducted [5], the original objective and role for DRL that the International Commission on Radiological Protection [14] had proposed has been sufficiently reached. In addition, widespread use of IR and low tube voltage has helped in managing the radiation dose throughout Japan.

The objective of CT is to deliver an accurate diagnosis when skeletal dysplasia is suspected after careful fetal ultrasound testing and to determine the strategy for perinatal patient care. From this study, it was heartening to find that 85% of obstetricians who order CT scans were aware of the approximate CT radiation dose at their site.

We intend to conduct another survey in 4 years to confirm whether there is a further decrease in DRL. In addition, compared with 2011, there is concern that image quality may have been affected by the decrease in dose. Ideally, the next study would also include an evaluation of image quality.

### Acknowledgments

We thank the following seven radiologic technologists and clinical researchers who were members of a subgroup that worked on the CT work sheet: Tsukasa Sasaki, Hokkaido University Hospital; Kiyooki Sasaki, Miyagi Children's Hospital; Toshiya Nasada, Hyogo University of Health Sciences Hospital; Rumi Imai, National Center for Child Health and Development; Tetsuya Horiuchi, National Center for Child Health and Development; Masao Kiguchi, Hiroshima University Hospital; and Shinji Sakai, Kurume University Hospital. We thank the obstetricians, radiologists, and radiologic technologists at the following medical institutions for filling out the

work sheet: Hokkaido University Hospital; Aomori Prefectural Central Hospital; Miyagi Children's Hospital; Tohoku University Hospital; Yamagata University Hospital; Chiba Kaihin Municipal Hospital; Juntendo University Urayasu Hospital; National Center for Child Health and Development; Jikei University Hospital; Tokyo Women's Medical University Hospital; Fujita Health University Hospital; Nagara Medical Center; University Hospital, Kyoto Prefectural University of Medicine; Osaka Medical Center and Research Institute for Maternal and Child Health; Hyogo College of Medicine Hospital; Shikoku Medical Center for Children and Adults; Perinatal Medical Center, Ehime Prefectural Central Hospital; Kochi Health Sciences Center; Tokushima University Hospital; Hiroshima University Hospital; Perinatal Medical Center, Yamaguchi Prefectural Grand Medical Center; and Kurume University Hospital. We thank the following people who work for each vendor and are in charge of CT applications: Takashi Ichibakase, GE Healthcare; Yukie Oosawa, Toshiba; Tetsuo Onishi, Siemens Healthcare; and Taisuke Fujioka, Philips Healthcare.

### References

1. Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. *Am J Med Genet A* 2015; 167A:2869–2892
2. Schumacher R, Seaver LH, Spranger J. Introduction. In: Schumacher R, Seaver LH, Spranger J, eds. *Fetal radiology, a diagnostic atlas*, 1st ed. Berlin, Germany: Springer, 2004:1–2
3. Toru HS, Nur BG, Sanhal CY. Perinatal diagnostic approach to fetal skeletal dysplasias: six years experience of a tertiary center. *Fetal Pediatr Pathol* 2015; 34:287–306
4. Miyazaki O, Nishimura G, Sago H, et al. Prenatal diagnosis of fetal skeletal dysplasia with 3D CT. *Pediatr Radiol* 2012; 42:842–852
5. Miyazaki O, Sawai H, Murotsuki J, et al. Nationwide radiation dose survey of computed tomography for fetal skeletal dysplasias. *Pediatr Radiol* 2014; 44:971–979
6. Brady Z, Framanuskas F, Cain TM, et al. Assessment of paediatric CT dose indicators for the purpose of optimization. *Br J Radiol* 2012; 85:1488–1498
7. Hopkins KL, Pettersson DR, Koudelka CK, et al. Size appropriate radiation doses in pediatric body CT: a study of regional community adoption in the United States. *Pediatr Radiol* 2013; 43:1128–1135
8. ACOG Committee on Obstetric Practice. ACOG committee opinion: number 299, September 2004 (replaces no. 158, September 1995)—guidelines for diagnostic imaging during pregnancy. *Obstet Gynecol* 2004; 104:647–651
9. Thomas KE. CT utilization: trends and developments beyond the United States' borders. *Pediatr Radiol* 2011; 41(suppl 2):562–566
10. Divrik Gökçe S, Gökçe E, Coşkun M. Radiology residents' awareness about ionizing radiation doses in imaging studies and their cancer risk during radiological examinations. *Korean J Radiol* 2012; 13:202–209
11. Haggerty JE, Smith EA, Kunisaki SM, et al. CT imaging of congenital lung lesions: effect of iterative reconstruction on diagnostic performance and radiation dose. *Pediatr Radiol* 2015; 45:989–997
12. Sekiguchi M, Miyazaki O, Wada S, et al. Case 13516: prenatal diagnosis of Pfeiffer syndrome type II using ultralow dose CT. EURORAD radiological case database website. [www.eurorad.org/eurorad/case.php?id=13516](http://www.eurorad.org/eurorad/case.php?id=13516). Published March 28, 2016. Accessed May 7, 2016
13. Goske MJ, Strauss KJ, Coombs LP, et al. Diagnostic reference ranges for pediatric abdominal CT. *Radiology* 2013; 268:208–218
14. Khong PL, Ringertz H, Donoghue V, et al.; ICRP. ICRP publication 121: radiological protection in paediatric diagnostic and interventional radiology. *Ann ICRP* 2013; 42:1–63